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ABSTRACT 
Described herein is my thesis work towards structural and biochemical characterization of 
bacterial proteins involved in metabolite regulation and natural product biosynthesis. In the first 
case, I will describe the structural basis for transcriptional regulation of a small molecule 
metabolite, p-coumarate, and the remaining cases involve enzymes responsible for biosyntheses 
of complex natural products. Among the natural product cases are those falling under the class of 
ribosomally synthesized and post-translationally modified peptides (RiPPs), with a particular 
emphasis on the thiopeptide subclass of RiPPs. Additionally, characterization of an off-loading 
enzyme involved in hybrid polyketide/non-ribosomal peptide (PK-NRP) natural product 
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Second to plants, bacteria represent a significant contribution to life on Earth, accounting 
for ~15% of the global biomass.1 Estimates of the earliest existing bacteria date as far as 3.8 billion 
years ago suggesting ample time for emergence of advantageous fitness traits accompanied by 
divergence of these traits selected for in a variety of habitats.2 With genome sequencing rates 
nearly doubling every year, the access to this biodiversity is exponentially growing and greatly 
outpacing the functional assignment of genes by experimentation.3 Because many of the genes 
lacking correct annotation likely encode for proteins with novel function, this highlights the need 
to collaborate experimental and computational protein science to efficiently narrow the gap 
between sequence and function. Of particular interest to medicine are the bacterial enzymes 
involved in complex natural product biosynthesis, as many of the therapeutic small molecules 
(~50% in the case of cancer-specific drugs) are directly taken from nature or closely related 
analogs thereof.4  
Bacteria are master organic chemists with elegant strategies to produce both the primary 
metabolites for energy production as well as the secondary metabolites involved in signaling, 
nutrient sequestration, and chemical weaponry, for example. Owing to their impressive ability to 
effectively synthesize bioactive compounds in resource limited environments, bacteria provide 
useful examples of synthetic routes towards potentially therapeutic compounds. As 
aforementioned, much of the sequence space remains understudied in terms of molecular function, 
suggesting enzymatic strategies to produce small molecules of interest remain undiscovered.  In 
addition to the application of natural products in mitigating dangers posed by microbial and viral 
infections in humans, the bacterial enzymes involved could serve as environmentally useful, green 
biocatalysts. In contrast to synthetic routes which may have any one of the following drawbacks 
of hazardous waste disposal, lower atom efficiency, costly energetics, and lower safety; enzymes 
offer an environmentally less taxing, more renewable, and safer alternative to chemical syntheses.5 
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Enzymatic synthesis does, however, suffer from its own disadvantages of catalyst stability, solvent 
tolerance, and substrate permissiveness, calling for protein engineering approaches to improve 
catalyst performance as well as hybrid, chemoenzymatic strategies which utilize both chemical 
and enzymatic techniques. Developing analogs of natural bioactive compounds will be highly 
important in the face of rising antibiotic resistance, and protein engineering represents one 
potential strategy to modulate the substrate scope and activity to create natural product analogs.6 
Towards this aim, biophysical and biochemical characterization of enzymes will be critical to 
assess enzyme function and amenability to engineering for downstream drug production and 
development.  
This thesis work presents several accounts of bacterial enzyme characterization whereby 
structural, binding, and reactivity experiments have been deployed in combination with mutagenic 
and bioinformatic analyses to enhance our understanding of natural small molecule biosynthesis.    
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CHAPTER 1: MOLECULAR BASIS OF P-COUMARATE REGULATION BY COUR, A 
MARR FAMILY TRANSCRIPTIONAL REPRESSORa 
 
1.1 ABSTRACT 
The MarR-family transcriptional regulator CouR, from the soil bacterium 
Rhodopseudomonas palustris CGA009, has recently been shown to negatively regulate a p-
coumarate catabolic operon. Unlike most characterized MarR repressors that respond to small 
metabolites at concentrations in the millimolar range, repression by CouR is alleviated by the 800 
Da ligand p-coumaroyl-CoA with high affinity and specificity. Here we report the crystal 
structures of ligand free CouR as well as the complex with p-coumaroyl-CoA, each to 2.1 Å 
resolution, and the 2.85 Å resolution cocrystal structure of CouR bound to an oligonucleotide 
bearing the cognate DNA operator sequence. In combination with binding experiments which 
uncover specific residues important for ligand and DNA recognition, these structures provide 
glimpses of a MarR family repressor in all possible states, allowing for an understanding for the 
molecular basis of DNA binding and the conformation alterations that accompany ligand-induced 
dissociation for activation of the operon.7  
 
1.2 INTRODUCTION 
Proteins of the Multiple antibiotic resistance Regulator (MarR) family constitute a large 
group of transcription factors that are widespread in bacteria and archaea. These transcription 
                                               
a This research was originally published in the Journal of Biological Chemistry. Part of this 
chapter was directly obtained, with permission, from: 
 
Cogan DP, Baraquet C, Harwood CS, and Nair SK. Structural Basis of Transcriptional 
Regulation by CouR, a Repressor of Coumarate Catabolism in Rhodopseudomonas palustris. J 
Biol Chem. 2018 Jul 27;293(30):11727-11735. Copyright © 2018, the American Society for 
Biochemistry and Molecular Biology.   
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factors control gene expression to regulate such diverse processes as antibiotic resistance, stress-
response, aromatic carbon source catabolism, and virulence. An analysis of 19 major families of 
bacterial transcription factors recently implicated the MarR family as a significant contributor, 
comprising roughly 8% of the total proteins analyzed. With ca. 130,000 deposited bacterial 
genomes to date nearly doubling annually, many MarR-family members have and will be 
annotated as such, however less than 1% of these sequences have been fully characterized with 
respect to physiological function. The founding member of this family was first identified in 
multidrug resistant E. coli, where the MarR protein regulates an operon encoding the AcrAB-TolC 
multidrug efflux system, in response to a wide range of antibiotics and phenolic.8–14 
Most MarR homologs act as gene repressors, and a typical organization of locus orients 
the marR gene distally from the genes that are under transcriptional control. The intergenic region, 
typically at sites that overlap the -10 and -35 promoter elements, contains a 16-20 base-pair 
palindromic DNA sequence that harbors the binding site for the transcriptional regulator. Binding 
of a MarR homodimer to this palindromic region represses expression of both the gene that is 
regulated as well as the repressor itself. Dissociation of the repressor from DNA and activation of 
gene expression occurs when binding of a small molecule ligand alters the conformation of the 
MarR homodimer. As a result of this autoregulated expression, the physiological concentrations 
of the repressor itself change very slightly, allowing for an exceptionally sensitive response to 
ligand concentrations.  
Structural studies of MarR homologs reveals two sets of N- and C-terminal α-helices that 
facilitate dimerization, and two winged helix-turn-helix motifs (wHTH) that bind to the 
palindromic DNA duplex via spacing that is established by dimer formation. Each monomer binds 
to one half-site of the palindromic DNA inverted repeat sequence, and residues along the 
dimerization interface help to establish the spacing between the two half-sites. Disruption of dimer 
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formation results in a loss in DNA binding affinity and a loss of the corresponding drug resistance 
phenotype. A clade of MarR members responds to oxidative stress through the oxidation of Cys 
residues, which results in a change to a conformation that is incompatible with DNA binding. 
Biochemical and biophysical studies on MarR family members are limited by low binding affinity 
for cognate ligands, which often results in confounding data. For example, several small molecule 
ligands can bind to MarR factors at multiple sites, and the physiological relevance of these 
interactions is unclear.15,16 
A recent analysis of the pathway for the catabolism of the aromatic compound p-coumarate 
by the alpha-proteobacterium Rhodopseudomonas palustris CGA009 revealed that genes encoding 
the enzymes for this pathway are regulated by a MarR-like transcriptional repressor. This soil  
 
Fig. 1.1: Overall structure of CouR, the p-coumarate catabolic operon, and multisequence alignment of related 
MarR family proteins. A, overall structure of the apo CouR homodimer labeled with secondary structural elements 
(one monomer is colored in plum and the other in sky blue, wHTH = α3-α4-β1-β2). B, the gene organization of the p-
coumarate catabolic operon regulated by CouR in R. palustris CGA009. Vertical black bars represent CouR binding 
motifs (GTTATAnnnTATAAC). C, coumarate catabolism pathway in R. palustrisCGA009. The plant-derived 
starting material p-coumaric acid is converted to its aryl-CoA thioester (pCC) by an ATP-dependent CoA ligase 
(CouB), followed by hydration of the alkene and retro-aldol cleavage catalyzed by CouA to afford p-
hydroxybenzaldehdye, which is readily oxidized to p-hydroxybenzoic acid and shunted into aromatic acid degradation 
or fatty acid metabolism. D, sequence of oligonucleotide duplex used in crystallization. E, a multisequence alignment 
of MarR family proteins featuring CouR from R. palustris CGA009 (CouR-RP), CouR from R. jostiiRHA1 (CouR-
RJ), MepR, HcaR, MexR, and PcaV.10,11,20–22 
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bacterium utilizes plant-derived phenylpropanoids, including p-coumarate, as carbon sources by 
first converting them to acyl/aryl-CoA and subsequently to p-hydroxybenzoates, which  are 
degraded aerobically by an oxidative meta-ring cleavage pathway or anaerobically by a reductive 
aromatic ring degradation pathway.17,18 In R. palustris, the transcription of an operon that encodes 
for enzymes involved in the catabolism of p-coumarate to p-hydroxybenzoate is under the control 
of a MarR family regulator named CouR. Recombinant CouR was shown to bind to an inverted 
repeated sequence in the -10 region of the promoter, and DNA binding was disrupted by the 
addition of low micromolar concentrations of p-coumaroyl-CoA (pCC) (Fig. 1.1 B,C).8,17,19 
An orthologous pathway for aromatic acid catabolism has been identified in Rhodococcus 
jostii RHA1, which also utilizes a similar strategy of CoA-thioesterification, followed by β-
oxidative deacetylation to generate hydroxybenzoates. However, the constituent enzymes encoded 
by this operon are different from those of R. palustris. For example, the R. jostii RHA1 cluster 
encodes an aryl-CoA dehydrogenase, and an aryl-CoA ligase (CouL) that can utilize 
dihydroferulate as a substrate, suggesting that the pathway functions on dihydro-p-
hydroxycinnamic acids rather than their unsaturated p-hydroxycinnamate counterparts. Lastly, 
although the MarR family repressor that regulates the R. jostii RHA1 operon has been named 
CouR, the sequence identity of this polypeptide to R. palustris CouR is only 36%, and the DNA-
binding site is divergent in sequence and size, as it contains a 5 nucleotide spacer between the two 
half-sites, rather than the 3 nucleotide spacer in the R. palustris promoter.23 
The R. palustris CouR represents a rare example of a MarR family regulator for which a 
physiologically relevant ligand has been verified, and the cognate ligand is shown to bind to the 
receptor with low-micromolar affinity. In order to elucidate the mechanism for recognition of the 
target promoter, and how binding of a large ligand compromises a protein-DNA interaction to 
relieve transcriptional repression, we determined the cocrystal structures of CouR in complex with 
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a 23-nucleotide duplex inverted repeat corresponding to the physiological DNA binding site (to 
2.85 Å resolution; Fig. 1.2A) and the corresponding structure of the repressor in the inactive state, 
bound to pCC (to 2.1 Å resolution; Fig. 1.3 A,B). The function of specific amino acids in DNA or 
ligand recognition were probed by analysis of structure-based site-specific variants using 
electrophoretic mobility shift assays (EMSAs; for DNA binding) or differential scanning 
fluorimetry (DSF) assays (for ligand binding). The combined biochemical and structural biological 
data provide a framework for understanding transcriptional regulation by CouR, which further 
extends the existing knowledge of MarR family repressors. 
 
1.3 RESULTS 
1.3.1 Structure determination and overall structure 
Cocrystallization efforts with CouR and various synthetic oligonucleotides bearing the 
inverted repeat DNA recognition sequence yielded several candidates, but most of these crystals 
did not diffract beyond 3.5 Å resolution. Altering the length and identity of the nucleotides flanking 
the recognition sequence finally produced crystals that diffracted to 2.85 Å resolution at an 
insertion device synchrotron beamline. Structures of ligand-free CouR and a complex with 
synthetic pCC each produced crystals that diffracted to 2.1 Å resolution. Due to ease of 
reproducibility, structure determination focused on using crystals of the CouR-DNA complex, and 
crystallographic phases were determined by the single wavelength anomalous diffraction method 
from data collected on crystals of selenomethionine labeled CouR. The apo-CouR and CouR-pCC 
structures were determined by molecular replacement using the coordinates of the polypeptide 
from the DNA-bound structure, followed by manual rebuilding of the polypeptide. 
The overall structure of the CouR homodimer is triangular in shape with a pseudo two-fold 
axis of symmetry. Each monomer consists of six α-helices and two β-strands containing a wHTH 
 8 
motif, where helices α3-α4 and strands β1-β2 define the DNA binding elements (Fig. 1.1 A,D). 
Dimerization between the two monomers is mediated by interlocking interactions between helices 
α1, α5, and α6 from each monomer, resulting in a burial of 4,487-4,497 Å2 of solvent-accessible 
surface area (depending on the conformational state). Dimerization between the two monomers is 
mediated by extensive burial of numerous hydrophobic residues to form the structural core. 
Residues at this interface include Leu51, Leu55, Val62, Phe66 from helix α1; Val152, Leu160, 
Leu164 from helix α5; and Leu172, Leu176, Ile179 from helix α6. Additional interactions include 
intramolecular (Asp65-Arg159), as well as intermolecular (Glu46-Lys149, Glu49-Arg169) salt 
bridges. Most notably, electron density is sparse for the β-strands that contain the wHTH motif, 
and the wings show different conformation for each of the two monomers. There is also weak 
density in the presumptive binding-pocket for one of the monomers, which may reflect a weakly 
bound molecule of HEPES from the buffer component, but this was too poorly defined and not 
modeled. 
A DALI search of the CouR monomer against the Protein Data Bank reveals a strong 
conservation of secondary structural elements with other transcriptional regulators. The closest 
homologs include a putative regulator of unknown function from Pseudomonas aeruginosa (PDB 
code 2NNN; Z-score of 17.5; RMSD of 1.4 Å over 133 aligned Cα atoms); the Streptomyces 
coelicolor β-ketoadipate regulator PcaV (PDB code 4FHT; Z-score of 17.1; RMSD of 2.7 Å over 
141 aligned Cα atoms); Escherichia coli MarR (PDB code 3VOE; Z-score of 17.1; RMSD of 2.7 
Å over 136 aligned Cα atoms); and the multidrug efflux regulator MexR from Pseudomonas 






Fig. 1.2. CouR–DNA cocrystal structure and EMSA. A, overall structure of CouR bound to its couR operator DNA 
sequence represented in two 90° related orientations. Gray rectangles highlight the location of α4 in the major groove. 
Minor groove protein–DNA interactions are mediated by a looped region between strands β1-β2 (khaki and green). B, 
the 23-mer dsDNA duplex used in cocrystallization experiments with CouR. C, close-up view of the wHTH motif 
with specific contacts labeled. Asn-107 forms bidentate hydrogen bonds with A15′, Gln-94 hydrogen-bonds with the 
phosphate of T6, Arg-130 interacts electrostatically with the T22′ phosphate, and Arg-131 forms multiple nucleobase 
interactions in the minor groove (e.g. T3, T22′, and A23′; see Ref. 7 Fig. S4 for a more comprehensive 2D diagram of 
CouR–DNA contacts). D, EMSAs showing the binding of CouR variants to the couA promoter (see Ref. 7 Fig. S1 for 
SDS-PAGE analysis of CouR variants). Purified CouR proteins were incubated at different quantities (2, 4, or 8 pmol) 
with 0.3 pmol of a 317-bp DNA fragment containing the couA promoter (see “Experimental procedures”). The 
reaction mixtures were separated on polyacrylamide gels. The last panel summarizes the results obtained with 4 pmol 
of protein. 
 
1.3.2 Cocrystal structure of CouR with operator DNA 
The cocrystal structure of CouR bound to a 23-basepair duplex bearing the two half-sites 
was determined to 2.85 Å resolution from crystals containing 2 copies of the CouR dimer-DNA 
duplex complex in the asymmetric unit (ASU). The CouR homodimer is situated on the pseudo-
palindromic duplex such that helix α4 from the wHTH motif is positioned into each of the two 
half-sites along consecutive major grooves that are roughly 34 Å apart. The DNA duplex is roughly 
B-form but is under-twisted by 1.3°, resulting in a shortening of the end-to-end distance by roughly 
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3.8 Å, relative to canonical B-DNA. Notably, these deviations arise from a widening of the major 
grooves, in order to accommodate binding of the CouR α4 recognition helix, and a corresponding 
slight narrowing of the minor groove (Fig. 1.2). 
Each CouR monomer contacts each half of the inverted repeat sequence through 
interactions with the wHTH motif, with the α4 helix positioned in the major groove and strands 
β1-β2 of the wHTH making contacts with nucleotides on the outer periphery of the recognition 
sites. As in other structures of MarR family regulators in complex with their cognate operator 
sequences, the number of contacts between CouR and DNA bases of the inverted repeat is limited. 
The only base-specific interaction occurs at helix α4 between the carboxamide of Asn107 and N6 
and N7 of Ade15. Van der Waals contacts with DNA bases of the recognition sequence are 
mediated via the wedging of Pro106 into the segment encompassing Thy6-Thy7-Ade8 of one 
strand, and the corresponding bases of the complementary strand. The Pro106-Asn107 sequence 
comprises the first two residues of the α4 helix, and the combination of extensive van der Waals 
contacts and sequence specific interactions mediated through these two residues establish the 
orientation of the recognition helix within the major groove of each half site.  
The wing portion of the DNA-binding region, spanning residues Val122 through Leu135 
(from strands β1-β2), mediates additional contacts with nucleotides at the periphery of the 
recognition sequence. Electron density for both strands, as well as for the intervening loop, is clear 
and continuous in the DNA cocrystal structure. Residues within the loop of this region are situated 
in the minor groove and are involved in extensive non-specific contacts with the DNA backbone. 
The phosphate backbone of the DNA duplex is within hydrogen bonding distance of several 
residues including the side chains of Arg123, Arg125, Arg130, Arg131, Ser132, and His133, as 
well as the main chain carbonyl of Ser128. The side chain of Arg131 is poised within hydrogen-
bonding distance of Thy3, but this nucleotide is outside the recognition half-site, and is not part of 
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the inverted repeat sequence of the naturally occurring couA operator. Arg131 interacts with the 
side chain carboxylate of Asp129 via a salt-bridge, and this Asp-X-Arg pairing, along with a 
similar interaction with thymine, is observed across various MarR family members.20,23–26 
Outside of interactions with the wHTH motif, there are a few additional residues that make 
contact with the DNA backbone. Specifically, the side chain of Lys56 (equivalent to Arg10 in 
MepR and Tyr19 in OhrR) from helix α1 is situated directly above the phosphate of Thy14, which 
is located at the inner periphery of the inverted repeat. As a result, interactions between equivalent 
Lys56 residues from each monomer occur at either side of the minor groove. In the CouR cocrystal 
structure, Asn107 makes direct interactions with the Ade15 nucleobase, and equivalent residues 
in MepR (Thr63) and OhrR (Thr70) are also involved in base pair recognition. Lastly, Gln94 
(equivalent to Gln50 in MepR) is located in helix α3 and is part of a framework of interactions 
with the phosphate of Thy6, which also engages Arg123 and His133 from each of the strands of 
the wing (for a detailed CouR-DNA interaction map, see Ref. 7 Fig. S4).  
 
1.3.3 Electrophoretic mobility shift assay (EMSA) 
In order to probe the CouR-DNA contacts in detail, we generated site-specific variants 
corresponding to a number of residues within the α4 helix, the β1-β2 wing, and two residues 
located outside of these elements, and probed the effects of each mutation on DNA binding using 
EMSAs (Fig. 1.2D). Four distinct bands are observed when the couA promoter fragment is 
presented with CouR, corresponding to four distinct oligomeric states, with the highest mobility 
band corresponding to free DNA. The presence of two bands observed at high protein 
concentrations (i.e. 8 pmol lanes for CouR wild-type and Asn107àAla in Fig. 1.2D) is likely a 
result of quaternary interactions between CouR-couA promoter complexes in non-denaturing 
conditions. Mutation of the highly conserved Arg131 to Ala completely abolished DNA-binding 
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activity, as previously observed in studies of the S. aureus multidrug resistance regulator MepR.20 
This result is reconciled by the crystal structure as numerous contacts are made between Arg131 
and the minor groove of the DNA binding partner. The Arg130àAla variant also shows a 
significant reduction in DNA binding, reflecting the multiple roles that this residue plays as both 
part of the Asp-X-Arg pairing common across MarR members, as well as facilitating interactions 
with the phosphate backbone. Notably, Arg130 is not conserved across other orthologs, and its 
provision in DNA interactions may be unique to CouR (Fig. 1.1D). 
Other notable residues identified in the EMSA as important for binding include Lys56 and 
Arg125 which form electrostatic interactions with the DNA phosphate backbone, and Gln94 that 
interacts with the phosphate group of Thy6 (Fig. 1.2D and Ref. 7 S4). Alanine mutations at these 
residues resulted in observable decreases in the formation of higher molecular weight complexes. 
The modest effect of the Gln94àAla variant suggests that while the DNA interaction mediated by 
this residue is important, it is not absolutely essential. Notably, the Asn107àAla variant results in 
a mobility shift commensurate with wild-type CouR suggesting the base-pair interaction is not 
important for binding.   
 
1.3.4 Cocrystal structure of CouR with ligand p-coumaroyl-CoA (pCC) 
CouR was observed to bind pCC in a 1:1 stoichiometric ratio without disruption of the 
homodimeric interface also observed in the ligand-free CouR and CouR-DNA cocrystal structures 
(Fig. 1.3A,B). The ligand-free and pCC-bound structures are very similar demonstrating that 
binding of the ligand does not cause any appreciable changes in global or local structure of CouR 
(Fig. 1.4A). A major difference between the two structures is reflected in the orientation of the β-
strands of the wHTH motif, which are partially disordered in the ligand-free structure but are well 
resolved in the pCC-bound structure. Moreover, the strands of each monomer in the pCC-bound 
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structure are nearly superimposable, suggesting that ligand binding may restrict the flexibility of 
these strands. 
Recognition of pCC appears to be driven primarily by hydrophobic interactions between 
the coumaroyl moiety of pCC and one of two equivalent clefts (one per monomer) in addition to 
some hydrogen bonding and hydrophobic interactions along the pantetheine group of pCC. The 
cleft exists adjacent to the dimeric interface surrounded by residues from helices α1, α2, and α5 
(e.g. Phe63, Phe66, Pro77, and Phe80) of one monomer in addition to residues from helix α1 (e.g. 
Leu47 and Tyr53) of its neighboring monomer comprising the homodimer. CouR residue Asn107, 
which is involved in base pair recognition of Ade15 of the operator, also interacts with a backbone 
amide of pCC.  
The location and secondary structural composition of this hydrophobic cleft is analogous 
to those observed in structures of MarR-family members bound to various phenolic acids and 
aldehyde ligands lacking coenzyme A.10,15,21,27 Sufficient electron density was observed to model 
four pCCs bound to four CouR monomers in the crystallographic ASU. Additional interactions 
near the opening of the cleft include hydrophobic contacts between the side-chain of Ile103 and 
the geminal dimethyl group of pCC as well as hydrogen bonding between the side-chain of Thr76 
and the β-phosphate of pCC (Fig. 1.3A).  
The electron density corresponding to the adenosine nucleotide of pCC is ambiguous, 
indicative of disorder due to the minimal interactions of this moiety with the protein and its 
residence within a solvent pocket in the crystal lattice. Similar disorder has been observed for the 
adenosine group in other CoA bound structures.28,29 These cross-subunit interactions with the pCC 
ligand result in an inward constriction of the second subunit upon binding of the ligand to the first 
subunit (Figs. 1.3A,B and 1.4A). 
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Fig. 1.3: CouR–pCC cocrystal 
structure and summary of DSF binding 
constants. A, simulated annealing 
difference Fourier map (Fo-Fc) contoured 
at 3σ reveals an electron density 
corresponding to pCC (dark khaki) bound 
to CouR. Each ligand is embedded in a 
hydrophobic cleft comprised of residues 
from both monomers of the homodimer 
(colored either plum or sky blue). 
Additional residues from the monomer 
in plum engage the phosphopantetheine 
group of pCC (i.e. Thr-76, Ile-103, and 
Asn-107). The electron density 
corresponding to the adenine ring is 
spurious. B, overall structure of CouR 
bound to pCC retains the homodimeric 
oligomerization state and binds pCC 
symmetrically in a 1:1 fashion. C, 
summarized dissociation constants of 
site-directed CouR variants analyzed by 
DSF (see Ref. 7 Fig. S1 for SDS-PAGE 
analysis of CouR variants). Mutation of 
Phe-63 to Ala results in the greatest 
reduction of binding affinity (see 
“Experimental procedures” and Ref. 
7 Fig. S2 for individual binding curves). 
The overall structures of the CouR monomer in either DNA or pCC bound forms do not 
differ appreciably, with an RMSD of 0.85 Å over 891 atoms. However, superimposition of CouR 
dimers (RMSD of 2.35 Å over 2061 atoms) reveals notable changes that occur in the quaternary 
structure especially with regards to the wHTH motif that mediates DNA binding. Specifically, a 
superposition of dimers of the DNA bound CouR with that of the pCC bound structure reveals that 
the wHTH motif is shifted outwards by 5 Å in the former structure, which facilitates a disposition 
compatible with binding of the homodimer across consecutive major grooves of the operator (Fig. 
1.4). Binding of DNA resulted in an outward shift of helix α4 that forms a portion of the pCC 
binding cavity, such that the wings of the wHTH motif are also suitably positioned for interactions 
with the duplex. The collapse of helix α4 necessary to form a viable pCC binding pocket would 
result in a CouR dimer that is not optimally aligned for binding across consecutive major grooves, 
suggesting a mechanism for ligand-mediated attenuation of operator binding. There are no relative 
rotational movements of the two CouR monomers between the DNA and pCC bound structures, 
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such as that observed in comparisons of ligand and DNA bound structures of the MarR related 
Rv2887 from M. tuberculosis.30 
Fig. 1.4: Comparative analysis of CouR structures reveals the structural basis for ligand-induced disruption of 
DNA binding. A, superposition of DNA-bound (sky blue) and pCC-bound (forest green) CouR homodimers reveals 
differences in global structure. Two representations are related by a 90° rotation about the axis, depicted by a black 
arrow. The top right shows only the wHTH motifs for clarity and the symmetrical, ligand-induced 5-Å inward shift 
that compromises protein–DNA contacts in the major and minor grooves. B, superimposition of pCC-bound CouR 
onto one of the monomers in the CouR–DNA structure accentuates the motion of helix α4 at one-half of the 
symmetrical binding site. Three 90° related orientations of the superposition are displayed with measurements of 
relative angles (bottom left) and separation between helices α4 (bottom right). 
 
1.3.5 Differential scanning fluorimetry (DSF)  
On the basis of the observed crystallographic contacts between CouR and pCC, residues 
involved in hydrophobic contacts (Phe63 and Ile103) and hydrogen-bonding interactions (Thr76 
and Asn107) were mutated to Ala. To probe the contributions of each residue to ligand binding, 
we carried out differential scanning fluorimetry (DSF) analyses for each variant. As the protein-
ligand complex demonstrated an increased melting temperature (Tm), melting curves were 
monitored as a function of pCC concentration, enabling the measurement of dissociation constants 
(KD) between pCC and each CouR variant.31  
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Analysis of wild-type CouR with pCC yielded a KD value of 68 ± 8 μM. The Phe63àAla 
and the Thr76àAla variants showed the greatest effect on the KD values for pCC binding. This 
result is consistent with crystallographic observations, which shows that Phe63 serves as a major 
contributor to the hydrophobic pocket that houses the ligand, and an Ala substitution at this site 
would likely compromise the integrity of the pCC binding pocket. Likewise, Thr76 is within 
hydrogen bonding distance of pCC, with a distance of 2.7 Å between the Oγ of this residue and 
the β-phosphate of pCC (Fig. 1.3).  
Notably, the thermal denaturation midpoint (Tm) of the Thr76àAla variant had decreased 
by 10 °C, relative to the wild-type. Consequently, this variant was tested to ensure it was properly 
folded and formed the requisite homodimeric assembly. Analytical size-exclusion 
chromatographic (SEC) analysis performed on CouR wild-type and the Thr76àAla variant 
resulted in retention times expected for that of a 40 kDa homodimer (see Experimental procedures 
and Ref. 7 Fig. S3). The Ile103àAla variant displays a slight binding impairment upon 
replacement of the sec-butyl group with a methyl group in the position found to associate with the 
geminal dimethyl group of pCC. No appreciable binding impairment was observed for the 
Asn107àAla mutant suggesting that proximity of Asn107 to the amide carbonyl of pCC may not 
be critical for tight binding of the pCC ligand (Fig. 1.3).  
 
1.4 DISCUSSION  
Detailed biochemical studies on MarR family proteins are often hampered due to a lack of 
details regarding the physiological effector. Even though surrogate small molecules may function 
at the protein level, the relevance of binding by such effectors is sometimes not clear. Here, we 
present a detailed characterization of CouR, a repressor of a p-coumarate catabolic pathway for 
which the genetic, and microbiological analyses have been carried out in detail.8,19 We complement 
 17 
the earlier studies using biochemical and structural biological approaches to elucidate details of a 
MarR member visualized in three different states: without any bound ligand, bound to the cognate 
operator element, and bound to the physiological effector molecule. Unlike other studies of MarR-
family members, pCC the effector for CouR is not metabolically ubiquitous, and the extensive 
contacts made throughout the entirety of this structurally unique ligand affords an unbiased 
delineation of the structural details with a bound ligand. To further dissect the mechanism of 
ligand-induced dissociation, additional studies will be necessary to confirm whether pCC binds 
directly to the CouR-DNA complex or free CouR.   
A prior effort also characterized a CouR-like pathway encoded in the soil bacterium 
Rhodococcus josti RHA1 (CouR-RJ).23 That system is distinct in that not all of the genes proposed 
in the catabolic pathway are within the same operon. Based on the sequences of the different 
promoters, it was proposed that a single repressor may regulate transcription, even though the 
promoters are divergently transcribed. Notably, the promoter sequence identified in R. josti RHA1 
(cATTGAnnnnnTCAATg) is entirely distinct from the R. palustris CGA009 CouR (CouR-RP) 
responsive promoter (GTTATAnnnTATAAC), and the two MarR-type regulators share only 36% 
sequence identity. The authors provide a molecular basis for DNA binding attenuation which 
invokes the sequestration of two Arg residues (numbered 36 and 38 in CouR-RJ; Fig. 1.1D) by 
pCC, however these residues are not present in CouR-RP, and similar contacts were not observed 
in the CouR structures presented here. Moreover, superimposing the CouR-RP DNA-bound 
structure with the orthologous CouR-RJ pCC-bound structure reveals that the separation of helices 
α4 are nearly equidistant, suggesting compatibility with major groove binding and a unique 
mechanism of repression (see Ref. 7 Fig. S5).   
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The crystal structure of CouR bound to the operator supports the idea of an indirect 
sequence readout, first suggested by Dolan et al. in the context of the SlyA-DNA structure.25 This 
is a result of primarily non-base specific contacts mediating DNA recognition and is corroborated 
by existing MarR-family/DNA cocrystal structures in the Protein Data Bank.20,24–26 The 
unexpected finding that many of the protein-DNA contacts are actually non-base-specific lends 
credence to the notion of an indirect sequence readout and suggests that newer in silico techniques 
may be necessary to predict three-dimensional topologies for correct assignment of protein-DNA 
binding partners. Indeed, computational techniques involving comparative and machine learning 
strategies have been utilized to predict protein-DNA binding interactions.32 Predictive methods 
will hopefully benefit from the experimental structures in this work to understand similar MarR 
family regulators for which experimental data is lacking.  
 
1.5 METHODS 
1.5.1 Cloning, expression, and purification of CouR 
The CouR gene was amplified by the polymerase chain reaction from purified 
Rhodopseudomonas palustris genomic DNA using the following set of primers: 5’ 
GCACAGGATCCGTGACCTCGTCGAACAGGATC 3’ (forward) and 5’ TAACACTC 
GAGTCAGAACTCGCGGGCGATGG 3’ (reverse). The PCR product was digested with BamHI 
and XhoI and ligated into a similarly digested pET28-MBP expression vector using T4 DNA ligase 
(NEB). The presence of CouR was tested by restriction digest analysis and verified by di-deoxy 
sequencing (ACGT Inc.) The resulting construct encodes a fused maltose-binding protein (MBP) 
protein followed by a hexahistidine (His6) affinity tag preceding the CouR reading frame.        
The recombinant plasmid described above was used to transform Escherichia coli (Rosetta) 
for overexpression of MBP-CouR. E. coli cultures were grown with shaking at 250 rpm in LB 
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medium supplemented with kanamycin (50 µg/mL) and chloramphenicol (25 µg/mL) until an 
OD600 of 0.5-0.6 was reached. The cultures were induced with 0.5 mM IPTG after cooling on ice 
for 20 min and grown for an additional 16 h at 18 °C. Cells were harvested by centrifugation at 
3500 rpm and resuspended in buffer A (500 mM NaCl, 25 mM Tris-HCl pH 8.0, and 10% glycerol) 
before lysing with a French-press at 8,000-10,000 psi for 4 cycles. The lysate was cleared by 
centrifugation at 14,000 rpm for 1 h at 4 °C and the supernatant was loaded on a 5 mL HisTrap 
nickel-nitrilotriacetic acid (Ni-NTA) affinity column (GE Healthcare) equilibrated with buffer B 
(1 M NaCl, 25 mM Tris-HCl pH 8.0, and 30 mM imidazole). The column was washed with 40 mL 
of buffer B before eluting with a linear gradient from 0-100% buffer C (1 M NaCl, 25 mM Tris-
HCl pH 8.0, and 250 mM imidazole) over 20 min at 2 mL/min. CouR was then subjected to TEV 
protease proteolysis at 4 °C to remove the MBP-tag while being dialyzed into 250 mM NaCl, 20 
mM Tris pH 7.5, and 1 mM DTT. The reaction ran to near completion after 24 h (as monitored by 
SDS-PAGE) before dialyzing into 250 mM NaCl, and 20 mM Tris-HCl pH 7.5 to remove DTT 
before subtractive nickel purification. Reaction contents were loaded onto a Ni-NTA column 
equilibrated with buffer A followed by a 30 mL wash with buffer A. Proteins were eluted in 4 mL 
increments using the following stepwise gradient of increasing buffer B: 5%, 10%, 20%, 30%, and 
100%. This was followed by additional stepwise elution steps of increasing buffer C: 50% and 
100%. Fractions containing CouR were dialyzed into 100 mM NaCl, 20 mM Tris-HCl pH 7.5 at 4 
°C before loading onto a 5 mL HiTrap SP HP column (GE Healthcare) equilibrated with buffer D 
(100 mM NaCl, 50 mM bicine pH 7.5). The column was washed with 20 mL of buffer D before 
eluting with a linear gradient of increasing buffer E (1 M NaCl, 50 mM bicine pH 7.5) for 35 min 
at a flow-rate of 1.5 mL/min. CouR-containing fractions indicated ≥95% purity by SDS-PAGE 
analysis (see Ref. 7 Fig. S1).  
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1.5.2 Differential scanning fluorimetry (DSF) binding assay 
CouR wild-type and mutant proteins were purified as described above followed by gel-
filtration on a 120 mL Superdex 75 column (GE Healthcare) in 50 mM KCl, 0.5 mM 2-
mercaptoethanol, 20 mM HEPES pH 7.0. The DSF assay was performed on a StepOnePlus RT-
PCR instrument (Applied Biosystems) using a 96-well plate format. Wild-type and mutant proteins 
were subjected to increasing concentrations of pCC from 0-10 mM while maintaining a constant 
protein concentration of 68 µM and 6X SYPRO orange dye (prepared from a 5,000X stock in 
DMSO). Samples were allowed to equilibrate for 30 minutes prior to initiating the melt curve. The 
melt curve program initiated with a 2 minute 25 °C hold step followed by a ramp up to 99 °C at 
1.7 °C/min (step and hold) and a final hold for 2 minutes at 99 °C. First derivatives of the melting 
curves were used to determine the Tm for each sample well. Plots were fit to a dose response curve 
using OriginPro 2015 and KD was taken to be equal to the substrate concentration at which melting 
temperature achieved 50% of the total change. 
 
1.5.3 Analytical size-exclusion chromatography (SEC) 
Analytical SEC was performed using a 40 mL Superdex 200 10/300 GL column (GE 
Healthcare) equilibrated with 0.1 M NaCl, 20 mM Tris pH 7.0. A similar running buffer was used 
to elute protein standards prepared from commercially available dry lyophilized powders (Sigma-
Aldrich Co.) at 1 mL/min. CouR variants were eluted similarly (see Ref. 7 Fig. S3).  
 
1.5.4 Crystallization and structure solution of CouR-couR operator complex 
Single-stranded DNA oligomers were ordered from Integrated DNA Technologies (IDT) 
that were made up to 10 mM by solvating in 20 mM Tris pH 7.5, 50 mM NaCl. The complementary 
ssDNA solutions were mixed 1:1 before using a thermocycler to heat at 95 °C for 5 minutes 
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followed by a decrease to 25 °C at a rate of 1 °C per minute. A series of dsDNA sequences ranging 
from 16-29 bp and containing either blunt-end or single-nucleotide overhangs were screened for 
cocrystallization with CouR before arriving at the optimally diffracting 23 nucleotide sequence 
(23-mer) used in the final model. Crystals of CouR bound to the 23-mer were obtained by mixing 
15 mg/mL CouR with 1.1 stoichiometric amounts of 23-mer and incubating on ice for 20 minutes. 
This solution was mixed with an equal volume of reservoir solution containing 0.1 M Tris pH 8.5, 
0.1 M ammonium phosphate, and polyethylene glycol 6,000 to generate 2 µL hanging drops. Thin 
plate-shaped crystals grew at 16 °C to maximum size (about 100 x 100 μm) in less than a week.  
Crystals were cryoprotected in crystallization buffer supplemented with 25% glycerol and 
vitrified by direct immersion into liquid nitrogen prior to data collection. Structure determination 
was carried out using single-wavelength anomalous dispersion data collected from crystals of 
selenomethionine derivatized CouR bound to DNA, using Phenix AutoSol with a Bayesian 
estimate of the map quality.33 Data were collected at the Advanced Photon Source, Argonne 
National Lab using the Life-Science Collaborative Access Team (LS-CAT) 21-ID-F, 21-ID-G, 
and 21-ID-D beamlines. After determining the phases and initial model from Phenix AutoSol, each 
structure was rebuilt using Phenix AutoBuild with multiple rounds of manual intervention.34 This 
new model was further refined using CCP4 refmac5 in combination with additional manual 
rebuilding in COOT.35,36  
 
1.5.5 Crystallization and structure solution of CouR-pCC complex 
CouR was concentrated to 24 mg/mL, combined with 3 mM pCC, and crystallized at 9 °C 
in similar 2 µL hanging drops containing a reservoir solution of 0.17 M Li2SO4, 23.5% 
polyethylene glycol 4,000, 1 mM DTT, 0.085 M Tris-HCl pH 8.5, and 15% glycerol. Rod-shaped 
crystals grew to maximum size in less than a week to about 200 × 50 μm at the largest face. Prior 
to data collection, crystals were directly flash-frozen in liquid nitrogen. Data were collected at the 
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Advanced Photon Source, Argonne National Lab using the Life-Science Collaborative Access 
Team (LS-CAT) 21-ID-G beamline. The structure was solved by molecular replacement using the 
protein coordinates from the CouR-couR operator structure. Molecular replacement derived phases 
were used to build an initial model in Phenix AutoBuild, followed by similar refinement 
procedures as described for the CouR-couR operator complex. Prior to fitting pCC into electron 
density difference maps, restraint parameters and geometry optimizations were produced by 
Phenix eLBOW.37 Water molecules were incorporated in the CouR-pCC structure using Phenix 
Refine.38 
 
1.5.6 Crystallization and structure solution of apo CouR 
CouR was concentrated to 15 mg/mL and crystallized at 9 °C in 1 µL sitting drops by 
mixing 1:1 (v/v) protein solution and reservoir solution containing 60% (v/v) Tacsimate pH 7.0. 
Diamond shaped crystals grew to maximum size in less than a week. The structure was solved by 
molecular replacement in a similar manner to that described for the CouR-pCC cocrystal structure. 















Lantibiotics are ribosomally synthesized and post-translationally modified antimicrobial 
peptides containing thioether rings. In addition to these cross-links, the clinical candidate 
lantibiotic NAI-107 also possesses a C-terminal S-[(Z)-2-aminovinyl]-d-cysteine (AviCys) and a 
unique 5-chloro-l-tryptophan (ClTrp) moiety linked to its potent bioactivity. Bioinformatic and 
genetic analyses on the NAI-107 biosynthetic gene cluster identified mibH and mibD as genes 
encoding flavoenzymes responsible for the formation of ClTrp and AviCys, respectively. The 
biochemical basis for the installation of these modifications on NAI-107 and the substrate 
specificity of either enzyme is currently unknown. Using a combination of mass spectrometry, 
liquid chromatography, and bioinformatic analyses, we demonstrate that MibD is an FAD-
dependent Cys decarboxylase and that MibH is an FADH2-dependent Trp halogenase. Most 
FADH2-dependent Trp halogenases halogenate free Trp, but MibH was only active when Trp was 
embedded within its cognate peptide substrate deschloro NAI-107. Structural comparison of the 
1.88 Å resolution crystal structure of MibH with other flavin-dependent Trp halogenases revealed 
that subtle amino acid differences within the MibH substrate binding site generates a solvent 
exposed crevice presumably involved in determining the substrate specificity of this unusual 
peptide halogenase. 
                                               
b This research was originally published in ACS Chemical Biology. Part of this chapter was 
directly obtained, with permission, from: 
 
Ortega MA, Cogan DP, Mukherjee S, Garg N, Li B, Thibodeaux GN, Maffioli SI, Donadio S, 
Sosio M, Escano J, Smith L, Nair SK, van der Donk WA. Two Flavoenzymes Catalyze the Post-
Translational Generation of 5-Chlorotryptophan and 2-Aminovinyl-Cysteine during NAI-107 





Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a growing 
class of natural products containing a wide array of unique pharmacophores.39 These moieties are 
introduced on a ribosomally synthesized precursor peptide by dedicated biosynthetic enzymes and 
bestow upon these molecules their biological activities. As such, characterization of RiPP 
biosynthetic enzymes provides an avenue to harness the potential of these catalysts as tools for the 
development of chemoenzymatic methodologies to generate novel therapeutic peptides. 
Within RiPPs, lanthipeptides (lanthionine-containing peptides) encompass one of the most 
abundant and well-studied subfamilies to date.39 The key structural features defining lanthipeptides 
are thioether rings formed by the bis-amino acids lanthionine (Lan) and/or methyllanthionine 
(MeLan; Fig. 2.1a). These cross-links are introduced enzymatically viadehydration of select 
Ser/Thr residues to 2,3-dehydroalanine (Dha) and (Z)-2,3-dehydrobutyrine (Dhb), respectively, 
within the C-terminal core region of a precursor peptide (LanA), followed by subsequent Michael-
type additions of Cys thiols onto the newly generated dehydroamino acids (Fig. 2.1a).40,41 The 
enzymes responsible for catalyzing both modifications require an N-terminal leader peptide 
sequence within the precursor peptide for efficient processing.42,43 After thioether ring formation, 
one or more proteases remove the N-terminal leader sequence from the precursor peptide releasing 
the mature natural product. Lanthipeptides exhibiting antimicrobial activity are known as 
lantibiotics (lanthionine-containing antibiotics). 
In addition to these common post-translational modifications, some lanthipeptides contain 
additional modified residues installed by tailoring enzymes. These modifications in many cases 
increase the stability and biological activity of the peptides. For instance, epilancin 15X contains 
an N-terminal lactate that serves to protect it against the action of aminopeptidases.44 Similarly, 
the lantibiotic NAI-107 (also known as microbisporicin) contains a C-terminal AviCys predicted  
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Fig. 2.1: Overview of NAI-107 biosynthesis. (a) Scheme for thioether ring formation during lanthipeptide 
biosynthesis. The enzymes that catalyze each step during NAI-107 biosynthesis are shown in parentheses. (Xn) 
connecting peptide. (b) Structure of NAI-107. The amino acid sequence of the precursor peptide MibA is shown. 
Negative numbers represent the position of amino acids within the leader peptide (underlined) with respect to the first 
amino acid in the core region. Dehydroamino acids, lanthionine, and methyllanthionine are shown in purple, red, and 
blue, respectively. The aminovinyl cysteine and 5-chlorotryptophan are colored green and orange. NAI-107 also 
contains a 3,4-dihydroxyproline moiety shown in cyan. (c) NAI-107 biosynthetic gene cluster. (d,e) Proposed 
reactions catalyzed by the enzymes (d) MibD and (e) MibH/MibS. Dhx, dehydroalanine or dehydrobutyrine; 
AviMeCys, S-[(Z)-2-aminovinyl]-(3S)-3-methyl-d-cysteine (Figure credit: Manuel Ortega and Wilfred van der Donk) 
 
to arise from the oxidative decarboxylation of a Cys residue within the NAI-107 precursor peptide 
(Fig. 2.1b).45 Presumably, this modification protects the peptide from carboxypeptidases and 
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removes a negative charge, which has proven beneficial for bioactivity in semisynthetic 
lanthipeptide analogs.46 In addition, NAI-107 contains a 3,4-dihydroxyproline (diHPro) and a 
unique ClTrp responsible for increasing its bioactivity 2-fold compared to its deschloro counterpart  
(Fig. 2.1b).45,47 The benefits these additional modifications confer to the stability and bioactivity 
of lantibiotics prompted biochemical characterization of the tailoring enzymes responsible for 
installing AviCys and ClTrp during NAI-107 biosynthesis. 
NAI-107 is a produced by the actinomycete Microbispora sp. 107891.45,48 NAI-107 acts as 
a peptidoglycan biosynthesis inhibitor by sequestering the cell wall precursor lipid II and is 
currently in preclinical trials for the treatment of multidrug resistant Gram-positive bacterial 
infections.49–51 NAI-107 biosynthesis commences with the translation of the precursor peptide 
MibA (Fig. 2.1b).48,52 Then, MibB dehydrates seven Ser/Thr residues within the core region of 
MibA in a glutamyl-tRNAGlu-dependent manner, and the lanthipeptide cyclase MibC catalyzes the 
nucleophilic addition of Cys residues onto five dehydroamino acids.53 The biosynthetic details 
regarding AviCys, ClTrp, and diHPro installation during NAI-107 biosynthesis are not known. 
Previous bioinformatic and genetic analyses of the NAI-107 biosynthetic gene cluster 
identified two genes coding for enzymes predicted to be responsible for the decarboxylation and 
halogenation (Fig. 2.1c).48 One of the open reading frames (ORFs), mibD, encodes an enzyme that 
has sequence similarity to lanthipeptide decarboxylases (LanD).54,55 These enzymes together with 
(R)-4′-phospho-N-pantothenoylcysteine (PPC) decarboxylases belong to the homo-oligomeric 
flavin-containing Cys decarboxylase (HFCD) superfamily that employs a flavin cofactor to 
catalyze the oxidative decarboxylation of C-terminal Cys-containing peptides (Fig. 2.1d).54–
56 Decarboxylation proceeds via oxidation of a Cys thiol to a thioaldehyde that subsequently serves 
to delocalize the negative charge developed at the former Cα upon decarboxylation.57–
61 Nucleophilic addition of the C-terminal aminoenethiolate to a nearby dehydroamino acid within 
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the core peptide yields the AviCys moiety (Fig. 2.1d).61 At present, it is unclear whether this latter 
reaction is catalyzed by lanthipeptide decarboxylases or lanthipeptide cyclases or if it proceeds 
nonenzymatically. 
A second ORF, mibH, shows homology to flavin-dependent Trp halogenases.48 Members 
of this enzyme class (Fig. 2.1e) use reduced flavin to activate molecular oxygen.62 A halide ion is 
believed to perform a nucleophilic attack onto the distal oxygen atom of a 4a-flavin hydroperoxide 
forming a hypohalite that subsequently transfers the halogen to a nearby conserved Lys residue 
(Lys102 in MibH). This chloramine intermediate is then believed to halogenate Trp.63–65 Within 
the NAI-107 biosynthetic gene cluster, mibS encodes a protein that shows sequence similarity to 
flavin reductases and is presumably responsible for providing reduced flavin to MibH (Fig. 2.1e).48 
In this study, we reconstituted the activity of MibD, MibS, and MibH in vitro. 
Decarboxylation assays revealed MibD to be specific for the C-terminal sequence in the precursor 
peptide MibA and to not require the N-terminal leader peptide for activity. MibH and MibS form 
an FAD-dependent halogenase system. Interestingly, halogenation assays with a panel of different 
substrate analogs revealed MibH to be highly specific for the modified MibA core peptide carrying 
thioether rings suggesting halogenation to occur in one of the last steps of NAI-107 biosynthesis. 
Last, the 1.88-Å-resolution crystal structure of holo MibH provides a structural basis for its 




2.3.1 Structural Characterization of MibH 
To determine the structural basis of such unusual peptide specificity, the crystal structure 
of MibH bound to FAD was determined to 1.85-Å resolution (Fig. 2.2a and Ref. 66 Supporting 
Information Table S2). MibH crystallized with four molecules in the asymmetric unit, and clear 
density corresponding to FAD and chloride ions was observed (Fig. 2.2b) in two out of four of  
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Fig. 2.2: Crystal structure of the lantibiotic halogenase MibH. (a) Overall cartoon representation of MibH. α 
helices are shown in purple. β sheets are shown in green. Flexible loops are shown in wheat, and the second protomer 
is shown in gray. FAD and the Cl– ion are shown as sticks and as a cyan sphere, respectively. (b) Simulated annealing 
omit difference Fourier map (Fo – Fc) contoured to 2.5σ of FAD and Cl–. The conserved Lys/Glu pair involved in 
chlorination is shown as sticks. The conserved WXWXIP motif is labeled in one amino acid code. (Figure credit: 
Satish Nair) 
 
these molecules, whereas spurious electron density was observed for the other two molecules. The 
overall structure of the MibH monomer consists of a large single domain consisting of a 
rectangular arrangement of several α-helices surrounding two β-sheets, with a triangular helical 
protuberance appended to the base of this rectangle. The FAD cofactor is positioned in a solvent 
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exposed groove, roughly parallel to the main body of each monomer, with the adenosine moiety 
positioned near one set of β-strands and the isoalloxazine ring situated at the other set of β-strands. 
MibH contains two signatures motifs that are conserved among other FADH2-dependent 
halogenases. The WxWxIP (Trp283-Pro288) motif, whose role in halogenation remains elusive, 
67 and the GxGxxG (Gly36-Gly41) flavin consensus sequence that is located in the vicinity of the 
FAD. A Lys/Glu pair that is catalytically relevant in other FADH2-dependent halogenases is also 
present in MibH (Lys102 and Glu355). In orthologous enzymes, the substrate Trp is located more 
than 10 Å away from the flavin and chlorination of the equivalent Lys facilitates halogenation via a 
covalent Lys chloramine intermediate.65 The conserved Glu may either facilitate proton 
abstraction from the Trp substrate following halogenation62 or enhance the electrophilicity of the 
chloramine. Electron density corresponding to a chloride ion is located at a pocket at the Re face 
of the isoalloxazine, where it interacts with the backbone amides of Ser357 and Gly358. Pro353 
forms the opposing edge of the binding pocket (Fig. 2.2b). As in other FADH2-dependent 
halogenases, the size of the binding pocket likely precludes the binding of halides such as iodide, 
but not bromide, consistent with the ability to purify brominated NAI-107 variants when the 
natural producer is supplemented with bromide sources.68 Comparison of MibH with other 
enzymes in the protein data bank (PDB) via the Dali server reveals a conserved global architecture 
shared among other Trp halogenases. The closest structural relatives to MibH include the 5-Trp 
halogenase PyrH involved in pyrroindomycin biosynthesis,69 and the 7-Trp halogenases PrnA and 
RebH from pyrrolnitrin and rebeccamycin biosynthesis, respectively,62,63 all of which utilize free 
Trp as a substrate but exhibit different regioselectivity. Visual inspection of the proposed MibH 
active site based on conservation of important catalytic residues and the spatial arrangement of 
FAD and chloride reveals that MibH has a noticeable larger accessible surface area in comparison 
to free-tryptophan utilizing halogenases, which likely serves to accommodate its larger peptidic 
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substrate (Fig. 2.3a). Interestingly, the similar structural topology of MibH to other FADH2-
dependent Trp halogenases suggests this larger crevice did not arise due to structural deletions. 
Instead, subtle amino acid variations within MibH are responsible for forming the cavity, as 
revealed by pairwise structural alignments of MibH with different members of this enzyme family. 
 
Fig. 2.3: Insights into the substrate specificity of the 5-tryptophan halogenase MibH. (a) Cartoon representation 
of the overall structure of (left) MibH and (right) PyrH(49) (PDB 2WET) with their respective substrate binding clefts 
shown as red surfaces. Color scheme is the same as in Figure 2.2. (b) Surface representation of the proposed Trp 
binding site (dashed white line) in (left) MibH and (right) PyrH colored by hydrophobicity (Figure credit: Manuel 
Ortega and Wilfred van der Donk).  
 
In the absence of a substrate-bound structure, we propose this region to serve as the 
substrate binding cleft in MibH. The CASTp server was used to identify residues delineating the 
proposed peptide binding site,70 allowing the calculation of its solvent accessible surface area in 
PyMOL, which reveals this region to be 718.5 Å2 larger than that of other members of this enzyme 
family. In addition, the greater relative hydrophobicity of the MibH binding cleft also supports its 
peptide substrate preference over free tryptophan (Fig. 2.3b). We next performed a docking 
analysis of MibH and its substrate deschloro NAI-107. Docking poses were obtained where the C-
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5 indole carbon is in closest proximity to the catalytic Lys102 with an 8.5-Å distance to its ε-
nitrogen (Fig. 2.4). For catalysis to occur, we envision this distance to be reduced upon substrate 
binding. 
 
Fig. 2.4: Autodock/Vina models of deschloro NAI-107 bound to MibH. (a, b) Two 
different conformations for deschloro NAI-107 were obtained differing mainly at the spatial arrangement of 
its C-terminus. (c) Distance measurement of the resulting deschloro NAI-107 bound models to the catalytic 
conserved Lys102 in MibH involved in chlorination (Figure credit: Satish Nair).  
 
2.4 METHODS 
2.4.1 MibH Structure Determination 
Following purification of MibH by nickel affinity chromatography as described in the SI, 
the protein was desalted by size exclusion chromatography using a HiLoad 16/600 Superdex 200 
column (flow rate of 1 mL min–1) connected to an ÄKTA purifier at 4 °C (buffer of 20 mM HEPES 
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at pH 8.0 and 150 mM KCl). Eluted protein was then concentrated to 22 mg mL–1 in the presence 
of 2 mM FAD prior to crystallization. Crystals were obtained within 24 h in hanging drops 
containing 12.5% MPD, 12.5% PEG 3.35K, 0.1 M MES/imidazole at pH 6.5, and 0.09 M NPS 
(1:1:1 NaNO3, Na2HPO4, (NH4)2SO4). Prior to data collection, crystals were transferred into the 
crystallization solution supplemented with 20% MPD and vitrified in liquid nitrogen. Data were 
collected at the Advanced Photon Source, Argonne National Lab using the Life-Science 
Collaborative Access Team (LS-CAT) 21-ID-G beamline. Raw data were integrated and scaled 
using the autoPROC software.71 The structure was determined by molecular replacement using the 
PHASER software72,73 and a modified model of PyrH (PDB: 2WET) with all nonidentical residues 
truncated to Ala. The initial model was further improved using Buccaneer74 and interspersed with 
rounds of manual building using COOT.36,75 Interim models were routinely adjusted through 
rounds of crystallographic refinement using Refmac5.35,76 Refinement converged to the final 
model for which statistics are presented in Ref. 66 Supporting Information Table S2. 
 
2.4.2 MibH-deschloro NAI-107 docking models 
Automated docking of deschloro NAI-107 onto the MibH coordinates were carried out 
using the Autodock/Vina PyMOL plugin.77 Ligand coordinates were obtained from the solution 
NMR structure of NAI-1079 and manually modified to generate deschloro NAI-107 with 
appropriate bond lengths. Details regarding two relevant poses are graphically represented in 









CHAPTER 3: STRUCTURAL INSIGHT INTO PYRIDINE FORMATION IN 
THIOPEPTIDE BIOSYNTHESISc 
 
3.1 ABSTRACT  
The [4+2] cycloaddition reaction is an enabling transformation in modern synthetic organic 
chemistry but there are only limited examples of dedicated natural enzymes that can catalyze this 
transformation. Thiopeptides (or more formally thiazolyl peptides) are a class of thiazole-
containing, highly modified, macrocyclic secondary metabolites made from ribosomally 
synthesized precursor peptides. The characteristic feature of these natural products is a six-
membered nitrogenous heterocycle that is assembled via a formal [4+2] cycloaddition between 
two dehydroalanine (Dha) residues. This heteroannulation is entirely contingent on enzyme 
activity, though the mechanism of the requisite pyridine/dehydropiperidine synthase remains to be 
elucidated. The unusual aza-cylic product is distinct from the more common carbocyclic products 
of synthetic and biosynthetic [4+2] cycloaddition reactions. To elucidate the mechanism of 
cycloaddition, we have determined atomic resolution structures of the pyridine synthases involved 
in the biosynthesis of the thiopeptides thiomuracin (TbtD) and GE2270A (PbtD), in complex with 
substrates and product analogs. Structure-guided biochemical, mutational, computational, and 
binding studies elucidate active site features that explain how orthologs can generate rigid 
macrocyclic scaffolds of different sizes. Notably, the pyridine synthases show structural similarity 
to the elimination domain of lanthipeptide dehydratases, wherein insertions of secondary structural 
                                               
c This research was originally published in the Proceedings of the National Academy of Sciences 
of the United States of America. Part of this chapter was directly obtained, with permission, 
from: 
 
Cogan DP, Hudson GA, Zhang Z, Pogorelov TV, van der Donk WA, Mitchell DA, Nair SK. 
Structural Insights into Enzymatic [4+2] Aza-Cycloaddition in Thiopeptide Antibiotic 
Biosynthesis. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):12928-12933. Copyright © 2017, 
National Academy of Sciences. 
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elements result in the formation of a distinct active site that catalyzes new chemistry. Comparative 
analysis identifies other catalysts that contain a shared core protein fold but whose active sites are 
located in entirely different regions, illustrating a principle predicted from efforts in de novo 
protein design.  
 
3.2 INTRODUCTION 
Thiopeptides are a class of ribosomally synthesized and post-translationally modified 
peptides (RiPPs)39 that display a range of biological activities.78–80 The identification of 
thiopeptides with impressive antibiotic activity towards drug-resistant Gram-positive bacteria, 
such as methicillin-resistant Staphylococcus aureus (MRSA), as well as others with 
antiproliferative and immunosuppressive activities, has spurred a resurgence in their research.78 
The antibacterial activity of thiopeptides is exerted through the inhibition of ribosomal protein 
synthesis. Curiously, the biological target of thiopeptides correlates with the size of the 
macrocyclic ring that embeds the heterocyclic core; thiostrepton and thiocillins (26-membered 
rings) inhibit the 50S ribosome, whereas GE2270 and thiomuracin (29-membered rings) (Fig. 
3.1A) bind to elongation factor thermal unstable (EF-Tu).81,82 To date, dozens of different types of 
thiopeptides have been identified, all of which share the class-defining 6-membered nitrogenous 
heterocycle that is at the center of a framework (pink circles) decorated with multiple thiazol(in)es 
(purple circles), and dehydro amino acids (green circles). The precursor peptide is of ribosomal 
origin and consists of a leader sequence that directs enzyme recruitment and a core sequence where 
the modifications occur.42,43,83 Access to many thiopeptide variants was facilitated owing to the 
precursor peptide being a direct gene product.80,84,85  
Reconstitution studies using purified enzymes have established both the nature and the 
timing of the modifications installed during the biosynthesis of thiomuracin from Thermobispora 
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bispora.86 Specifically, TbtG, a YcaO-type cyclodehydratase87 converts Cys residues in the core 
sequence of the TbtA precursor peptide to thiazolines, which are then dehydrogenated to the 
corresponding thiazoles. A split class I (LanB) lanthipeptide dehydratase88 modifies the resultant  
Fig. 3.1: Scheme of enzyme-catalyzed pyridine formation and leader peptide binding of the pyridine synthase, 
TbtD. (A) Chemical structures of representative thiopeptides with residues color-coded by posttranslational 
modification. (B) Proposed enzymatic route for the installation of the central nitrogenous six-membered ring from 
two dehydroalanine residues, followed by the elimination of water and the leader peptide. (C) Primary sequence and 
numbering scheme of the TbtA leader peptide with the fragment that is engaged by TbtD colored in green. (D) 
Competition fluorescence polarization binding experiments where TbtD saturated with fluorescently labeled full-
length leader peptide is challenged with either unlabeled full-length leader peptide (black curves), or fragments 
corresponding to the N-terminal (green curve and sequence) or C-terminal (purple curve and sequence) regions of the 
leader peptide. The N-terminal fragment is sufficient to compete with avidity similar to that of the full-length leader 
peptide. (E) ITC shows that the N-terminal leader peptide fragment binds to TbtD. (F) Overall structure of TbtD in 
complex with the N-terminal leader fragment, showing insertions 1 (cyan) and 2 (green) that distinguish the [4+2] 
enzymes from the LanB elimination domains. (G) Simulated annealing difference Fourier map (Fobs – Fcalc) contoured 
at 2.5σ showing residues from the leader peptide that bind to a region near insertion 2 (green) in TbtD (Figure credit: 
Satish Nair).  
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hexathiazole-containing peptide by first O-glutamylating Ser residues in the core sequence, 
followed by glutamate b-elimination, to yield the corresponding a,b-unsaturated amino acids  
termed dehydroalanine (Dha). Finally, the central six-membered nitrogenous ring is formed 
through the heteroannulation of two Dha residues in the modified core, possibly after 
tautomerization of one Dha to a conjugated iminol (Fig. 3.1B). Subsequent aromatization of the 
central pyridine is established with a dehydration and b-elimination of the leader peptide as a 
carboxamide (Fig. 3.1B). Recent in vitro studies using recombinant pyridine synthases 
demonstrated that a single enzyme plays a direct role in annulation via a formal [4+2] aza-
cycloaddition.86,89,90 Ala-scanning mutational analysis of TbtA suggested the recognition by TbtD 
to be most influenced by N-terminal residues of the leader peptide.86 
While other enzymes have been identified as [4+2] cycloaddition catalysts,91,92 they 
frequently serve only to enhance a reaction that can occur spontaneously and/or favor product 
stereochemistry via conformational restriction of the reactant(s).91 In contrast, the reaction 
catalyzed by the thiopeptide pyridine synthase is not spontaneous and synthetically equivalent 
reactions require either prolonged incubation (~1 week) at high temperatures, or microwave 
irradiation for non-enzymatic catalysis, often with competing side reactions.93 The thiopeptide-
forming pyridine synthases are dedicated [4+2] cycloaddition catalysts whose only function is 
catalyzing the cyclization of two Dha residues within the precursor peptide.94 Notably, pyridine 
synthases catalyze the unique formation of an aza-cyclic product, in contrast to the carbocyclic 
products formed in other biosynthetic pathways, such as those for spinosin A,95,96 





3.3 RESULTS AND DISCUSSION 
3.3.1 TbtD binds the N-terminus of its leader peptide 
We initially focused our studies on TbtD, a pyridine synthase from the thiomuracin 
biosynthetic cluster from T. bispora. We previously established TbtD activity in vitro utilizing the 
TbtA precursor substrate with six thiazoles and four Dha residues enzymatically pre-installed.86,89 
Proteolytic removal of the N-terminal 31 residues (out of 34) of the leader peptide from this 
substrate abolished pyridine formation by TbtD. A similar leader peptide dependency was 
observed for TclM, the orthologous enzyme from the thiocillin biosynthetic cluster.100 Maltose-
binding protein (MBP)-tagged TbtD bound to a fluorescently labeled TbtA leader peptide with a 
dissociation constant (KD) of 1.4 x 10-7 M.86 However, sequence analysis of the pyridine synthases 
failed to identify a precursor peptide recognition element (RRE) that mediates leader peptide-
binding in many other RiPP enzymes (see Fig. 3.1C for leader peptide numbering scheme).83 We 
carried out fluorescence polarization competition assays to identify the minimal leader peptide-
binding motif and provide a quantitative affinity assessment for TbtD independent of any catalytic 
events (Fig. 3.1D). Competition studies using tag-free TbtD and unlabeled full-length TbtA leader 
peptide yielded an inhibition constant (KI) value of 1.5 × 10−6 M. Prior studies demonstrated that 
engagement by TbtD is compromised by mutations at residues at the N terminus of the leader 
peptide.86 Accordingly, a 17-residue peptide corresponding to the C-terminal portion of the leader 
peptide [from Val(-17) to Ala(-1)] failed to compete against the full-length leader peptide, while a 
16-residue N-terminal portion [from Met(-34) to Ser(-19)] yielded a KI of 2.8 × 10−6 M. The 
binding of this peptide by TbtD was corroborated using isothermal titration calorimetry (ITC), 
which yielded a Kd of 1.3 × 10−6 M (Fig. 3.1E), while the C-terminal region of the leader peptide 




Fig. 3.2: Secondary-structure–based multiple sequence alignment (MSA). Included in the MSA are the pyridine 
synthases TbtD, PbtD, and TclM in addition to the class I LanB dehydratase elimination domains (-elim) NisB-elim, 
and MibB-elim generated using ALINE software (45). A majority of secondary structural elements are conserved in 
these functionally divergent enzymes and notable differences are observed in the insertion regions (INS 1, INS 2, and 
INS 3) found mainly in the pyridine synthases (Figure credit: Satish Nair).  
 
3.3.2 Overall fold and new leader peptide binding mode of the pyridine synthase 
Given the lack of an RRE, we determined crystal structures of TbtD both alone and in 
complex with the N-terminal region of the leader peptide to define its binding site. TbtD is 
structurally homologous to the core of the lanthipeptide dehydratase elimination domain (Pfam 
identifier PF14028; abbreviated as Lant_Dehydr_C) elucidated in NisB101 and MibB,53 but 
contains numerous secondary structural insertions (Figs. 3.1F and 3.2). Notable examples include 
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a helical insertion in the region spanning Pro86 through Asp116 (insertion region 1), a 
reorganization of the region encompassing Pro183 through Pro241 (insertion region 2), and a large 
insertion spanning Gly264 through Arg301 (insertion region 3), which is a short connection loop 
in the Lant_Dehydr_C domains. Importantly, each of the insertions help to configure the binding 
sites for the substrates specific to the pyridine synthases, and insertion 3 is only visible in structures 
with bound pyridine core (see PbtD Binds a Trisubstituted Pyridine Product Analog of 
GE2270A; Fig. 3.3C). The cocrystal structure with the N-terminal 16 residues of the TbtA leader  
peptide shows electron density corresponding to residues Leu(-32) through Leu(-22) in the vicinity 
of insertion region 2 (Fig. 3.1G). Residues Ser200 through Ala234 of TbtD form a large, bent 
helical insert that abuts the enzyme core and form the binding pocket for the leader peptide. The 
equivalent region in both MibB (Gly990 through Glu1035) and NisB (Asp882 through Gly919) is 
largely devoid of secondary structure (Fig. 3.2). 
 
3.3.3 Mutagenesis and leader peptide binding studies 
Previous binding experiments between TbtD and site-directed alanine variants of TbtA 
identified several residues within the leader peptide that are important for binding,86 which can 
now be rationalized in light of the structural data. For example, an Ala substitution at Leu(-29) 
severely impairs TbtA binding, and in the cocrystal structure, this residue is docked into a 
hydrophobic pocket that is ensconced by residues from insertion 3. Similar hydrophobic docking 
interactions are important for leader peptide engagement by enzymes involved in the biosynthesis 
of lanthipeptides101 and cyanobactins.102 Additionally, binding by TbtD is compromised by 
substitutions at one of several acidic residues in TbtA, including Asp(-30), Asp(-26), and Glu(-
23)86 and the structural data reveal that TbtD engages some of these residues through electrostatic 
complementarity. We carried out mutational analysis of the binding site in TbtD (see Ref. 103 SI 
Appendix, Fig. S2 and Table S3) to establish the importance of residues in mediating interactions 
 40 
with TbtA, using a shorter peptide corresponding to the N-terminal 12 residues visualized in the 
structure. Binding of TbtA by the pyridine synthase is compromised upon substitutions at enzyme 
residues that define the hydrophobic pocket for Leu(-29), including Phe166, Phe220, and Val335. 
An Ala mutation at Arg223, which is involved in additional hydrophobic contacts with Leu(-29) 
and hydrogen-bonding interactions with main-chain amides of the leader peptide, also diminishes 
TbtA binding (see Ref. 103 SI Appendix, Fig. S2 and Table S3). These structural and mutational 
data establish the validity of a leader peptide-binding site in TbtD and demonstrate that the C-
terminal region of the leader peptide is dispensable for precursor binding to the enzyme. 
 
3.3.4 PbtD binds a tri-substituted pyridine product analog of GE2270A 
Repeated attempts to crystallize a complex of hexazole-containing tetradehydrated TbtA 
(designated as the [4+2] substrate in Fig. 3.1B) bound to catalytically deficient variants of TbtD  
proved recalcitrant. Binding measurements using fluorescently tagged, modified TbtA hexazole 
demonstrated that TbtD binds with nanomolar affinity (see Ref. 103 SI Appendix, Fig. S3), ruling 
out weak binding as the cause of crystallization issues. TbtD also binds with micromolar affinity 
a fluorescently tagged and modified TbtA hexazole treated with endoproteinase GluC, containing 
only three leader peptide residues, Val(-3) through Ala(-1) (see Ref. 103 SI Appendix, Fig. S5), 
but crystallization attempts using this substrate were not fruitful. Likewise, attempts at 
cocrystallization of PbtD with intact GE2270A failed. Rationalizing that flexible regions of the 
modified peptide substrate may interfere with lattice packing, we focused efforts on studies using 
analogs that retained the central pyridine moiety (Fig. 3.3A). Prior studies have shown that acid 
hydrolysis of GE2270A produced a trithiazole-substituted pyridine (TSP);81 therefore, we acid-
treated GE2270A and purified two resultant TSP variants to near homogeneity (Fig. 3.3A and Ref. 
103 SI Appendix, Fig. S8). We exploited the overlap in the absorption spectrum of TSP-F (λex ∼  
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Fig. 3.3: Structural and binding studies of the PbtD–TSP complex. (A) Chemical structure of the trisubstituted 
pyridine (TSP) core produced by acid hydrolysis of GE2270A. (B) Binding of TSP to PbtD as measured by the changes 
in FRET upon complex formation. (C) Overall structure of PbtD in complex with TSP shows that residues in insertion 
3 (yellow) become ordered upon ligand binding. (D) Simulated annealing difference Fourier map (Fobs – Fcalc) 
contoured at 2.5σ showing the TSP core binds to a region near insertion 3 (yellow) in PbtD. Active-site residues 
implicated in catalysis, without influencing leader peptide binding, are shown in stick figures (Figure credit: Satish 
Nair).  
 
333 nm) and the emission spectrum for the corresponding PbtD pyridine synthase from its 
biosynthetic cluster (λex = 275 nm; λem = 333 nm) to directly measure binding using Förster 
resonance energy transfer (FRET), yielding a Kd of 2.1 × 10−5 M (Figs. 3.3B and 3.7). 
 
3.3.5 Structure-guided active site mutagenesis 
To discern active-site details of the pyridine synthases, we determined the structure of PbtD 
both alone and in complex with the GE2270A TSP. The overall structure of PbtD recapitulates the 
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architecture observed in the homologous TbtD, including the lack of interpretable electron density 
for residues Glu248 through His273 within insertion 3, despite the much higher resolution of this 
structure. In contrast, the structure with bound TSP reveals that these residues organize and form 
two short α-helices that define a periphery of the binding pocket for the ligand (Fig. 3.3C). The 
helix from insertion 2 forms a base at the bottom of the binding groove. Previous Ala-scanning 
analysis of TbtD implicated several residues in catalysis. Indeed, substitutions at His191 
(equivalent PbtD numbering is given in parentheses; His182), Ser287 (Thr260), His290 (His263), 
Tyr319 (Tyr293), and Arg332 (Arg306) diminish activity.89 Following a structure-guided 
mutagenesis approach, this study has revealed an additional residue, Phe308 (Phe282), to be 
important for product formation after a panel of conserved residues proximal to TSP were tested 
using similar Ala-scanning mutational approaches (see Ref. 103 SI Appendix, Fig. S11). Each of 
these residues is near the bound TSP but are located ∼5–7 Å from each other and are not all 
spatially clustered (Fig. 3.3D). Rather, these residues line alternate sides of a shallow cleft that is 
located at the juncture of the leader peptide-binding site (on TbtD) and bound TSP. It should be 
noted that some of these variants may carry out the [4+2] cyclization and only be deficient in 
dehydration activity but are refractory to identification as there would be no net change in mass. 
 
3.3.6 Model of pyridine formation 
A feasible model of pyridine formation involves a looped substrate embedded within the 
shallow cleft in PbtD, where the aforementioned residues may play roles in catalyzing iminol 
formation, water elimination, and/or leader peptide ejection as the peptide transverses along the 
binding cleft. In this model, the anchored N terminus of the leader peptide would allow a flexibly 
tethered core peptide to form this looped structure within the cleft, orienting the C terminus of the 
substrate away from its N terminus and at the interface of insertion 1 and the periphery of the cleft 
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(Fig. 3.4). To test this hypothesis, we carried out docking of the [4+2] substrate, as well as various 
intermediates, and evaluated the stability of each state over a 1-ns time course molecular-dynamics 
simulation (Figs. 3.8-3.11 and see Ref. 103 SI Appendix, Fig. S16). Among the lowest energy 
poses obtained, we observed the maturing substrate and product docking results to be consistent 
with the predicted substrate-binding site based on the TSP cocrystal structure (i.e., C terminus and 
macrocycle orientations). Residues within insertion 3 that are specific to the [4+2] enzymes are 
largely disordered in the  
 
Fig. 3.4: Model of pyridine formation catalyzed by PbtD. The PbtA [4+2] substrate is superimposed onto the 
structure of PbtD, with active-site residues drawn as gray sticks (Figs. 3.8-3.10; state 1). Five-membered heterocycles 
along the substrate backbone are represented as pentagons (purple outline/yellow center, thiazole; purple outline/red 
center, oxazoline; black outline/blue center, proline). Dehydroalanine and iminol double bonds involved in a formal 
[4+2] cycloaddition are drawn in green. The N-terminal leader peptide fragment (N12-mer: LNDLPMDVFELA) 
observed in the TbtD cocrystal structure has also been superimposed and is represented as yellow sticks. 
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absence of substrate, and the proximity of this region to the active-site cleft suggests that these 
residues may serve a role in active-site capping and/or modified core binding. Indeed, ordering of 
insertion 3 upon binding of TSP is consistent with this proposal. Recruitment of the true substrate 
may lead to additional ordering of insertion 3 to facilitate substrate threading, whereupon the 
resultant macrocycle becomes solvent exposed and is directed away from the binding cleft. The  
central nitrogenous ring in thiopeptides varies both in the pattern of substitution, as well as in the 
oxidation state.87 We generated a sequence similarity network3 using the available sequences for 
thiopeptide [4+2] cycloaddition enzymes. This network revealed clear clustering into clades that 
correlate directly with the substitution pattern and oxidation state of the six-membered heterocycle, 
even at a fairly low primary sequence similarity cutoff of ∼30% (Fig. 3.5). Sequence analysis 
reveals large differences in the composition and length of residues in insertion 3, consistent with  
Fig. 3.5: (A) Sequence similarity network of [4+2] cycloaddition proteins found across various thiopeptide 
biosynthetic clusters showing that the sequences cluster based on the nature of the central nitrogenous ring. Nodes 
represent protein sequences while edges denote sequences with at least ∼30% amino acid identity. PbtD and TbtD are 
highlighted. The macrocycle compositions are as follows: thiostrepton-like, 26-membered dehydropiperidines; 
thiocillin/nosiheptide-like, 26-membered pyridines; thiomuracin/GE2270-like, 29-membered pyridine; lactazole-like, 
32-membered pyridine; berninamycin-like, 35-membered pyridine. (B) Structures of the central ring found in different 
thiopeptide natural products with colored circles to indicate changes in the substitution pattern. The colors correspond 
with the clusters shown in A. It is noted that the nocathiacin and nosiheptide [4+2] enzymes form two unique clusters, 
despite these thiopeptides bearing high structural homology and an identical pattern of pyridine substitution. This is 
likely due to limited sample size and some variation at the N terminus between sequences in these clusters (Figure 
credit: Graham Hudson).  
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our proposed role of this region in directing the path of the core region of the modified peptide 
substrate, and thus the size of the macrocycle. 
 
3.3.7 A conserved scaffold catalyzes new chemistry by active site shifting 
Mapping the primary sequences of nine pyridine synthases onto the structure of the PbtD–
TSP cocrystal structure reveals a pattern of conservation at the active site (Fig. 3.6A). As noted, 
this active site of the [4+2] enzyme is distinct from that of other Lant_Dehydr_C domains, which  
Fig. 3.6: Pyridine synthase scaffold is conserved in enzymes with divergent functions. (A) PbtD surface rendering 
with the bound TSP shown as a stick figure in cyan. Using the ConSurf server, the surface has been color-coded 
according to conservation in primary sequence based upon the alignment of nine sequences of pyridine synthases and 
colored according to regions of most variability (cyan), modest (white) or highest conservation (magenta) (see SI 
Appendix, SI Materials and Methods for a list of proteins and accession numbers used in alignment). The strongest 
sequence conservation occurs near the active site where the [4+2] cycloaddition occurs. (B) Ribbon diagram of the 
LsrG epimerase (PDB entry 3QMQ) with active-site residues shown as yellow sticks. (C) Ribbon diagram of the 
allantoate amidohydrolase AAH (PDB entry 4PXD) with active-site residues shown as yellow sticks and a manganese 
ion shown as a red sphere. (D) Ribbon diagram of the elimination domain of the lanthipeptide dehydratase MibB 
(PDB entry 5EHK) with active-site residues shown as yellow sticks. The ferredoxin-like α+β folds of AAH and MibB 
are demarcated within the rectangle, and the active sites are colored in orange (Figure credit: Satish Nair).  
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are built upon a common scaffold observed in the LsrG epimerase,104 involved in quorum sensing. 
LsrG contains a ferredoxin-like domain, a prevalent α+β fold observed in numerous metabolic 
enzymes (Fig. 3.6B).105 For example, the architecture of allantoate amidohydrolase, an enzyme 
involved in purine degradation in both plants and bacteria,106 is formed through the fusion of the 
LsrG scaffold with a second domain containing a metal-binding active site (Fig. 3.6C).107 
Likewise, the elimination active site of NisB is formed by the insertion of an additional subdomain  
onto the LsrG ferredoxin-like fold (Fig. 3.6D). Here, we demonstrate that the thiopeptide [4+2] 
cycloaddition enzymes amend the Lant_Dehydr_C fold with functionally relevant insertion 
regions to achieve gain of function. A comparison of the TbtD/PbtD structures with that of MibB, 
and LsrG also provides an unexpected occurrence of proteins that contain active sites located at 
different regions of the polypeptide and catalyze different reactions, illustrating how a common 
scaffold can accommodate new chemistry at a new active-site region (Fig. 3.6). Recent de novo 
protein design efforts by Baker and coworkers108 describe methodologies for engineering proteins 
with entirely new primary sequences through considerations of long-range interactions observed 
in prevalent folds such as the ferredoxin-like domain. These studies predict the possibility of 
engineering custom-designed large assemblies from such robust building blocks. The structure of 
the pyridine synthase provides a conspicuous example of how nature has already employed this 
strategy to yield new catalysts, based on an ancestral ferredoxin-like fold. 
 
3.4 METHODS 
3.4.1 Peptide purification 
Peptides used for co-crystallization and fluorescence polarization (FP) experiments were 
synthesized by GenScript and purified by high-performance liquid chromatography (HPLC) using 
a Grace VisionHT C18 HL column with 5 μm particle size and 250 mm length (Part No. 5151988). 
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A gradient of 5-55% aqueous acetonitrile (MeCN) containing 0.1% formic acid (v/v) was used to 
separate peptides. Peptide identity was verified using a Bruker UltrafleXtreme matrix-assisted 
laser desporption/ionization time-of-flight/time-of-flight (MALDI TOF-TOF) mass spectrometer 
(Bruker Daltonics) in reflector positive mode at the University of Illinois School of Chemical 
Sciences Mass Spectrometry Laboratory.  
 
3.4.2 Purification of wild-type and site-directed variants of TbtD and PbtD  
All protein expression constructs were generated using the following procedure with the 
exception of N-terminal hexahistidine maltose-binding protein (His6-MBP) tagged TbtD, TbtD-
R332A, and PbtD which were cloned according to methods previously described.89 Details of 
protein production and purification are provided in the Supporting Materials and Methods. 
 
3.4.3 Fluorescence polarization (FP) binding assay 
To determine the dissociation constants (KD) of the TbtD variants towards N-terminally 
fluorescein isothiocyanate-labeled leader peptide (FITC-TbtA leader), an FP assay was carried out 
in a 384-well format using flat-bottom black polystyrene non-binding plates (Corning) and a 
Synergy H1 plate reader (BioTek Instruments) equipped with a green FP filter cube (λex = 485 
nm and λem = 528 nm). Samples were prepared using the following binding buffer: 0.2 M NaCl, 
50 mM HEPES pH 7.5, 2.5% glycerol, and 2 mM β-mercaptoethanol. All other experimental 
procedures and data analyses were performed as previously described (see Ref. 103 SI Appendix, 





3.4.4 Competition fluorescence polarization (FP) binding assay  
For each TbtD variant, protein concentrations were selected to achieve initial polarization 
values of 250-300 mP in the presence of 25 nM FITC-labeled peptide. Protein and labeled peptide 
concentrations were held constant while TbtA N12-mer peptide (LNDLPMDVFELA) was serially 
diluted from 1 mM to 5.6 nM in binding buffer. Data were collected in a similar manner to that 
described above. Inhibition constants (KI) were determined by taking the IC50 values 
(concentration of peptide required to diminish maximum polarization by 50%) derived from a 











Where L50 is the concentration of free labeled ligand at 50% inhibition, KD is the 
dissociation constant between protein and labeled ligand, and Po is the initial protein concentration 
(Fig. 3.1D, and see Ref. 103 SI Appendix Fig. S3 and Table S3).109 
 
3.4.5 Isothermal titration calorimetry (ITC)  
ITC data were collected on a Nano ITC calorimeter (TA Instruments) using the low volume 
sample cell (190 µL) maintained at 25 °C with stirring at 220 rpm. All protein and peptide dilutions 
were prepared using the same binding buffer as used in FP experiments. The sample cell contained 
TbtD at 40 μM and peptides at 0.5 mM were injected into the sample cell in 0.2 µL increments for 
26 total injections (Fig. 3.1E). All downstream data processing was carried out using the 
AFFINImeter online data analysis tool (https://www.affinimeter.com/; Software for Science 
(1) 
 49 
Developments). The first and sixth injections from the left in Figure 3.1E were omitted in the 
calculations.  
 
3.4.6 Production and purification of TSP, TSP-F, FITC TbtA-hexazole, FITC GluC TbtA-hexazole, 
and TbtA tetradehydrate 
Tri-thiazole-substituted pyridines (TSP and TSP-F) were generated by acid hydrolysis of 
GE2270A (a gift from Novartis) (see Ref. 103 SI Appendix Fig. S9A). Hydrolysis was carried out 
at 110-120 °C for 12 h in the presence of 6 M HCl. The reaction mixture was subsequently 
lyophilized and extracted with 10% (v/v) MeCN. Insoluble material was removed by centrifugation 
at 10,000 ´ g for 15 min, and the supernatant was purified on a Shimadzu Prominence Preparative 
Liquid Chromatography system equipped with a Phenomenex Luna C18 column (250 ´ 10 mm, 
10 μm particle size, 100 Å pore size). MeCN and 10 mM aq. NH4HCO3 were used as the mobile 
phases with a gradient of 2 - 80% aq. MeCN over 45 min at 7 mL/min for separation. TSPs eluted 
from the column with a retention time around 13 and 16 min (see Ref. 103 SI Appendix Fig. S9B). 
Fluorescein-labeled TbtA hexazole (see Ref. 103 SI Appendix Fig. S4; FITC TbtA-hexazole), and 
TbtA tetradehydrate (Fig. 3.8; compound 1) were prepared and purified as previously 
described.89,86 Fluorescein-labeled and GluC-treated TbtA-hexazole (FITC GluC TbtA-hexazole) 
was prepared using methods previously described86 and HPLC purified using a Grace Vydac 
DENALI C18 column (250 ´ 4.6 mm, 5 µm particle size, 120 Å pore size) with a similar gradient 
of mobile phases described above for TSP and TSP-F and a 1 mL/min flow-rate. Desired product 





3.4.7 Förster resonance energy transfer (FRET) binding assay 
Binding experiments were initially carried out using TSP; however, due to insolubility, we 
opted to use the more soluble TSP-F (see Ref. 103 SI Appendix Fig. S9). To ensure a spectral 
overlap between PbtD native protein fluorescence and TSP-F absorbance, emission and 
absorbance scans were performed on a Synergy H4 Hybrid plate reader (BioTek) and an Epoch 
microplate spectrophotometer (BioTek), respectively. PbtD (5 μM) was excited at 275 nm before 
collecting an emission scan from 300 to 600 nm. An absorbance spectrum of TSP-F (0.5 mM) was 
collected over a similar range (see Ref. 103 SI Appendix Fig. S7). A λex of 275 nm and λem of 333 
nm were selected to satisfy spectral overlap. Emission spectra were also taken of TSP-F in water 
and methanol by exciting at 333 nm and monitoring emission from 333 to 750 nm. Fluorescence 
of TSP-F was only observed in methanol, preventing detection of fluorescence in aqueous binding 
buffer. Instead, quenching of PbtD fluorescence (observed in aqueous binding buffer) at 333 nm 
was monitored as a function of TSP-F concentration. To ensure adequate fluorescence signal above 
the instrument background emission, PbtD was maintained at 5 μM, while TSP-F was serially 
diluted from 2 mM to 122 nM. To correct for background emission quenched by TSP-F, the 
following formula was applied:  
 
𝐹𝐹𝐹𝐹(𝑥𝑥) + [𝐹𝐹𝐹𝐹4 − 𝐹𝐹𝐹𝐹4(𝑥𝑥)] − 𝐹𝐹𝐹𝐹4 
 
where Fl(x) is the total fluorescence in the presence of PbtD and some ligand concentration (x), 
Flb is the total background fluorescence in the absence of protein or ligand, and Flb(x) is the total 
background fluorescence in absence of protein and presence of some concentration of ligand (x). 
In order to obtain values for Flb and Flb(x), a blank solution containing only binding buffer was 
measured in addition to serially diluted TSP-F in the absence of PbtD. Measurements of KD were 
(2) 
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approximated by fitting the curves to a dose-response curve using OriginPro 2016 (OriginLab) and 
taking KD to be equal to the ligand concentration at 50% Flmax (Fig. 3.2B and see Ref. 103 SI 
Appendix Fig. S8).109,110  
 
3.4.8 Protein Crystallization 
TbtD (apo): Following SEC, TbtD was concentrated to 5 mg/mL before crystallization in 
hanging drops at 16 °C whereby protein solution and reservoir solution (0.4 M NaH2PO4, 1 M 
KH2PO4 pH 6.5) were incubated 1:1 (2 µL drops). Cube-shaped crystals grew in 2-3 d.  
TbtD-16mer: Following SEC, TbtD was concentrated to 6 mg/mL before equilibrating with 
1 mM 16mer peptide (MDLNDLPMDVFELADS) for 30 min on ice. Thick plate-shaped crystals 
grew within 48 h in hanging drops at 16 °C by equilibrating 1:1 protein solution and reservoir 
solution (2 µL drops) containing 0.2 M magnesium formate and 17.5% polyethylene glycol (PEG) 
3350.  
PbtD (apo): Following SEC, PbtD was concentrated to 3 mg/mL before crystallization in 
hanging drops at 9 °C by equilibrating 1:1 protein solution and reservoir solution (2 µL drops) 
containing 15% 2-methyl-2,4-pentanediol (MPD), 8% PEG 6K, 0.1 M 2-(N-
morpholino)ethanesulfonic acid (MES) pH 6.5. Large, cube-shaped crystals grew within 18 h. 
Selenomethionine-containing PbtD (SeMet-PbtD) was crystallized in the same manner with the 
following reservoir solution: 17% MPD, 10% PEG 6K, and 0.1 M MES pH 6.5.  
PbtD-TSP: Following SEC, PbtD was concentrated to 4.5 mg/mL before equilibrating with 
a 1.5 mM TSP suspension for 1 h at room temperature. Clustered rod-shaped crystals grew within 
48 h in hanging drops at 9 °C by equilibrating 1:1 protein solution and reservoir solution (2 µL 
drops) containing 1.9 M Li2SO4, 2% PEG 400, and 0.1 M tris pH 8.5.  
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3.4.9 Crystallography data collection, structure determination, and refinement 
Prior to data collection, crystals were cryoprotected in similar crystallization conditions 
supplemented with 20% ethylene glycol and flash-frozen in liquid nitrogen. Data were collected 
at the Advanced Photon Source (APS) at Argonne National Lab using the Life-Science 
Collaborative Access Team (LS-CAT) 21-ID-D, 21-ID-F, and 21-ID-G beamlines. Initial 
diffraction data were processed using autoPROC.71 Experimental phases for PbtD were determined 
by using diffraction data from SeMet-PbtD and running Phenix AutoSol.33 The initial structure 
was built using Phenix AutoBuild and further refined using REFMAC535,76 in combination with 
manual rebuilding using COOT36,75. Solvent molecules were incorporated using Phenix Refine.38 
Prior to fitting ligands into electron density difference maps, geometry optimization and restraint 
parameters for tri-thiazole-substituted pyridines (TSPs) were produced using Phenix eLBOW.37 
Crystallographic phases for TbtD were determined by molecular replacement using PbtD 
coordinates as a search model for Phaser.111 Calculated phases were used to build an initial model, 
followed by manual and automated refinements as described for PbtD.  
 
3.4.10 ConSurf analysis 
Pyridine synthases selected for ConSurf112 analysis are as follows with the protein name 
and corresponding thiopeptide listed (if applicable): AGY49590.1 (PbtD; GE2270 from 
Planobispora rosea), WP_000438834.1 (TclM; thiocillin), ACS83769.1 (TpdD; GE2270 from 
Nonomuraea sp. WU8817), AGN11669.1 (BerD; berninamycin), WP_025357078.1 (suspected 
thiomuracin-like), ACR48344.1 (NosO; nosiheptide), WP_013130812.1 (TbtD; thiomuracin), 




3.4.11 Docking analysis 
Preliminary docking studies of PbtD and modified PbtA substrates were carried out using 
the AutoDock Vina PyMOL plugin.77 Prior to docking, ligands were generated and 3D optimized 
in MarvinSketch 16.4.11 (ChemAxon). The dehydration and leader peptide ejection requirements 
of the proposed reaction mechanism catalyzed by pyridine synthases were taken into account by 
docking different substrate intermediate states of modified PbtA (Fig. 3.8C). In addition to the full 
suite of azol(in)e modifications present in GE2270A, the remaining post-translational 
modifications (i.e. oxidations, methylations, and C-terminal amide) were also included in the 
PbtA-derived substrates (Fig. 3.8B). The leader peptide was truncated substantially to N-acetyl-L-
alanine at the N-terminus to simplify the docking experiments and avoid complications of non-
specific binding. The only chemical variation from states 1 through 4 involves the substitution and 
connectivity of atoms 1 through 6 involved in the formal [4+2] cycloaddition and constituting the 
final pyridine ring (Fig. 3.9A,B; labeled in red). Stereocenters at atom positions 2 and 3 in state 2 
were selected as R and S, respectively, to reflect the conserved stereochemistry observed in all 
characterized (to the best of our knowledge) dehydropiperidine-containing thiopeptides (i.e. 
thiostrepton, siomycin, thiopeptin, 8 and Sch 18640).113–117 Correspondingly, the R stereocenter at 
position 3 was chosen for state 3 (Fig. 3.9C,D). In state 2, we also considered the inverted 
configuration at the 2 position (Fig. 3.9C,D; corresponding to the (R,R)-stereoisomer) and 
comparative docking analyses reveals the (R,S) to be more favorable on the basis of binding energy 
and interatomic distance measurements between the oxygen of water to-be-ejected and terminal 
guanidinium nitrogen of Arg306 (Fig. 3.11). Receptor coordinates used in AutoDock Vina were 
generated from PbtD crystal structures (this study) to represent an “open” state derived from the 
apo PbtD structure lacking residues Val247 - Ser281. AutoDock Vina was performed with a large 
grid size (>27,000 Å3 ) and a grid step of 0.375 Å centered near the active site residues identified 
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in TbtD as important for catalysis (corresponding PbtD residues: His182, Thr260, Phe282, Tyr293, 
and Arg306).89 Initial poses were selected on the basis of docking scores, proximity to active site 
residues, and expected substrate orientation with respect to the PbtD-TSP co-crystal structure. 
These poses were then subjected to further docking experiments using the Molecular Operating 
Environment 2016.08 (MOE) software (Chemical Computing Group Inc.). Prior to docking in 
MOE, ligands were solvated within a sphere of gas-phase water (10 Å radius) and energy 
minimized using the MMFF94x force field with a non-bonded interaction cutoff of 10-12 Å.118,119 
The interior region dielectric constant for electrostatic interactions was set to 1 and that for the 
exterior solvent region was set to 80. Due to the lack of structural resolution of 11 residues (Val247 
– Glu257 in PbtD) in all PbtD and TbtD crystal structures, an unstructured loop was built prior to 
docking using the “Loop Modeler” function in MOE with the PDB loop search enabled. Initial 
coordinates containing the missing residues were generated using the SWISS-MODEL modeling 
tool with a user template file consisting of the PbtD-TSP cocrystal structure coordinates containing 
only protein atoms.120–122 Using the “Dock” function in MOE, the energy-minimized ligands were 
docked onto both the loopmodified PbtD receptor and the PbtD “open” state receptor using the 
sites identified in AutoDock Vina. The triangle matcher placement method was used along with 
the London dG scoring methodology.123,124 Low energy poses obtained in MOE satisfy the criteria 
mentioned above (i.e. docking scores, active site proximity, and orientation; Figs. 3.10-3.11).  
 
3.4.12 Molecular dynamics (MD) simulations 
All MD simulations were carried out using the “Dynamics” interface in MOE 2016.08. 
Poses obtained in MOE using both PbtD receptor variants (“open” state or containing MOE-
derived loop region) and all four states containing the R,S-stereoisomer at state 2 and 9 R-
stereoisomer at state 3 (Figs. 3.9C,D) were used as the protein-ligand complexes under study. 
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These complexes were solvated and energy minimized using the MMFF94x force field with the 
same parameters described above. The Nose-Poincare-Andersen (NPA) algorithm was selected to 
solve the equations of motion.125 Waters within 10 Å from the solute atoms were made explicit 
throughout the simulation. An equilibration time of 50 ps followed by a production time of 1 ns 
was specified, and the system temperature was set to 300 K. A time step of 2 fs was used and data 





3.5 SUPPORTING FIGURES 
Fig. 3.7: Förster resonance energy transfer (FRET) analysis between PbtD and tri-thiazolesubstituted pyridine 
containing β-hydroxyphenylalanine (TSP-F; see Ref. 103 SI Appendix Fig. S8A). (A) Emission spectrum of native 
PbtD fluorescence (λex = 275 nm) and absorption spectrum of TSP-F indicates spectral overlap for FRET to take 
place. (B) Fluorescence spectrum of TSP-F when excited at 333 nm in water (black) and methanol (red) indicates a 






Fig. 3.8: Summary of PbtD ligand structures used in docking experiments. (A) Cartoon drawing of modified PbtA 
substrate where bold lines indicate portions of the macrocycle and LP represents the truncated leader peptide (N-
acetyl-L-alanine). (B) Structure of GE2270A to highlight structural features of the macrocycle and C-terminus shared 
in all of the ligand states where the only differences arise from substitution pattern and connectivity of the atoms in 
red. (C) States of the modified PbtA substrates highlighting the structural differences at atom positions 1–6 (*MD data 
only shown for the (R,S)-stereoisomer at state 2 and R-stereoisomer at state 3). (D) Structures of two unique 






Fig. 3.9: Summary of docking energies (S) and poses obtained in MOE with built-in loop residues (Val247 – 
Glu257; omitted for clarity). The energies for poses used in the figure are colored red. State 2 corresponds to the 
(R,S) intermediate. In all relevant states, the leader peptide residues (including superimposed TbtA N12-mer from 
TbtD co-crystal structure) are displayed as yellow sticks and crystallographically observed TSP as blue slate. Atoms 
1–6 (Fig. 3.8A) are colored orange, and active site residues H182, T260, F282, Y293, and R306 as grey sticks. 
Insertions 1-3 are color coded consistent with the main text and Figure 3.2 (i.e. INS 1 = blue; INS 2 = green; INS 3 = 
yellow; remaining PbtD surface = grey) 
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Fig. 3.10: Summary of docking energies (S) and poses obtained in MOE using the “open” receptor state as 
described in the experimental section. The energies for poses used in the figure are colored red. State 2 corresponds 
to the (R,S) intermediate. In all relevant states, the leader peptide residues (including superimposed TbtA N12-mer 
from TbtD co-crystal structure) are displayed as yellow sticks and crystallographically observed TSP as blue slate. 
Atoms 1–6 (Fig. 3.8A) are colored orange, and active site residues H182, T260, F282, Y293, and R306 as grey sticks. 
Insertions 1-3 are color coded consistent with the main text and Figure 3.2 (i.e. INS 1 = blue; INS 2 = green; INS 3 = 
yellow; remaining PbtD surface = grey).  
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Fig. 3.11: Comparative docking analysis performed in MOE of the state 2 (R,S) and (R,R) stereoisomers. 
Ligands were docked onto a loop-containing PbtD receptor (containing residues Val247 – Glu257; omitted for clarity) 
and docking pose energies (S) are tabulated where values in red correspond to graphically represented poses. Distance 
measurements between the oxygen of the water to-be-ejected and terminal guanidium nitrogen of Arg306 are 
displayed (in Å). The leader peptide residues (including superimposed TbtA N12-mer from TbtD co-crystal structure) 
are displayed as yellow sticks and crystallographically observed TSP as blue slate. Atoms 1–6 (Fig. 3.8A) are colored 
orange, and active site residues H182, T260, F282, Y293, and R306 as grey sticks. Insertions 1-3 are color coded 
consistent with the main text and Figure 3.2 (i.e. INS 1 = blue; INS 2 = green; INS 3 = yellow; remaining PbtD surface 
= grey).  
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CHAPTER 4: STRUCTURAL BASIS FOR SUBSTRATE-ASSISTED AND ENZYMATIC 
LYSINOALANINE FORMATION IN DURAMYCIN BIOSYNTHESISd 
 
4.1 ABSTRACT 
Duramycin is a heavily post-translationally modified peptide that binds 
phosphatidylethanolamine. It has been investigated as an antibiotic, an inhibitor of viral entry, 
a therapeutic for cystic fibrosis, and a tumor and vasculature imaging agent. Duramycin 
contains a β-hydroxylated Asp (Hya) and four macrocycles, including an essential lysinoalanine 
(Lal) cross-link. The mechanism of Lal formation is not known. Here we show that Lal is 
installed stereospecifically by DurN via addition of Lys19 to a dehydroalanine. The structure 
of DurN reveals an unusual dimer with a new fold. Surprisingly, in the structure of duramycin 
bound to DurN, no residues of the enzyme are near the Lal cross-link. Instead, Hya15 of the 
substrate makes interactions with Lal, suggesting it acts as a base to deprotonate Lys19 during 
catalysis. Biochemical data suggest that DurN preorganizes the reactive conformation of the 
substrate, such that the Hya15 of the substrate can serve as the catalytic base for Lal formation. 
 
4.2 INTRODUCTION 
Duramycin and closely related compounds are ribosomally synthesized and post-
translationally modified peptides (RiPPs) produced by various actinomycetes126–130 and marine 
symbionts.131 Duramycin binds phosphatidylethanolamine (PE), a major structural phospholipid 
in mammalian and microbial cell membranes.132,133 Duramycin contains 19 amino acids, and five 
posttranslational modifications (PTMs), one lanthionine (Lan), two methyllanthionines (MeLan), 
                                               
d This research was originally published in Nature Chemical Biology. Part of this chapter was 
directly obtained, with permission, from: 
 
*An L, *Cogan DP, Navo CD, Jiménez-Osés G, Nair SK, van der Donk WA. Substrate-Assisted 
Enzymatic Formation of Lysinoalanine in Duramycin. Nat Chem Biol. 2018 Oct;14(10):928-933. 
Copyright © 2018, Springer Nature.  
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an erythro-3-hydroxy-L-aspartic acid (Hya) resulting from the hydroxylation of Asp15, and one 
(2S,9S)-Lal (Fig. 4.1). The carboxylate and hydroxyl groups of Hya15 make key interactions with 
the ethanolamine head group of PE, providing nanomolar affinity and high specificity.133,134 As 
such, duramycin has been investigated as an antibiotic,126–128 inhibitor of viral entry,135 therapeutic 
for cystic  
 
 
Fig. 4.1: Duramycin biosynthesis. a, Co-expression of a minimal biosynthetic gene cassette and in vitro 
proteolytic removal of the LP from peptide 2 produces duramycin. b, Peptide 3 is converted to 4 by DurN in vitro 
(blue). Formation of the Lal is monitored by reaction with DTT, which provides an adduct (5) if Lal is not 
generated (yellow). The characteristic y1 fragment ion is marked with an orange line. c, Compound 3 was reacted 
with MBP-DurN (top) or MBP (bottom), treated with DTT, and analyzed by LC–MS (see Ref. 136 Supplementary 
Fig. 2). Expected and observed masses are listed in Ref. 136 Supplementary Table 2. Experiment was performed 
independently three times with similar results. d, LC–MS/MS analysis of the products in c. Because of the 
extensive cross-linking, the only fragments observed in addition to the y1 ion are likely an a2 ion at m/z 191 and 
a phenyl fragment at m/z120 (Figure credit: Linna An and Wilfred van der Donk).  
 
fibrosis,137 and tumor and vasculature imaging agent.138,139 Recently, divamide A, a close homolog 
of duramycin discovered from the symbiotic microbiome of small marine animals, was reported 
to display potent anti-HIV activity.131 
Previous studies have identified the biosynthetic genes (dur) that introduce these PTMs in 
Streptomyces cinnamoneus ATCC12686.140 The precursor peptide DurA is synthesized with an N-
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terminal leader peptide (LP), which is removed after maturation of a C-terminal core peptide (CP) 
(Fig. 4.1a). Serine and threonine residues in the CP region of DurA are dehydrated by DurM to 
form dehydroalanine (Dha) and dehydrobutyrine (Dhb) residues. Subsequently, DurM catalyzes 
addition of cysteine thiols onto the β-carbon of Dha or Dhb to produce Lan or MeLan, respectively 
(Fig. 4.1a). The final two PTMs are hydroxylation of Asp15 by DurX to generate Hya15 and 
formation of (2S,9S)-Lal, putatively by DurN-catalyzed addition of Lys19 to Dha6 (Fig. 4.1a).140 
A previous study demonstrated that duramycin lacking Lal does not have antimicrobial activity,140 
indicating that the Lal linkage is critical to set up the PE binding pocket. DurN and its orthologs 
have no sequence homology with any characterized proteins, their mechanism of Lal formation is 
not known, and previous attempts to reconstitute activity of orthologs in vitro were 
unsuccessful.141,142 Instead, prior studies have resorted to non-enzymatic base-catalyzed formation 
of Lal.131,141 
In this study, we demonstrate DurN activity in vitro and present the co-crystal structures 
of the protein with a substrate analog and product. We compared Lal formation under enzymatic 
and non-enzymatic conditions, indicating that only DurN catalyzes stereospecific and 
diastereoselective Lal formation. Our data suggest that DurN promotes Lal formation via an 
unusual substrate-assisted mechanism. 
 
4.3 RESULTS 
4.3.1 The structure of DurN with a substrate analog 
We removed the MBP tag from MBP-DurN (see Methods) and obtained crystal structures 
of DurN in complex with a substrate analog and in complex with duramycin. We generated an 
unreactive variant of 3 in which Dha6 (originating from Ser6 in DurA) was mutated to Ala (3-
Dha6Ala, compound 6, see Ref. 136 Supplementary Fig. 3a). The structure of DurN with 3-
Dha6Ala was solved to 1.90 Å resolution by single wavelength anomalous dispersion (SAD)  
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Fig. 4.2: Structural analysis of DurN. a, Apo-DurN with the two monomers represented as green and blue ribbons. 
Two potassium ions are depicted as red spheres. b, Secondary structure mapped onto the DurN homodimer. For clarity, 
only the green monomer is labeled. c, DurN bound to 6 (black sticks). A difference Fourier map (Fo—Fc) contoured 
at 2.5σ is superimposed and shows electron density for portions of the ligand, including one Lan, one MeLan, and 
Hya15. Critical catalytic DurN residues are represented as green and blue sticks. d, DurN bound to duramycin (orange 
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Fig 4.2 (cont.) sticks) with a difference Fourier map (Fo—Fc) contoured at 2.5σ revealing occupancy for nearly the 
entire ligand. e, Two representations of the DurN homodimer featuring two molecules of duramycin related by a 90° 
rotational translation about the axis, depicted by the black arrow. f, Superimposition of 6 and duramycin-bound 
structures of DurN. Phe7 in DurA is not modeled in the ligand structures (c, d, and f) because of insufficient electron 
density. g, Close-up view of the DurN–Hya15 interactions (interatomic distances are calculated averages between two 
ligand-binding sites comprising chains C and G in PDB 6C0Y). For residue numbering, see Fig. 4.1a. 
 
methods using an iodide-soaked crystal. DurN also crystallized in the apo form and the structure 
was solved to 2.15 Å by molecular replacement using the SAD-derived coordinates (Fig. 4.2a). 
The overall structure of DurN consists of an interlaced homodimer where α-helix 1 of each 
monomer is engaged with residues from α-helices 2-6 in the adjacent monomer. The α-helices are 
followed by a single β-strand that forms an intermolecular, antiparallel interaction with its 
neighboring β-strand (Fig. 4.2a,b). A query against the PDB142 using the DALI server143 shows 
that DurN does not confidently resemble any known domain, indicating DurN contains a new 
protein fold and dimerization mode. 
The homodimer contains two structural ions that are related by the pseudo two-fold 
symmetry axis of the DurN homodimer. Our data are consistent with potassium as the bound metal 
ions (see Ref. 136 Supplementary Figs. 4-5). DurN coordinates potassium at both sites via an 
octahedral array of oxygen ligands derived from amides in the backbone (see Ref. 136 
Supplementary Fig. 4). In addition to potassium, we also considered the possibility of magnesium 
ions bound at the ion binding sites and carried out equivalent rounds of refinement in REFMAC535 
after modeling either potassium or magnesium ions independently. Whereas no positive signal was 
observed in the difference Fourier map (Fo – Fc) at 3σ for the corresponding potassium bound 
model, a positive difference signal was observed for the magnesium bound model (see Ref. 136 
Supplementary Fig. 4c). Additional support for structural potassium ions was gathered by 
performing differential scanning fluorimetry (DSF), whereby DurN melting curves were obtained 
in the presence of various potassium or magnesium ion concentrations. While potassium ions 
conferred an increase in thermal stability of DurN as a function of ion concentration, magnesium 
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ions had no effect on DurN thermal stability (see Ref. 136 Supplementary Fig. 4a,b). Molecular 
dynamics (MD) simulations also favor a structural potassium ion over magnesium (see Ref. 136 
Supplementary Fig. 5), and we needed potassium in our assays for enzymatic activity and to 
prevent precipitation. 
Analysis of simulated annealing difference Fourier maps (Fo – Fc) of the apo-structure and 
the structure with the bound substrate analog revealed electron density for 3-Dha6Ala from Gln3 
to Gly16 (Fig. 4.2c), with the reactive Lys19 invisible due to disorder. Only one of the two 
symmetric binding sites of the homodimer is occupied by ligand because of occlusion of the other 
site by residues from the N-terminus of a different protomer. Recognition of the ligand is mediated 
by residues from α-helix 1 of one polypeptide and α-helices 4-6 of the second monomer. 
Surprisingly, the ligand bound to the periphery of DurN and Ala6 (corresponding to the Dha6 
involved in Lal formation) is far removed from any residues of the enzyme (Fig. 4.2c). 
 
4.3.2 The structure of DurN with duramycin 
The observed binding pose of 3-Dha6Ala does not provide an obvious mechanism of 
catalysis. We therefore determined the 1.66 Å resolution structure of DurN bound to duramycin. 
This structure revealed additional electron density in both binding sites of the DurN dimer, 
enabling modeling of the entire duramycin, including the Lal linkage (Fig. 4.2d,e). Globally, the 
two ligand-bound structures are highly similar with an RMSD of 0.45 Å over 1400 atoms 
(including ligands) (Fig. 4.2f). The duramycin-bound structure reaffirms that DurN does not 
provide any residues that could catalyze the Michael-type addition and suggests that DurN may 
mediate Lal formation by serving as a molecular scaffold to bring Dha6 and Lys19 in close 
proximity. Notably, a bidentate hydrogen-bond is observed between the guanidine of Arg17, the 
Hya15 hydroxyl group, and an amide backbone oxygen of Cys14 of duramycin (Fig. 4.2g). The 
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Gln20 and Gln89 side chains of DurN further extend the hydrogen-bond network, and an 
electrostatic interaction is also observed between the carboxylate of Hya15 and Lys66 (Fig. 4.2g). 
These interactions position one of the carboxylate oxygens of Hya15 at 3.3 Å from the Lal 
secondary amine nitrogen. Thus, it appears that DurN holds the Hya15 carboxylate of the substrate 
in a conformation that is poised to activate Lys19 (Fig. 4.3). The other Hya15 carboxylate oxygen 
is 4.1 Å from the α-carbon of Ala6. This suggests that it would shield the Si face of the reactive 
Dha6, thus promoting protonation by solvent of the enolate formed upon the addition of Lys19 
from the more accessible Re face, resulting in the correct (2S,9S)-Lal diastereomer (Fig. 4.3). The 
structures do not provide any evidence for activation of the carbonyl oxygen of Dha6. In fact, the  
 
Fig. 4.3: Proposed substrate-assisted Lal formation catalyzed by DurN. Features in blue and green correspond to 
residues coming from the two monomers of DurN (see Fig. 4.2) and those in black correspond to its substrate/product 
(Figure credit: Linna An and Wilfred van der Donk).  
 
Ψ angle in Ala6 in duramycin is close to zero, very likely due to electrostatic repulsion between 
the carboxylate of Hya15 and the amide carbonyl of Ala6, which is directed towards the solvent. 
This strongly suggests that the reacting Dha6 is fixed in an s-cis conformation prior to cyclization, 






In this study, we provide the first in vitro demonstration that DurN catalyzes Lal 
formation, a step that had been recalcitrant in previous studies.131,141 By comparing enzymatic 
and nonenzymatic Lal generation, our data suggest that DurN greatly facilitates the reaction 
and controls its stereoselectivity. Furthermore, our data shows that the enzyme does not require 
the leader peptide for catalysis. DurN has a unique fold and dimeric architecture, and in co-
crystal structures, the Lal is entirely solvent exposed and the Hya15 of the substrate is 
positioned to potentially act as a base during catalysis to deprotonate Lys19 to initiate the 
Michael-type addition. Additionally, Hya15 appears to shield the Si face of the enolate 
intermediate such that protonation will only occur from the Re face, resulting in the correct 
(2S,9S)-Lal product. Mutational studies show that substrates that lack either the hydroxyl or 
carboxylate groups of Hya15 are not processed by DurN despite maintaining binding affinity, 
suggesting that both of these groups on the substrate are indispensable for catalysis. Merging 
the biochemical findings with structural and computational insights points to a mechanism 
whereby the substrate employs its own Hya15 as a catalytic base to facilitate a Michael addition 
and stereo selective enolate protonation, resulting in Lal formation between Lys19 and Dha6. 
The biosynthetic gene clusters of lysinoalanine-containing natural products such as 
duramycin and cinnamycin are very similar (see Ref. 136 Supplementary Fig. 12a) and all 
encode a DurN-like protein. This relatively small protein family is comprised of similar 
proteins, as shown by a tight sequence similarity network (SSN) of members identified by a 
BLAST search with DurN as query (see Ref. 136 Supplementary Fig. 12b).3 All identified 
homologs belong to duramycin-like lanthipeptide biosynthesis clusters that contain a type II 
lanthionine synthetase-like protein, a duramycin-like LanA precursor peptide, and a DurX-like 
protein. The natural products for some of these clusters have been characterized, and some of 
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the LanN proteins (CinN, MarN) have been demonstrated to be important for Lal installation in 
vivo.129,131,140,141,145 Because all of the LanA precursor peptides have a conserved Asp and a Lys 
close to the C terminus, it is likely that the substrate-assisted mechanism reported here is general 
for Lal formation in the biosynthesis of duramycin-like lanthipeptides. 
 
4.5 METHODS 
4.5.1 Strains and plasmids 
E. coli DH5α was used as host for cloning and plasmid propagation and E. coli BL21 
(DE3) as host for expression of proteins/peptides. pRSFDuet-1, pACYCDuet-1, and pETDuet-
1 were obtained from Novagen. The pET His6 small ubiquitin-like modifier (Sumo) tobacco 
etch virus (TEV) protease LIC cloning vector (2S-T) was a gift from S. Gradia (Addgene 
plasmid #29711).  
 
4.5.2 Production and purification of MBP-DurN and its mutants 
E. coli BL21 (DE3) cells were transformed with pET28a/MBP-DurN (or mutants). 
Single colonies of chemically competent E. coli BL21(DE3) were grown in Luria-Broth (LB) 
media supplemented with kanamycin (50 µg/mL). A 5-mL starter culture was grown overnight 
and used to inoculate 1 L of LB media supplemented with kanamycin. Liquid cultures were 
grown at 37 °C with shaking (200 r.p.m.) and induced with 0.15 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) when the OD600 reached 0.75, which was followed by a 20 min 
ice-bath incubation and further shaking for 20 h at 18 °C and 200 r.p.m. Cells were harvested 
by centrifugation at 4 °C, followed by suspension of the pellet in ∼30 mL of binding buffer 
(50 mM Tris pH 7.5, 0.5 M NaCl, 2.5% (v/v) glycerol, 0.1% (v/v) Triton X-100) and lysis by 
sonication. The lysates were clarified by centrifugation at 4 °C. The supernatant was loaded 
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onto a 5 mL amylose resin pre-equilibrated with binding buffer. The column was washed with 
50 mL of wash buffer (50 mM Tris pH 7.5, 0.5 M NaCl, 2.5% (v/v) glycerol) and eluted with 
20 mL of elution buffer (50 mM Tris pH 7.5, 0.15 M NaCl, 10 mM maltose, 2.5% (v/v) 
glycerol). Fractions containing the highest purity protein as judged by SDS–PAGE were pooled 
and further purified by size-exclusion chromatography (SEC) using storage buffer (50 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 50 mM NaCl, 2.5% (v/v) 
glycerol). The purified protein was concentrated using Amicon Ultra-4 centrifugal filters 
(30 kDa molecular weight cut-off (MWCO); Millipore Sigma) and frozen in liquid nitrogen for 
storage at −80 °C. Protein concentration was quantified by NanoDrop (Thermo Fisher 
Scientific) using an extinction coefficient of 83,070 M−1 cm−1 at 280 nm. 
 
4.5.3 Tag removal of MBP-DurN and its mutants 
Tobacco etch virus (TEV) protease was added to MBP-tagged protein at a 1:10 (w/w) 
ratio in digestion buffer (50 mM HEPES pH 7.5, 300 mM KCl, 50 mM NaCl, 2.5% (v/v) 
glycerol), and the reaction was left at 4 °C overnight. The sample was loaded onto 5 mL of 
HisTrap resin pre-equilibrated with digestion buffer and washed with 10 mL of the same buffer. 
Tag-free proteins were eluted with elution buffer (10 mM imidazole, 50 mM HEPES pH 7.5, 
300 mM KCl, 50 mM NaCl, 2.5% (v/v) glycerol). Fractions containing the highest purity 
protein as judged by SDS–PAGE were pooled and concentrated using Amicon Ultra-4 
centrifugal filters (10 kDa MWCO, Millipore Sigma) to ≤5 mL and injected onto a 120 mL 
Superdex 200 10/300 GL column (GE Healthcare) to purify by SEC using 300 mM KCl, 20 mM 




4.5.4 Analytical size-exclusion chromatography 
Following amylose-resin and size-exclusion chromatography, N-terminal MBP-tagged 
DurN variants were concentrated to ≥5 mg/mL before injecting 0.5 mL onto a 30 mL Superdex 
200 10/300 GL column (GE Healthcare) equilibrated with 0.1 M KCl, 20 mM HEPES, pH 7.5. 
A similar running buffer was used to elute proteins at a flow rate of 1 mL/min. N-terminal 
Sumo-tagged and tag-free DurN variants were analyzed similarly following their purification 
by Ni-affinity and size-exclusion chromatography. The retention times of DurN variants were 
compared to those of commercially available protein standards: carbonic anhydrase (bovine 
erythrocytes; 29 kDa), albumin (bovine serum; 66 kDa), and alcohol dehydrogenase (yeast; 
150 kDa) purchased from Sigma-Aldrich and analyzed using a similar procedure. Overlaid 
chromatograms for each DurN variant suggest similar homodimeric states (see Ref. 136 
Supplementary Fig. 11). 
 
4.5.5 Protein crystallization 
Pooled fractions from MBP tag removal and purification of MBP-DurN were 
concentrated to ≤5 mL and injected onto a 120 mL Superdex 200 10/300 GL column (GE 
Healthcare) to purify by SEC using 300 mM KCl, 20 mM HEPES pH 7.5 as running buffer. 
4.5.5.1 DurN (apo)  
Following SEC, DurN was concentrated to 7 mg/mL and crystallized in 2 µL hanging 
drops at 16 °C, whereby DurN solution was mixed 1:1 (v:v) with a reservoir solution containing 
25% polyethylene glycol (PEG) 3350, 0.2 M magnesium chloride, and 0.1 M Bis–Tris pH 6.5. 
Apo DurN also produced similar diffraction quality crystals using a different reservoir solution 
containing 20% PEG 8000, 0.2 M magnesium acetate, and 0.1 M sodium cacodylate pH 6.0. In 
both cases, rod-shaped crystals grew to a maximum size within 48 h. 
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4.5.5.2 DurN + compound 6 
Following SEC, DurN was concentrated to 9 mg/mL and incubated with 1.8 mM 
compound 6 for 30 min on ice. This solution was mixed 1:1 (v:v) with a reservoir solution 
containing 25% PEG 3350, 0.2 M MgCl2, and 0.1 M Bis–Tris pH 6.0 in 2 µL hanging drops 
incubated at 16 °C. Hexagonal shaped crystals grew to maximum size within 48 h. 
4.5.5.3 DurN + duramycin 
Following SEC, DurN was concentrated to 6 mg/mL and incubated with 1.5 mM 
duramycin for 30 min on ice. Insoluble particulates were pelleted by centrifugation and the 
supernatant was mixed 1:1 (v:v) with a reservoir solution containing 22.5% PEG 3350, and 
0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) pH 5.6 in 2 µL hanging drops at 16 °C. 
Thick rod-shaped crystals grew to a maximum size within 72 h. 
 
4.5.6 Crystallographic data collection, structure solutions, and refinement 
Data were collected at the Advanced Photon Source at Argonne National Lab using the 
Life-Science Collaborative Access Team 21-ID-D, 21-ID-F, and 21-ID-G beamlines. Before 
collecting data, crystals were cryoprotected by immersing the crystals in similar solutions 
supplemented with 20% ethylene glycol and then flash-freezing in liquid nitrogen. To obtain 
phases experimentally, co-crystals of DurN and compound 6 were soaked with 0.5 M potassium 
iodide for 24 h at 16 °C and used to collect diffraction data at 8 keV. Data were initially 
processed using autoPROC and further processed in autoSHARP to obtain phase 
information.71,146 The initial model was rebuilt using Buccaneer and refined using REFMAC5 
in the CCP4 Software Suite.35,74,76 Diffraction data sets corresponding to apo-DurN crystals and 
DurN-duramycin co-crystals were phased after similar processing in autoPROC followed by 
molecular replacement using Phaser MR.73,111 Ligand parameters for compound 6 and 
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duramycin were determined using Phenix eLBOW and modeled into their corresponding 
electron densities, followed by iterative rounds of automated REFMAC5 refinement and 
manual rebuilding in Coot.36,37 Solvent molecules and potassium ions were first incorporated 
using Phenix Refine or REFMAC5 then manually curated in Coot.38 
 
4.5.7 Differential scanning fluorimetry (DSF) 
Tag-free DurN purified by SEC was solvent exchanged into a buffer lacking potassium 
or magnesium ions by subjecting to additional SEC on a 30 mL Superdex 200 10/300 GL 
column (GE Healthcare) equilibrated with 0.25 M NaCl and 20 mM HEPES pH 7.5. Protein 
was eluted using a similar running buffer, and pooled fractions were concentrated to 1 mg/mL. 
SYPRO orange dye was added to the protein at 8x final concentration and incubated at r.t. for 
20 min. High-Profile 96-Well Semi-Skirted PCR plates (Bio-Rad Laboratories, Inc.) were used 
to serially titrate either KCl or MgCl2 into the protein-dye mixture from 300 mM to 150 µM or 
200 mM to 100 µM, respectively, and incubated for 25 min at 22–25 °C. Melting curves were 
obtained using a CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.) 
for which the sample was initially held at 25 °C for 3 min and then incrementally ramped to 
98 °C at 0.5 °C every 10 s with plate-reading steps at every increment. The channel was set to 
“FRET” to satisfy the excitation and emission wavelengths of the SYPRO orange dye 
(λex 470 nm /λem 570 nm). Data corresponding to the melt curves and first derivatives of the 
melt curves were obtained in the Bio-Rad CFX Manager 3.1 Data Analysis tool and 





4.5.8 Mutational studies of DurN 
A number of residues make hydrophobic contacts at the dimeric interface (i.e., Leu22, 
Val24, Leu25, Leu28, Leu39, Leu43, Leu51, Ile54, Trp68, Leu72, Trp73, Leu85, Ile111, and  
Fig. 4.4: Melt curves, negative first derivatives of the melt curves obtained by differential scanning fluorimetry 
(DSF), and potassium coordination by DurN. a, DSF data corresponding to DurN in the presence of increasing 
potassium ion concentrations (2.34 mM – 300 mM). The dose-dependent stabilization of DurN by potassium ions is 
made evident by the increasing melting temperature as a function of potassium ion concentration (i.e. right-shifting 
inflection point in the left panel and minima in the right panel). b, Similar DSF data corresponding to DurN in the 
presence of increasing magnesium ion concentration (i.e. 1.56 mM – 200 mM). No appreciable difference in the melt 
curves and persistence of high initial fluorescence across all magnesium ion concentrations suggests that DurN thermal 
stability is not influenced by magnesium ion concentration. c, 2Fo – Fc maps (blue) at 1.5σ and positive Fo – Fc maps 
(green) at 3σ of one structural ion binding site when potassium or magnesium ions are modeled and refined in 
REFMAC5.35,76 d, Octahedral potassium ion coordination by DurN involving amide carbonyl oxygen ligands from 
the DurN backbone of both monomers color-coded green or light blue. Experiments were performed once but are 
supported by potassium requirement for activity and stability and MD simulations. 
 
Leu113). Additional electrostatic interactions are observed intermolecularly between Asp12–
Lys103 and Arg18–Glu106, as well as intramolecularly between Lys34–Glu37 and Arg53–
Glu82. Several MBP-tagged and site-directed DurN variants were constructed based on the co-
crystal structures and sequence conservation between DurN homologs (see Ref. 136 
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Supplementary Fig. 12). Specifically, Ala substitutions were generated at Arg17, Arg18, Gln20, 
Cys26, Lys66, Trp68, Ser79, Gln89, and Glu101 in addition to a Lys substitution at Arg17, and 
an end-point substrate conversion assay using compound 3 was performed (see Methods). 
Aside from DurN variants C26A and S79A, a diminution in activity relative to the wild-type 
DurN was observed for all DurN variants. These activity data are rationalized by the structural 
data, as residues Arg17, Gln20, and Lys66 are implicated in substrate binding, and residues 
Arg18, Trp68, and Glu101 are important for dimerization. Unsurprisingly, mutations at Cys26 
and Ser79 exhibit no activity loss, as these residues are solvent exposed and distal to the ligand-
binding site in the crystal structures. 
 
Fig. 4.5: DurN residues selected for site-directed mutagenesis. DurN activity is abolished upon mutating the 
selected residues (drawn as sticks) to Ala (i.e. R17A, R18A, Q20A, K66A, W68A, Q89A, and E106A). Loss in activity 
is attributed either to compromising substrate recognition or disruption of the homodimer interface. Residues involved 
in intermonomer contacts at the dimer interface are highlighted with an asterisk. A magenta circle is drawn to 





CHAPTER 5: STRUCTURAL AND BIOCHEMICAL CHARACTERIZATION OF AN 
OFF-LOADING DIECKMANN CYCLASE IN NOCAMYCIN BIOSYNTHESIS 
 
5.1 ABSTRACT  
A recently identified family of stand-alone off-loading enzymes found in hybrid polyketide 
synthase/non-ribosomal peptide synthetase (PKS/NRPS) biosynthetic gene clusters catalyzes a 
Dieckmann condensation to afford five and six membered tetramate and pyridone heterocycles, 
respectively. While several tetramate containing natural products have been described, structural 
and mechanistic information on the enzymatic transformations that impart this functionality has 
largely been limited. Here we report the first structure of one such Dieckmann cyclase, NcmC, 
from nocamycin biosynthesis in its apo form (1.6 Å) and covalently bound to the epoxide 
containing inhibitor and substrate-mimic cerulenin (1.6 Å) guiding additional structure-based 
mutagenesis and activity analyses. The overall fold of NcmC closely resembles off-loading 
thioesterase and macrolactone synthase domains. Notably, only subtle active site changes are 
necessary to convert the Dieckmann cyclization activity to thioester hydrolysis. Bioinformatic 
analysis of NcmC and its homologs, combined with docking and modeling, identifies likely 
candidates for heterocycle formation in underexplored gene clusters and suggests a structural basis 
for substrate selectivity and additional engineering experiments. 
 
5.2 INTRODUCTION 
Natural products containing a core tetramic acid (pyrrolidine-2,4,-dione) or pyridone 
heterocycle are found throughout all ecology, and have been purified from marine and terrestrial 
species including cyanobacteria, actinobacteria, fungi, and sponges (Fig. 5.1A). While 
pharmacological profiles of tetramate-based natural products reveal a wide breadth of bioactivities 
including antiviral, antimicrobial, and antineoplastic properties, knowledge of the detailed  
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Fig. 5.1: Tetramate and pyridone containing natural products and nocamycin biosynthesis. (A) Representative 
set of bacterial natural products containing tetramate and pyridone heterocycles. (B) PKS/NRPS domain assembly in 
nocamycin biosynthesis. Stereochemical assignments for intermediate structures are based on bioinformatic 
predictions using the specificity conferring motifs of ketoreductase (KR) domains (57). The dehydratase (DH) domain 
from module 4 (DH4) is considered to be catalytically inactive in accordance with retention of the oxygen from C9 in 
nocamycin I and prior studies on the related natural product tirandamycin (58). Following NcmC catalyzed off-loading 
by Dieckmann condensation, a variety of tailoring enzymes (i.e. NcmDEFGOPQ) are putatively involved in formation 
of nocamycin I. The overall gene organization of the nocamycin BGC is drawn below (~61 kb). 
 
biosynthetic steps towards such molecules remains limited.147–157 In general, these scaffolds are 
secondary metabolites assembled from polyketide and a/β-amino acid precursors by the concerted 
actions of type I polyketide synthase (PKS) and non-ribosomal peptide synthetase (NRPS) 
machines. In most cases, the carbon skeleton is assembled from acetyl- and malonyl-CoA 
precursors by the actions of the PKS, which in fungi are often iterative and highly reducing. In 
tetramate and pyridone containing natural products, the NRPS module then appends the a- or β-
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amino acid to generate an N-β-ketoamide aminoacyl thioester. The mechanism for the subsequent 
carbon-carbon bond forming reaction necessary to produce the lactam ring has only been 
elucidated for a small number of the ~300 substituted tetramate and ring-expanded pyridone 
secondary metabolites isolated to date.155,158–160  
There are currently four biosynthetic routes that have been characterized for the installation 
of the carbon-carbon bond that elaborates the tetramate core. Biochemical reconstitution studies 
of equisetin biosynthesis illustrates that off-loading of the enzyme-bound thioester intermediate 
from the fungal PKS-NRPS hybrid is catalyzed by an R domain (R*) that resembles redox-active 
NAD(P)H-dependent modules but carries out a cofactor-independent Dieckmann condensation to 
produce the pyrrolidine-2-one.161 Analogous non-reductive R* domains install the tetramic acid in 
other fungal metabolites fusaridione A and cyclopiazonic acid.149,162 A second route towards 
tetramate formation is orchestrated by the terminal thioesterase (TE) in bacterial PKS-NRPS 
hybrids. These modules catalyze carbon-carbon bond formation reactions via Dieckmann 
condensation in contrast to hydrolytic release, as demonstrated for the polycyclic tetramate 
macrolactams frontalamides A and B, dihydromaltophilin, and ikarugamycin.155,163–166 The TEs 
are conceptually analogous to the fungal Claisen cyclase modules from non-reducing PKSs that 
catalyze the formation of aromatic polyketides by sequestering the substrate in a hydrophobic 
pocket that favors cyclization over hydrolysis.167–169 A third biosynthetic route consists of two 
proteins that catalyze tetramate formation in the biosynthesis of spirotetramate-containing 
pyrroindomycins through a yet to be established mechanism.170 
Examination of the putative pathways for actinomycete-derived metabolites bearing 
tetramic acid or pyridone moieties failed to identify either an off-loading TE or homologs of the 
R* domains. Bioinformatics analysis identifies an open reading frame adjacent to the PKS-NRPS 
in the tirandamycin pathway that encodes for a ~280 residue polypeptide, and homologous genes 
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could be located directly upstream of NRPS genes in the assembly lines of several 3-
acyltetramate/pyridone biosynthetic gene clusters (BGCs) including those encoding for the 
biosynthesis of streptolydigin, a-lipomycin, factumycin, and kirromycin (2, 25-30). Enzymatic 
reactions using recombinant proteins and N-acetylcysteamine thioesters of N-acetoacetyl-Gly, -
Ala, or -b-Ala as substrate surrogates resulted in conversion into the tetramic acid or pyridone 
scaffolds establishing these polypeptides as bona fide Dieckmann cyclases (DCs).171 While 
sequence based bioinformatic searches failed to reveal sequence or structural similarities to 
characterized genes in the NCBI or UniProt databases, hidden Markov Model profiling detected 
similarities to TE domains. Notably, the active site catalytic triad Ser of canonical TEs is replaced 
with a Cys in the DCs and the CysàSer replacement did not demonstrate the anticipated hydrolytic 
activity. 
Utilizing the primary sequences of these DCs as a query seed, we identified a putative 
biosynthetic pathway for a tetramate or pyridone natural product in Saccharothrix syringae NRRL 
B-16468. Fermentation and tandem mass spectrometry (MS/MS) analysis of culture supernatants 
and methanolic extracts identified nocamycin I as the product, consistent with the organization of 
the BGC (Figs. 5.1B and 5.6-5.7). A recent study also identified the nocamycin BGC using a 
cosmid library approach and corroborates our fermentation analysis.172 In order to elucidate the 
mechanistic basis for Dieckmann cyclization, we characterized the stand-alone catalyst for 
tetramate formation from this BGC using chemical and structural biological approaches. We 
further demonstrate that the mycotoxin cerulenin modifies NcmC through formation of a covalent 
adduct with the active site Cys89, consistent with the involvement of this residue in covalent 
catalysis. The cocrystal structure reveals that cerulenin binds to NcmC as a cyclic hemiaminal, 
providing a plausible mimic of a tetramate-like reaction intermediate. Combining the structural 
data with product profile analysis and docking studies points to residues which may be involved 
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in acid-base catalysis, as well as solvent shielding to facilitate carbon-carbon bond formation. 
Notably, a single amino acid change (Q128A) is sufficient to partially convert this Dieckmann 
cyclase enzyme into a TE. Structure-based modeling of NcmC homologs offers a potential 
explanation for substrate selection, which may guide future engineering efforts.  
 
5.3 RESULTS 
5.3.1 In vitro characterization of the Dieckmann cyclase NcmC 
The location of the ncmC gene immediately adjacent to the NRPS module in the nocamycin 
BGC, and the high sequence identity (45%) shared with the biochemically established DC (TrdC) 
from the tirandamycin biosynthetic cluster suggests that NcmC likely catalyzes Dieckmann 
condensation to facilitate off-loading of the hybrid PK-NRP metabolite.171 Given the biosynthetic 
logic and structure of nocamcyin, we reasoned that the NRPS adenylation (A) domain should select 
for a Gly substrate for adenylation and thiolation in vivo, and the natural substrate of NcmC should 
be a PCP-linked PK-NRP thioester (Fig. 5.1B). We used a minimal substrate mimic, N-
acetoacetyl-glycl-SNAC (1), to measure NcmC activity in vitro, as performed previously (Figs. 
5.2A and 5.8-5.16).161,171 Following incubation of 1 in the presence or absence of wild-type NcmC, 
an enzyme-dependent rate enhancement was observed by liquid chromatography-mass 
spectrometry (LC-MS) analysis, demonstrating that NcmC catalyzes Dieckmann condensation in 
vitro (Fig. 5.17). 
 
5.3.2 Overall structure of NcmC 
To gain further insights into the mechanism of the enzymatic Dieckmann condensation, we 
determined the crystal structure of NcmC to 1.6 Å resolution, using phases calculated from data  
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Fig. 5.2: Structure and activity of NcmC. (A) Reaction scheme for enzymatic or non-enzymatic Dieckmann 
condensation (red) or hydrolysis (blue) of 1. Normalized 1 turnover determined by quantitative LC-MS is plotted for 
eight NcmC variants and the non-enzymatic reaction (ne). Error bars represent standard deviation (n=3). (B) NcmC-
cerulenin cocrystal structure with secondary structural elements mapped onto the ribbon diagram (PDB 6E6T). (C) 
Comparison of the DC and TE catalytic triads. NcmC is superimposed with TEs from EntF (PDB 3TEJ) and PKS13 
(PDB 5V3W).173,174 
 
collected on a mercurial derivative. The overall structure contains two subdomains consisting of 
an  a/b hydrolase fold (composed of residues Arg5-Ser119, and Val214-Ala272) with a four-
helical bundle (composed of residues Thr121-Ala210) inserted between strands b5 and b6 (Figs. 
5.2B and 5.18). Surprisingly, the a/b hydrolase fold subdomain resembles that found in chain 
termination TEs from bacterial NRPSs, PKSs, and the multi-subunit mammalian fatty acid 
synthase complex, despite the lack of any appreciable sequence similarity with these other 
proteins. The four-helical bundle subdomain is unique to the DCs and is not a feature common to 
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any of the TEs. A DALI search against the Protein Data Bank identifies various off-loading 
domains as the closest structural homologs, due to the similarities in the a/b hydrolase fold 
subdomain, and examples include the termination module from the NRPS AB3403 (PDB 4ZXH; 
Z-score of 17.0; RMSD of 3.4 Å over 215 aligned Ca atoms),175 the TE domain from NRPS EntF, 
which catalyzes macrolactonization (PDB 3TEJ; Z-score of 16.7, RMSD of 3.7 Å over 207 aligned 
Ca atoms),173 the termination TE domain from PKS13 (PDB 5V42; Z-score of 15.9 RMSD of 4.0 
Å over 219 aligned Ca atoms),174 and the TE domain from the human fatty acid synthase (hFAS) 
(PDB 1XKT; Z-score of 15.7 RMSD of 3.7 Å over 217 aligned Ca atoms).143,176 While each of 
these subdomains contain an insertion between the equivalent strands b5 and b6, the helical 
subdomains themselves are structurally divergent and cannot be accurately aligned with each other 
(Fig. 5.19). Prior structural studies of the hFAS-TE domain in complex with the inhibitor orlistat 
led to the proposal that this helical subdomain is responsible for recognition of the aliphatic tail 
region of its substrate palmitoyl-ACP.177  
The a/b hydrolase fold domain houses residues that are shown to function as the catalytic 
triad for the cyclization reaction, and consists of Cys89, Asp116, and His254. In canonical TE 
domains, the Asp/His pair acts to lower the pKa of the nucleophilic Ser in order to promote 
reactivity of the alkoxide towards its thioester substrate, and the proximity of the catalytic His 
serves this function.  For example, the distance between the catalytic His2481 and Ser2308 in the 
TE domain of hFAS is 2.7 Å, and His1699 and Ser1533 are 2.8 Å apart in the PKS13 TE.174 In 
contrast, the distance between His254 and Cys89 is 4.9 Å in NcmC, and the orientation of the 
His254 imidazole side chain is sub-optimal, relative to the thiol of Cys89. Crystallographic 
analysis of the C89S variant reveals a comparable separation of 4.7 Å between Ser89 and the 
His254 imidazole side chain, suggesting a sulfur to oxygen swap is not sufficient to recapitulate 
the triad geometry observed in catalytic Ser-containing TEs (Fig. 5.2C). Notably, Cys89 is located 
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at the N-terminus of helix a3 and the a-helical dipole may be sufficient to lower the pKa of the 
thiol to promote reactivity (Figs. 5.2B and 5.18). Prior studies on elongation b-ketoacyl-ACP 
synthase III (FabH) support a role for the helix dipole in tuning the pKa of the nucleophilic Cys, 
and experiments with model peptides show a pKa decrease of 1.6 for Cys residues positioned at 
the N-terminus of an a-helix.28 
 
5.3.3 Structure of a covalently bound mimic of the cyclization reaction 
With the goal of visualizing NcmC with a bound substrate, we generated the Cys89àAla 
and Ser variants and incubated crystals of each with 1 but were unable to observe convincing 
electron density corresponding to features of 1. As the catalytic triad and active site elements were 
reminiscent of features observed in structures of fatty acid biosynthetic enzymes, we tested a panel 
of small molecule fatty-acid biosynthesis inhibitors against NcmC. Surprisingly, cerulenin, a 
mycotoxic, covalent inhibitor of b-ketoacyl-ACP synthase (KAS)178 formed a complex with 
NcmC as detected by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)  
Fig. 5.3: Covalent modification of NcmC by cerulenin. (A) Close-up view of the cerulenin-modified active 
site of NcmC with residues targeted for mutagenesis represented as sticks (residues derived from looped regions 
in white and helical regions in green). A difference Fourier map (Fobs - Fcalc) contoured at 2s is shown for Cys-
cerulenin in blue mesh. Catalytic triad residues are denoted with an asterisk. (B) Solution 1H/13C NMR 
previously demonstrated cerulenin prefers its cyclic hemiaminal form (1a) in polar protic solvents.185 NcmC is 
proposed to bind the cyclic form (1a) in aqueous buffer with stereospecific ring opening to afford the product 
(1b) supported by the crystal structure. 
 
 84 
(Fig. 5.20), and crystals of the covalent complex diffracted to 1.6 Å resolution (Fig. 5.3A). The 
cerulenin mycotoxin contains a 12-carbon acyl chain that mimics a fatty acyl chain substrate and 
extends into the hydrophobic pocket of various KASs.178–184 It also contains a reactive epoxide 
that undergoes ring opening by a nucleophilic Cys to form a covalent complex.  
By crystallographic observations, NcmC reacts with cerulenin stereospecifically to give 
the (3S,4R,5R) cyclic hemiaminal product (Fig. 5.3B). The stereospecificity is achieved as a result 
of favorable hydrophilic interactions occurring between the 4R-hydroxyl and Glu32/His254 where 
Phe88 is situated at the opposite face engaged in hydrophobic interactions with the C4-hydrogen. 
Similarly, specificity for the 5R position is established by H-bonding between Arg30 and the 5R-
hydroxyl, and favorable hydrophobic interactions take place along the aliphatic tail between side 
chains of Phe201 and the methylene groups of Arg30 (Fig. 5.3A).    
 
5.3.4 Structure-guided mutagenesis and end-point analysis of NcmC 
To understand the contribution of individual residues to catalysis, we generated site-
directed variants of NcmC residues based on sequence conservation and their proximity to the 
active site. NcmC variants were incubated with 1 for 1.5 h at 28 °C before quenching the reactions 
and quantifying amounts of 3 and 4 by LC-MS using authentic standards. Assuming that 
production of 4 results only from one of two mechanisms (i.e. hydrolysis or Dieckmann 
condensation) the amount of tetramate product (2) was taken to be equal to 4 – 3 (Fig. 5.2A). 
Production of 4 could also result from the formation of a covalent enzyme-bound intermediate, 
limiting accurate quantitation of 2 by this assumption. However, long incubation times ensured 
that near steady-state conditions were achieved as monitored by a spectrophotometric 2,6-
dichlorophenolindophenol (DCPIP) coupled assay (Fig. 5.21), thus the quantity of any covalent 
intermediate is likely to be very low.186,187 Consistent with the proposed role in hydrogen-bonding 
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interactions, Arg30 shows a high degree of conservation across all 98 NcmC homologs identified 
by NCBI BLAST.188 Consequently, the R30A variant resulted in a 56% decrease in enzymatic 2 
formation. In the crystal structures, Arg30 forms an electrostatic interaction with Asp24, and an 
Nh of the guanidium is involved in H-bonding with water and cerulenin (Fig. 5.3A). Surprisingly, 
the R30K variant, which would be expected to maintain the electrostatic environment but with 
impaired H-bonding interactions, resulted in a 42% increase in enzymatic 2 production with a 10% 
decrease in total turnover (including hydrolysis). This suggests that Arg30 may play more of a 
structural role and maintenance of the electrostatic interaction may help forge the integrity of the 
substrate binding site. Both mutations at Cys89 (i.e. C89A and C89S) resulted in 2 production 
commensurate with the non-enzymatic reactions, supporting that Cys89 is critical for the enzyme 
catalyzed reaction.  
Notably, the Q128A mutation results in a 74% increase in the hydrolytic product (3), 
relative to wild-type NcmC (5.2-fold increase in 3 relative to non-enzymatic hydrolysis). In the 
cocrystal structure, Gln128 is situated adjacent to the C-S bond formed in the epoxide ring opening 
reaction with NcmC, and there are no bridging water molecules in between, suggesting that Gln128 
serves to shield the enzyme-bound thioester intermediate against solvent hydrolysis. Similar to the 
C89A/C89S variants, the Y204F variant resulted in 2 formation comparable with the reaction 
lacking enzyme, indicating its loss in enzymatic DC activity. Considering the structurally observed 
H-bond network between the side chain of Tyr204, water, and cerulenin, the high degree of 
sequence conservation (conserved across 67 sequences identified by BLAST), and the apparent 
importance of Tyr204 for tetramate formation determined by quantitative LC-MS, we propose that 
Tyr204 may participate in a proton-shuttle mechanism to activate the substrate enol for 
nucleophilic attack and cyclization (Fig. 5.4). The H254N mutation nearly diminishes all 
enzymatic 2 formation with a 77% decrease relative to the wild-type reaction. This observation 
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suggests that His254 may lower the pKa of Cys89, in spite of the relatively long distance between 
these residues, or it may stabilize an intermediate by interacting with the thioester, amide, or  b-
keto/enol moieties during the transformation (Fig. 5.4).  
Fig. 5.4: Proposed mechanism of NcmC-catalyzed tetramate formation. 
 
While the wild-type enzyme is the most proficient at total turnover, it is not the most 
proficient tetramate producer (i.e. second to the R30K variant), and a considerable amount of 
hydrolysis occurs (i.e. 3.4-fold increase relative to the enzyme-free reaction). We hypothesized 
this may arise due to the differences in minimal substrate (1) and the natural PCP-linked substrate, 
causing alterations in substrate recognition that may compromise protection from solvent 
hydrolysis. To investigate this further, we synthesized the N-acetoacetyl-glycyl-S-PCP (1.8) 
substrate chemoenzymatically using a synthetic intermediate (1.4) from the synthesis of 1 and 
employing the promiscuous phosphopantetheinyl transferase, Sfp, from surfactin biosynthesis 
(Fig. 5.22).189  
Previous studies of the structural homolog EntF demonstrated hydrophobic interdomain 
contacts between the PCP and helical bundle region of TE (in cis) which appropriately positions 
the phosphopantetheine (PPant) arm into the TE active site.173,190 Reasoning that NcmC catalysis 
may be driven by similar interdomain interactions, especially as it acts in trans, we probed the 
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interaction between NcmC and its holo-PCP using size-exclusion chromatography (SEC). Co-
incubating the two proteins and subjecting them to SEC gave rise to a peak with shorter elution 
time and increased absorbance relative to that of NcmC alone, indicative of an intermolecular 
interaction (Fig. 5.23). We modeled this interaction by superimposing NcmC and a homology 
model of its cognate apo-PCP (NcmB1020-1094) onto the structures of NRPSs EntF and AB3403. 
Additional inspection of the electrostatic potential maps reveals complementarity between the 
helical bundle of NcmC and apo-PCP, providing a feasible picture of the interaction (Fig. 5.24-
5.25).  
Despite the wild-type enzyme’s proclivity to catalyze the TE reaction on 1 in vitro, MS 
analysis of the S. syringae NRRL B-16468 extracts failed to detect any of the corresponding linear 
nocamycin that would result from hydrolytic off-loading, suggesting the PCP-linked substrate is 
predominantly off-loaded via Dieckmann condensation in vivo. Attempts to produce additional 
NcmC variants heterologously in E. coli resulted in insoluble protein (i.e. D116A, D116N, H254A, 
and H254L) or the protein degraded during purification (i.e. E32A, E118A, R30A/E32A, and 
R30A/H254N) preventing further analysis.  
 
5.3.5 Bioinformatics and modeling to understand evolution of function 
In order to develop an understanding of the functional evolution of this conserved scaffold, 
we employed a combination of bioinformatics, docking, and modeling approaches to structurally 
rationalize differences in reactivity and substrate selection. Using the Enzyme Function Initiative’s 
Enzyme Similarity Tool (EFI-EST), we created a sequence similarity network (SSN) using the 
BLAST results from NcmC as a query sequence (Fig. 5.5).3 Owing to the relatively small 
population (78 sequences) and high sequence conservation in the SSN, we used a stringent 
alignment score (E-value = 10-56) to separate clusters and begin annotation (SI Appendix Materials 
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and Methods). The tetramate-containing natural product vancoresmycin is represented in the SSN 
with a corresponding node (Var15) that is likely responsible for heterocyle formation.191 
Curiously, the BGC for the tetramate-containing natural product pyrroindomycin contains an 
NcmC homolog (PyrG2), in contradiction to prior assignment of the enzymes PyrD3/PyrD4 as 
responsible for tetramate formation.170 The natural products WS9326 and bleomycin have no  
Fig. 5.5: Sequence similarity network (SSN) of NcmC homologs reveals clustering by natural product type and 
substrate specificity. (A) SSN using the BLAST results from query sequence NcmC (alignment score = 56). Larger 
circles denote proteins found in BGCs for which the natural product has been characterized. The genome context of 
each protein was analyzed to assign the natural product type color-coded according to homology with characterized 
natural products (Table 5.1). (B) Core structures of the different natural product types. Bonds in red are proposed to 
be formed by the NcmC homologs in the SSN. (C) General reaction scheme for tirandamycin-like DCs. The aminoacyl 
side chain specificity of the A-domains and DCs are tabulated for the tirandamycin-like DCs as revealed by the SSN. 
The specificity conferring “Stachelhaus” codes for each adenylation domain in cluster 1 were analyzed by the 
PKS/NRPS Analysis webtool (http://nrps.igs.umaryland.edu/)193 and the resulting codes were input into the MEME 
Suite 5.0.1 Motif Discovery tool “MEME” to generate a consensus motif (DILQLGVI) predicting for Gly 
incorporation (Table 5.2).194 
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tetramate or pyridone rings yet each of these BGCs contain sequences represented in the SSN 
suggesting a similar scaffold may be used for alternative chemistry (e.g. macrolactonization). This 
is consistent with our observation that NcmC exhibits structural homology to enzymes with 
alternative function (e.g. PKS13-TE and EntF-TE).173,174  
In cases where sequences have no obvious associated natural product structure or 
homology to characterized BGCs, we analyzed the local genomic regions using the antiSMASH 
web tool.192 Many of the closest related natural products identified were macrolide and 
macrolactam polyketides, and some include tetronate oxo-heterocycles in their final structures (i.e. 
maklamicin, tetronasin, and chlorothricin), perhaps indicating that these DC homologs can utilize 
an ester substrate. Interestingly, with respect to the tirandamycin-like nodes, the SSN also reveals 
a clustering that is dependent on the NRPS-derived aminoacyl side chain of the substrate (Fig. 
5.5C and Table 5.2). 
To better visualize how NcmC might engage its substrate during catalysis, we performed 
docking with truncated analogs of the tetramate product in AutoDock.77 Inspection of the lowest 
energy poses for both the keto and enol forms of the product shows the tetramate head group 
situated in the active site nearby the Cys89 of the catalytic triad and the aliphatic tail embedded 
along the outer face of helices a4 and a7 in the helical bundle (Fig. 5.26). Relative to the 
orientation of cerulenin in the NcmC cocrystal structure, consistencies were observed for the 
orientation of the head and tail groups as well as the proximity of Arg30 and Glu32 for H-bonding.  
Given the docking poses, in addition to the bioinformatic and structural data, we sought to 
understand the basis for substrate selection by the tetramate-forming DCs.  
We generated NcmC template-guided homology models (HMs) using the SWISS-MODEL 
server.195 Considering the lack of structural information with respect to the polyketide tail of the 
NcmC substrate, we focused our attention on recognition of the aminoacyl group of the substrate. 
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Following inspection of the docking and structural data, we identified a region of the active site 
(occupied by Glu118 in NcmC) that is most likely to accommodate the aminoacyl side chain of 
the substrate (Figs. 5.3 and 5.26).  
Comparison of the TamC, FacHI, and KirHI HMs with NcmC revealed no considerable 
difference in this region, consistent with their function in selecting similar non-bulky Gly or β-Ala 
derived substrates. However, HMs for SlgL and Var15 (putative DC in the vancoresmycin BGC) 
whose substrates contain bulkier N,β-dimethylasparagine and (dehydro)leucine side chains, 
respectively, contain some notable differences in the proposed aminoacyl binding site, offering a 
potential explanation for substrate selection. Specifically, when overlaid with NcmC, the SlgL HM 
contains Ser132 in place of Glu118 (NcmC) potentially providing a more spacious active site, and 
this Ser is conserved in SlgL putative orthologs identified by BLAST and antiSMASH (Table 5.1 
and Fig. 5.27). Similarly, the Var15 HM reveals a Thr117 in this position that is also conserved in 
its putative orthologs identified by BLAST and antiSMASH (i.e. AUO14856.1, WP_103348671.1, 
and WP_086863360.1; Table 5.1 and Fig. 5.27). Curiously, the LipX2 HM provided no obvious 
difference in the putative aminoacyl binding site, despite its preference for an L-Glu side chain. 
However, scanning of additional active site residues around the catalytic Cys revealed a His129 in 
place of Thr122 (NcmC) and an Arg241 in place of Ala242 (NcmC) which could feasibly interact 
with the carboxylate side chain of the substrate (Fig. 5.27). These His/Arg residues are also 
conserved in the putative LipX2 ortholog WP_061441796 (Table 5.1). Notably, the multisequence 
alignment reveals an 11-residue deletion in SlgL, LipX2, Var15, and WP_061441796 spanning 
helix a9 in NcmC and resulting in an apparent opening of the active site cleft near the putative 





Metabolite off-loading from PKS/NRPS assembly lines represents an important step in the 
production and manipulation of bioactive compounds. Here, we examine a reoccurring protein 
scaffold that has been selected for a variety of chemical transformations, imparting chemical 
diversity in a number of off-loaded products found in nature. Specifically, we use structural and 
mechanistic methods to address how one type of stand-alone, off-loading enzyme catalyzes a 
Dieckmann condensation to afford a five-membered tetramate heterocycle. The noted structural 
homology to enzymes that catalyze alternative reactions, namely thioester hydrolysis and 
macrolactonization, suggests that these protein scaffolds can be engineered to alter their 
reactivities but maintain substrate specificity. Indeed, a single point mutation (Q128A) of NcmC 
was sufficient to increase hydrolysis to 5.2-fold greater than the non-enzymatic reaction with a 
corresponding 41% decrease in its natural DC activity, demonstrating partial conversion of this 
enzyme to a TE.  
Structural and biochemical considerations point to why the DCs employ a catalytic Cys 
rather than a Ser found in the TEs. Additional effects on enzyme activity using structure-based 
NcmC variants enable a mechanistic proposal for activation of a nucleophilic enol involved in 
cyclization. Finally, NcmC homologs were assembled into a SSN that reveals a clustering of DCs 
from similar BGCs that is dependent on the identity of the aminoacyl side chains of the substrate. 
A deeper look into the structural features underpinning the substrate selectivity was facilitated by 
template-guided homology modeling and active site comparisons. Our data suggest that polyketide 
tail recognition is governed by the four-helical bundle, consistent with studies of the hFAS-TE 
structural homolog, and recognition of aminoacyl functionality is segmented into the a/b-
hydrolase domain.176 The apparent modularity of the polyketide and aminoacyl recognition sites 
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may lend itself to engineering of hybrid DCs where recognition features are swapped in related 
biosynthetic pathways to assist in off-loading artificial, hybrid metabolites.  
 
5.5 METHODS 
5.5.1 Materials  
Oligonucleotides were purchased from Integrated DNA Technologies. Enzymes used for 
PCR, plasmid digestion, and Gibson Assembly were purchased from New England Biolabs. Buffer 
and media components were purchased from Thermo Fisher Scientific and other reagents were 
purchased from Sigma-Aldrich (MilliporeSigma).   
 
5.5.2 General Methods 
Purification of protein was performed using an ÄKTAprime plus purifier (GE Healthcare). 
High-performance liquid chromatography (HPLC) was carried out using a Shimadzu Prominence 
Preparative Liquid Chromatography system. Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) experiments were conducted using an 
UltrafleXtreme mass spectrometer (Bruker Daltonics).  
 
5.5.3 Homologous production of nocamycin I from Saccharothrix syringae NRRL B-16468 
A lyophilized mycelial stock of Saccharothrix syringae NRRL B-16468 was used to 
inoculate 6 x 5 mL solid R5A medium agar plates incubated at 28 °C for one week.196 The media 
became dark red in color and agar slices were excised to inoculate 2 x 500 mL liquid R5A medium, 
and the liquid cultures were grown at 28 °C with shaking at 220 rpm. The cells were harvested by 
centrifugation at 3000 × g and cells were soaked in MeOH for 3 h followed by filtration on 
Whatman filter paper. The supernatant from centrifugation was extracted twice with 2 x 500 mL 
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of ethyl acetate. The MeOH filtrate and ethyl acetate fractions were pooled and concentrated in 
vacuo. The crude, concentrated extract was used for HR-MS and MS/MS analysis.  
 
5.5.4 Tandem mass-spectrometry (MS/MS) analysis of nocamycin I  
Organic extracts derived from culture supernatant and methanolic cell soaks of S. syringae 
NRRL B-16468 were directly infused into a ThermoFisher Scientific Orbitrap Fusion electrospray-
ionization mass-spectrometer (ESI-MS) using an Advion TriVersa Nanomate 100. The following 
parameters were used: resolution = 120,000; isolation width (MS/MS) = 2 m/z; normalized 
collision energy (MS/MS) = 35; activation q value (MS/MS) = 0.4; and activation time (MS/MS) 
= 30 ms. Collision-induced dissociation (CID) and high-energy collisional dissociation (HCD) 
were used to fragment the parent ion at 35%. Data analysis was performed in the Qualbrowser 
application of Xcalibur software (Thermo Fisher Scientific).   
 
5.5.5 Cloning and heterologous expression of NcmC, NcmC site-directed variants, and NcmB 
(di)domains.  
All heterologous expression plasmids were generated via the pET hexahis (His6) small 
ubiquitin-like modifier (SUMO) tobacco etch virus (TEV) protease ligation-independent cloning 
(LIC) vector (2S-T). This vector was a gift from Scott Gradia (Addgene plasmid # 29711). Primers 
were designed to include the LICv1 tags specific to this vector. Genomic DNA template for PCR 
was obtained via cultivation of Sacchrothrix syringae NRRL B-16468 in ISP2 medium while 
shaking at 30 °C (15 mL) followed by isolation using the DNeasy UltraClean Microbial Kit 
(QIAGEN, Inc). PCR products were ligated into SspI-linearized 2S-T via the Gibson Assembly 
method to construct an N-terminally labeled His6-SUMO-NcmC, His6-SUMO-NcmB-PCP, or 
His6-SUMO-NcmB-A-PCP expression plasmid.197 Site-directed mutants of ncmC were generated 
 94 
via three-component assemblies of the SspI-linearized 2S-T and two ncmC gene fragments 
containing the PCR-derived mutations. Gibson assembled plasmids were maintained and 
propagated in E. coli DH5α. Sequencing services were provided by ACGT Inc. (Wheeling, IL). E. 
coli Rosetta (DE3) competent cells were subsequently transformed with the sequence-verified 
plasmids and used to overexpress all proteins by growing at 37 °C in Luria-Broth (LB) to an optical 
density at 600 nm (OD600) of 0.5-0.6. Protein expression was then induced with 0.5 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) and allowed to grow for an additional 18-20 h at 18 °C.  
 
5.5.6 NcmC protein purification 
2-4 L of LB media was used for overexpression in E. coli Rosetta (DE3) for each NcmC 
variant. After induction, cells were centrifuged at 3,000 ´ g and resuspended in buffer A (500 mM 
NaCl, 25 mM tris-HCl pH 8.0, and 10% glycerol (v/v)) before subjecting to French press lysis at 
8,000 – 10,000 psi for five total cycles. Lysate was cleared by centrifugation at 15,400 ´ g for 1 h 
at 4 °C and the supernatant was loaded onto a 5 mL HisTrap nickel-nitrilotriacetic acid (Ni-NTA) 
affinity column (GE Healthcare) equilibrated with buffer B (1 M NaCl, 25 mM tris-HCl pH 8.0, 
and 30 mM imidazole). This was followed by a 50 mL wash with buffer B before eluting the His6-
tagged protein by employing a linear gradient of 0-100% buffer C (1 M NaCl, 25 mM tris-HCl pH 
8.0, and 500 mM imidazole) over 35 min at 2 mL/min. Pooled fractions containing His6-SUMO-
NcmC were proteolyzed using 30 µg/mL of tobacco etch virus (TEV) protease to remove the His6-
SUMO tags. Proteolysis was carried out while simultaneously dialyzing into 200 mM NaCl, 20 
mM tris pH 8.2, and 2.5 mM β-mercaptoethanol (BME) for 12 h at 4 °C. Protein solution was 
dialyzed again into a similar buffer lacking BME for 4 h at 4 °C before loading onto a Ni-NTA 
column equilibrated with buffer A for subtractive Ni-NTA affinity purification. The column was 
washed with 35 mL of buffer A before using a stepwise gradient of increasing buffer B to elute 
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tag-free NcmC variants. Steps of buffer B increased as follows: 10%, 20%, 30%, 40%, 50%, and 
100% in 5-10 mL increments depending on the absorption at 280 nm (peaks were allowed to fully 
elute before moving to the next increment). NcmC eluted primarily in the flow-through and wash 
fractions. Prior to crystallography experiments, NcmC variants were purified by size-exclusion 
chromatography (SEC) using a 120 mL Superdex 200 10/300 GL column (GE Healthcare) and 
100 mM KCl, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5 as 
running buffer. NcmC eluted with ~90% purity at this stage by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Fig. 5.28).  
 
5.5.7 NcmB PCP-, and A-PCP-(di)domain purification 
Cells were harvested, lysed, and supernatant-cleared similar to NcmC samples. 
Supernatant was applied to 2 mL of HisPur nickel-nitrilotriacetic (Ni-NTA) resin (Thermo 
Scientific) and injected by gravity elution. The resin was washed with 40 mL of buffer B prior to 
eluting the protein with buffer C in 2 mL increments for 10 total fractions. His6-SUMO-NcmB-
PCP was treated with TEV protease and subjected to subtractive nickel affinity purification as 
described for NcmC. Tag-free NcmB-PCP (apo-PCP) eluted primarily in the flow-through, wash, 
and 10-30% buffer B fractions. Concentrated fractions were used directly in enzymatic reactions 
to synthesize holo-PCP or purified by acetone precipitation before synthesizing N-acetoacetyl-
glycyl-S-PCP (see 5.5.9 In vitro enzymatic synthesis of holo-PCP and N-acetoacetyl-glycyl-S-
PCP). A majority of His6-SUMO-NcmB-A-PCP was observed in the cell pellet following lysis, 
and the small amount of soluble protein purified by Ni-NTA was observed in an aggregate state 




5.5.8 Synthesis of N-acetoacetyl-glycyl-SNAC (1) and N-acetoacetyl-glycyl-S-CoA (1.7) 
5.5.8.1 3-oxobutanoic acid; acetoacetic acid (1.1) 
To a stirring solution of 200 mL 1 N NaOH in a 500 mL round-bottom flask was added 25 
mL (196 mmol; 1 eq) of ethyl acetoacetate. The reaction was stirred at room temperature for 12 h 
before adding saturating amounts of (NH4)2SO4 and then acidifying to pH 2 with concentrated 
HCl. The solution was then extracted twice with 150 mL of diethyl ether, dried with Na2SO4, and 
concentrated in vacuo to afford 15.6 g (78%) of a pale-yellow liquid. 1H NMR (400 MHz, CDCl3): 
δ 11.55 (1H, s), 3.47 (2H, s), 2.22 (3H, s) ppm (Fig. 5.10). 
5.5.8.2 methyl (3-oxobutanoyl)glycinate (1.3) 
In a flame-dried 100 mL round-bottom flask, 1.3 g (12.7 mmol; 1 eq) of 1.1 and 3.2 g (12.7 mmol; 
1 eq) of disuccinimidyl carbonate (DSC) were added to 100 mL of stirring acetonitrile (ACN) 
cooled at 0 °C. Following a 20 min incubation, 1.5 mL (19.1 mmol; 1.5 eq) of pyridine was added 
dropwise and a cloudy white suspension was allowed to stir for another 20 min at 0 °C. The 
reaction was heated to room temperature and stirred for 1 h while the solution became clear. The 
solution was reduced to approximately half of its initial volume in vacuo and cooled to 0 °C after 
adding an equal volume of dry CH2Cl2.  In situ generation of 1.2 was followed by addition of 1.6 
g (12.7 mmol; 1 eq) glycine methyl ester hydrochloride. While maintaining at 0 °C, 2.7 mL (19.1 
mmol; 1.5 eq) of Et3N was added dropwise over 3 min. After stirring on ice for 1 h, the reaction 
was heated to room temperature and stirred for an additional 12 h. The reaction was concentrated 
in vacuo followed by resuspension in CH2Cl2. The solution was washed once with an equal volume 
of 1 N HCl and once with an equal volume of H2O. After drying the organic phase with Na2SO4, 
the contents were concentrated in vacuo and subjected to silica gel flash-chromatography. A 
mobile phase of 80:15:5 EtOAc:CH2Cl2:MeOH  was used and 1.3 eluted with an Rf = 0.4. 650 mg 
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(30%) of 1.3 was obtained as a light-yellow solid. 1H NMR (400 MHz, CDCl3): δ 7.53 (1H, s), 
4.01 (2H, d, J = 5.2 Hz), 3.70 (3H, s), 3.45 (2H, s), 2.23 (3H, s) ppm (Fig. 5.11). 
5.5.8.3 (3-oxobutanoyl)glycine (1.4) 
In a 10 mL round-bottom flask 650 mg (3.8 mmol; 1 eq) of 1.3 was stirred in 2 mL of EtOH at 
room temperature followed by the addition of 4 mL of 1 N NaOH (4 mmol; 1.1 eq). The reaction 
was stirred for 1 h at room temperature before removing the EtOH in vacuo and acidifying the 
solution to pH 3. The aqueous contents were then extracted using ethyl acetate (5 x 20 mL). 
Organic phases were pooled, dried using Na2SO4, and concentrated in vacuo to yield 350 mg (59%) 
of 1.4 as a yellowish white solid. 1H NMR (500 MHz, DMSO-d6): δ 3.77 (2H, d, J = 5.5 Hz), 3.35 
(2H, s), 2.15 (3H, s) ppm (Fig. 5.12). 
5.5.8.4 S-phenyl 2-(3-oxobutanamido)ethanethioate (1.5) 
Following slight modification to the procedure of Sims et al., 50 mg of 1.3 (0.31 mmol; 1 eq) was 
added to 5 mL of ACN in a 15 mL flame-dried round-bottom flask along with 96 µL of thiophenol 
(0.94 mmol; 3 eq) and 196 mg of (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) (0.38 mmol; 1.2 eq).161 After stirring for 1 h at room temperature, 
25 mg of K2CO3 (0.19 mmol; 0.6 eq) was added and stirred for an additional 2 h. After 
concentrating in vacuo, the contents were dissolved in minimal EtOAc for purification by silica 
gel flash-chromatography with a gradient mobile phase of 0-20% hexanes in EtOAc over 100 mL. 
The product eluted with an Rf = 0.5 in 1:4 hexanes:EtOAc. Fractions containing crudely purified 
material were concentrated in vacuo and resuspended in DCM. Filtration of the suspension 
afforded pure product in the filtrate (50 mg; 63%). 1H NMR (400 MHz, CDCl3): δ 7.70 (1H, m), 
7.62 (1H, m), 7.41 (1H, m), 7.26 (2H, m), 4.18 (2H, d, J = 8 Hz), 3.39 (2H, s), 2.14 (3H, s) ppm 
(Fig. 5.13).  
5.5.8.5 3-acetyl-4-hydroxy-1,5-dihydro-2H-pyrrol-2-one (1.6) 
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Following slight modification to the procedure of Sims et al., 4.6 mg of sodium methoxide (86 
µmol; 1.2 eq) was added to a 10 mL flame-dried round-bottom flask and dissolved in 2 mL of dry 
benzene, followed by the addition of 18 mg of 1.5 (72 µmol; 1 eq).161 The reaction was refluxed 
for 5 h then extracted with water. The aqueous layer was acidified to pH 2 using concentrated 
H2SO4 and extracted into diethyl ether. After concentration in vacuo, the product was purified by 
HPLC using a Grace Vydac DENALI C18 column (250 ´ 4.6 mm, 5 µm particle size, 120 Å pore 
size) and monitoring by absorbance at 230 nm. A two-component mobile phase consisted of H2O 
+ 0.1% formic acid (A) and ACN + 0.1% formic acid (B). Initially 5% B (v/v) was held for 10 min 
followed by a linear gradient of 5 - 60% B (v/v) over 21 min. 1.6 eluted around 15 min and was 
concentrated in vacuo to afford a white solid (2.0 mg, 20%) 1H NMR (500 MHz, CDCl3): δ 5.71 
(1H, s), 3.82 (2H, s), 2.48 (3H, s) ppm (Fig. 5.14).  
5.5.8.6 S-(2-acetamidoethyl) 2-(3-oxobutanamido)ethanethioate (1) 
100 mg (0.63 mmol; 1 eq) of 1.4 was added to a flame-dried 25 mL round-bottom flask containing 
5 mL of DMF and stirred briefly at 0 °C followed by addition of 133 mg (0.69 mmol; 1.1 eq) N-
(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and 106 mg (0.69 mmol; 1.1 
eq) 1-hydroxybenzotriazole (HOBt). After stirring at 0 °C for 10 min 164 µL (0.94 mmol; 1.5 eq) 
of N,N-diisopropylethylamine (DIPEA) was added dropwise over 2 min followed by dropwise 
addition of 67 µL (0.63 mmol; 1 eq) N-acetylcysteamine over 5 min. The reaction was stirred at 0 
°C for 30 min then heated to room temperature and stirred for another 6 h. DMF was removed 
from the reaction by running silica gel flash-chromatography with a 60:35:5 
EtOAc:CH2Cl2:MeOH mobile phase. Crudely purified 1 eluted with an Rf = 0.2-0.3 as verified by 
1H NMR. 1 was further purified using HPLC with monitoring by absorbance at 230 nm and a 
Grace VisionHT C18 HL column (5 μm particle size; 250 mm length; part No. 5151988). The 
same elution program for 1.6 was used with mobile phases lacking formic acid. 1 eluted around 3 
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min and was concentrated in vacuo to afford a white solid (4 mg; 2%). 1H NMR (500 MHz, 
CDCl3): δ 7.72 (1H, s), 5.85 (1H, s), 4.22 (2H, d, J = 6.0 Hz), 3.52 (2H, s), 3.43 (2H, q, J = 6.0 
Hz), 3.07 (2H, t, J = 6.3 Hz), 2.30 (3H, s), 1.97 (3H, s) ppm (Fig. 5.15). HRMS: calculated [M+H]+ 
= 261.0909 Da; observed [M+H]+ = 261.0909 Da (Fig. 5.16).   
5.5.8.7 N-acetoacetyl-glycyl-S-CoA (1.7) 
Following slight modification to the procedure of Sims et al., 12 mg of 1.5 (48 µmol; 1.5 eq) was 
added to 25 mg of coenzyme A (CoA) trilithium salt dissolved in 20 mM sodium phosphate buffer 
(200 µL; pH 8).161 After 30 min of stirring at room temperature, 10% THF was added to increase 
solubility of 1.5 followed by additional stirring for 2.5 h. The reaction was neutralized by addition 
of 10 µL of 1 N HCl and products were purified by HPLC intially using a Grace VisionHT C18 
HL column (5 μm particle size; 250 mm length; part No. 5151988) and an isocratic elution of 2% 
(v/v) aqueous ACN over 35 min. Crudely purified product eluted from 3.5 – 8 min was subject to 
additional HPLC purification using a YMC-Triart Diol-HILIC column (5 μm particle size; 250 
mm length; part No. 0425087425) with a two-component mobile phase (i.e. A = 10 mM 
ammonium bicarbonate pH 7.0; B = ACN) and an intial linear descent from 95 – 50% B over 10 
min followed by a 15 min hold at 50% B. The product 1.7 co-eluted with free CoA from 16-20 
min and was not further purified for downstream phosphopanthetheinylation reactions (see 1.8 
synthesis).  
 
5.5.9 In vitro enzymatic synthesis of holo-PCP and N-acetoacetyl-glycyl-S-PCP (1.8) 
The surfactin phosphopantetheinyl transferase (Sfp) from Bacillus subtilis (gifted from Dr. 
John Cronan) was employed in the modification of the apo peptidyl carrier protein (PCP) domain 
from the NRPS NcmB to generate N-acetoacetyl-glycyl-S-PCP and holo-PCP. Holo-PCP was 
synthesized by adding 8 µM Sfp to a mixture of 500 µM apo-PCP (from subtractive Ni-
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purification), 2 mM CoA, 1 mM TCEP, 2.5 mM MgCl2, and 50 mM tris pH 7.0 (500 µL total), 
and the reaction contents were incubated at 30 °C for 12 h. Holo-PCP was purified by adding 500 
µL ice-cold acetone to precipitate protein impurities. The precipitate was removed by 
centrifugation, and the acetone layer was concentrated by applying a stream of N2. The concentrate 
was resuspended in 500 µL H2O and buffer exchanged into 50 mM tris pH 7.0 using a Sephadex 
G-25 in PD-10 Desalting Column (GE Healthcare). The eluate was concetrated by lyophilization 
to yield 1.5 mg (71%) holo-PCP (≥95% pure by SDS-PAGE; Fig. 5.29) quantified by the Bradford 
assay.198 N-acetoacetyl-glycyl-S-PCP (1.8) was synthesized in a nearly identical manner to holo-
PCP, except 125 µM apo-PCP substrate was used (purified by acetone precipitation as described 
for holo-PCP), 625 µM 1.7 was used rather than 2 mM CoA, and the reaction was terminated by 
flash-freezing in liquid N2 after 3 h. The reaction mixture was used directly for downstream NcmC 
reactions. 
 
5.5.10 MALDI-TOF MS analysis of Sfp reactions (holo-PCP and 1.8) 
A small aliquot of 5 µL from Sfp enzymatic reactions was desalted following the 
manufacturer protocol using a C4 ZipTip (Millipore Sigma). Desalted samples contained 50% aq. 
ACN + 0.1% trifluoroacetic acid (v/v) and were spotted onto a Bruker 384-well MALDI plate 
using a 2,5-dihydroxybenzoic acid maxtrix for analysis by MALDI-TOF MS in linear positive 
mode (Fig. 5.22). 
 
5.5.11 In vitro enzymatic reactions with NcmC and N-acetoacetyl-glycyl-SNAC (1) 
Following subtractive Ni-NTA affinity purification, NcmC variants were concentrated to 
£ 5 mL and incubated with 1 mM dithiothreitol (DTT) for 30 minutes before injecting onto a 120 
mL Superdex 75 10/300 GL column (GE Healthcare) and eluting with 0.1 M NaCl, 20 mM HEPES 
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pH 7.0, 30 µM DTT running buffer. To minimize the amount of non-enzymatic consumption and 
maximize the enzymatic consumption of 1, a panel of buffers was tested for optimal product 
production determined by relative HPLC peak areas. Both tris and HEPES buffers ranging from 
pH 7 - 7.5 were tested before arriving at an optimal tris pH 7.2 buffer. Additionally, it was found 
that NcmC was most active in the presence of DTT and was included at a low concentration (i.e. 
30 µM) to minimize potential transthioesterification of 1, thus an optimal reaction buffer of 100 
mM NaCl, 20 mM tris pH 7.2, and 30 µM DTT was used for all in vitro enzyme reactions. 50 µL 
reactions were run at 28 °C for 1.5 h with 23 µM enzyme and 100 µM substrate (1) in reaction 
buffer. To quench the reactions, an equal volume of ACN was added and incubated for 15 min at 
room temperature to precipitate the proteins. Precipitates were pelleted by centrifugation, followed 
by addition of 0.1% formic acid to the supernatants for downstream HPLC and LC-MS analysis. 
 
5.5.12 Analytical size-exclusion chromatography  
5.5.12.1 NcmC variants: The SEC-purified NcmC variants used in in vitro assays were 
further purified by SEC on a 30 mL Superdex 200 10/300 GL column (GE Healthcare) equilibrated 
with 0.3 M KCl, 20 mM HEPES pH 7.5 and using a similar running buffer at a flow rate of 0.6 
mL/min. Commercially available protein standards (Millipore Sigma) were run under similar 
conditions, enabling standard curve generation (Fig. 5.28). NcmC variants eluted as a monomer in 
solution (in agreement with the crystallographic data).  
 
5.5.12.2 NcmC + holo-PCP: Wild-type NcmC (20 nmol), holo-PCP (20 nmol), or NcmC 
+ holo-PCP (20 + 22 nmol) were separately injected in 200 µL volumes onto a 30 mL Superdex 
200 10/300 GL column (GE Healthcare) equilibrated with 0.3 M KCl, 2 mM BME, 20 mM HEPES 
pH 7.5 and eluted with a similar running buffer while monitoring absorbance at 254 nm (Fig. 5.23). 
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Before co-injecting NcmC + holo-PCP, the sample was allowed to incubate at room-temperature 
for 20 min.  
 
5.5.13 HPLC analysis of the in vitro NcmC reactions  
Quenched reactions were analyzed by HPLC using a Grace Vydac DENALI C18 column 
(250 ´ 4.6 mm, 5 µm particle size, 120 Å pore size). Elution consisted of a two-component mobile 
phase (i.e. A = H2O + 0.1% formic acid; B = ACN + 0.1% formic acid) at 1 mL/min with the 
following linear gradient: 0-5 min, 2% B; 5-15 min, 2-35% B; 15-27 min, 90% B. LabSolutions 
5.81 software was used for data analysis.   
 
5.5.14 LC-MS analysis of the in vitro NcmC reactions  
Samples were analyzed with the 5500 QTRAP LC/MS/MS system (Sciex, Framingham, 
MA) in the Metabolomics Lab of Roy J. Carver Biotechnology Center, University of Illinois at 
Urbana-Champaign. Software Analyst 1.6.2 was used for data acquisition and analysis. The 1200 
series HPLC system (Agilent Technologies, Santa Clara, CA) includes a degasser, an autosampler, 
and a binary pump. The LC separation was performed on an Agilent SB-Aq (4.6 x 50mm, 5μm) 
with a two-component mobile phase (A = H2O + 0.1% formic acid; B = ACN + 0.1% formic acid). 
The flow rate was 0.3 mL/min. The linear gradient was as follows: 0-2 min, 0% B; 2-6 min, 0-
98% B; 6-9 min, 98%B; 9-10 min 98-0% B; 10-14min, 0%B. The autosampler was set at 10 °C. 
The injection volume was 5 μL. Mass spectra were acquired under both positive (ion spray voltage 
was +5500 V) and negative (ion spray voltage was -4500 V) ESI modes. The source temperature 
was 450 °C. The curtain gas, ion source gas 1, and ion source gas 2 were 33, 65, and 60, 
respectively. Multiple reaction monitoring (MRM) was used for quantitation: in positive mode, 
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compound 4 was monitored at m/z 120.0 --> m/z 86.0; in negative mode, compound 3 was 
monitored at m/z 158.1 --> m/z 100.0.  
 
5.5.15 Monitoring reaction progress: 2,6-dichlorophenolindophenol (DCPIP) spectrophotometric 
coupled assay  
In vitro NcmC reactions with 1 were initiated as described above with 15 µL reaction 
volumes and containing 150 µM DCPIP. Reactions were contained in a tape-sealed Corning 384-
well black with clear bottom, low flange polystyrene plates (MilliPore Sigma; CLS3764). 
Absorbance at 600 nm was measured using an Epoch Microplate Spectrophotometer equipped 
with Gen5 2.09 software (BioTek Instruments, Inc.).  
 
5.5.16 Covalent modification of NcmC by cerulenin  
Wild-type NcmC (40 µM) purified by SEC as described for the in vitro reactions was 
incubated with 1 mM cerulenin at 28 °C for 4 h in reaction buffer (50 µL total volume). Half of 
the sample was treated with 7.5 µg trypsin and incubated at 24 °C for 30 min prior to desalting 
both the trypsinized and non-trypsinized reactions using a C4 resin ZipTip (MilliPore Sigma). 
Samples were spotted on a Bruker matrix-assisted laser desorption/ionization (MALDI) plate with 
2,5-dihydroxybenzoic acid matrix and analyzed using a Bruker Daltonics UltrafleXtreme MALDI 
time-of-flight mass spectrometer (MALDI-TOF MS) in reflector positive mode at the University 
of Illinois School of Chemical Sciences Mass Spectrometry Laboratory.  
 
5.5.17 Protein crystallization  
5.5.17.1 NcmC: Following SEC, NcmC was concentrated to 20 mg/mL prior to 
crystallization in 2 µL hanging drops by incubation at 9 °C of 1:1 (protein:reservoir solution) above 
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a reservoir solution containing 1.75 M (NH4)2SO4, 1.9% (w/v) polyethylene glycol (PEG) 400, 0.1 
M HEPES pH 7.0, and 3 mM DTT. Long rod-shaped crystals grew to maximum size within 36 h.  
 
5.5.17.2 NcmC-C89S: The NcmC-C89S variant was crystallized similarly to wild-type 
NcmC with the exception of using a reservoir solution of 1.70 M (NH4)2SO4, 2.5% (w/v) PEG 400, 
0.1 M HEPES pH 7.0, and 5 mM tris(2-carboxyethyl)phosphine (TCEP). Long rod-shaped crystals 
grew to maximum size within 48 h.  
 
5.5.17.3 NcmC-cerulenin: Following SEC and concentration of NcmC to 20 mg/mL, 
NcmC was incubated with 2 mM DTT for 30 min followed by incubation with 4 mM cerulenin 
for 1 h at room temperature. Covalently modified NcmC (Figs. 3 and S14) was then crystallized 
at 9 °C in 2 µL hanging drops by incubation of 1:1 (protein:reservoir solution) above a reservoir 
solution containing 1.8 M (NH4)2SO4, 1.8% (w/v)  PEG 400, 4% (v/v) formamide, 0.1 M HEPES 
pH 7.0, and 3 mM DTT. Long rod-shaped crystals grew to maximum size within 36 h.  
 
5.5.18 X-ray data collection, and structure solution 
Prior to flash-freezing in liquid nitrogen, crystals were immersed in their crystallization 
reservoir solution supplemented with 25% ethylene glycol. Data were collected using the 21-ID-
D, 21-ID-F, and 21-ID-G beamlines at the Life Science Collaborative Access Team (LS-CAT) at 
the Advanced Photon Source (Argonne National Laboratory). Crystals mounted on an MD2 
diffractometer (Arinax Scientific Instrumentation) were maintained at 100 K under an aerosolized 
nitrogen stream. NcmC crystals soaked in 5 mM mercury (II) acetate for 5 h at room temperature 
were used to collect diffraction data at 12.4 keV. Initial diffraction data were processed using XDS 
and autoPROC to obtain scaled and merged intensities.71,199 Experimental phases were obtained 
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by the single-wavelength anomalous diffraction method using Phenix AutoSol.33 An initial model 
was built in Phenix AutoBuild and further refined using Phenix Refine and REFMAC5 along with 
manual fitting in Coot.34–36,38 Diffraction data for the NcmC-C89S and NcmC-cerulenin variants 
were collected at wavelengths of 0.97856 Å and 0.97872 Å, respectively, and their structures were 
solved by similar XDS/autoPROC data processing followed by molecular replacement using the 
NcmC coordinates (PDB 6E6Y) in Phaser.72 Initial models were similarly refined in Phenix Refine 
and REFMAC5 and manually refined in Coot. The crystallographic information file (cif) library 
and coordinate (pdb) files were created in PRODRG for the ring-opened and cyclic hemiaminal 
form of cerulenin (structure 1b in Fig. 5.3B omitting the protein-derived atoms).200 The resultant 
cif/pdb files were used to fit the ligand manually into the difference Fourier map (Fobs – Fcalc) and 
further refined in REFMAC5. Overall Ramachandran statistics are as follows: NcmC (98% 
favored, 1.9% allowed, and 0.2% outliers); NcmC-C89S (98% favored, 1.5% allowed, and 0.0% 
outliers); NcmC-cerulenin (97% favored, 2.4% allowed, and 0.4% outliers).  
 
5.5.19 Sequence Similarity Network (SSN) of NcmC homologs 
The Enzyme Function Initiative’s Enzyme Similarity Tool (EFI-EST; 
https://efi.igb.illinois.edu/efi-est/) was used to perform a BLAST search of the UniProt database 
with NcmC as a query amino acid sequence. An alignment score of 56 was used to generate the 
SSN containing 78 sequences restricted in length between 240-292 residues. Analysis of the 
network was carried out in Cytoscape 3.6.1.201   
 
5.5.20 SSN node and associated NRPS adenylation (A) domain annotation 
We initially identified the in vitro characterized DCs (i.e. NcmC, TrdC, SlgL, and KirHI), 
bioinformatically inferred DCs (i.e. FacHI and LipX2), and additional nodes in the SSN which are 
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associated with characterized BGCs (larger circles in Fig. 5.5A). The RODEO web tool was then 
used to assign the genomic context of each node (for node details see Tables 5.1-5.2).202 Based on 
natural product structure and co-occurrence of genome neighbors, we assigned each node to a 
particular cluster type. In silico prediction of NRPS A-domain specificity was carried out using 
the webtool developed by Bachmann et al. (http://nrps.igs.umaryland.edu/).193 Analysis of cluster 
1 predicts a consensus Gly motif (i.e. DILQLGVI; Table 5.2).203,204 Similar A-domain prediction 
failed for cluster 2, but prior work on the methyltransferase SlgM (from streptolydigin 
biosynthesis) suggests an NRPS-bound N,β-dimethylasparagine to be a substrate prior to off-
loading.205 The lipomycin A-domain in cluster 5 was also resistant to specificity prediction but is 
presumed to select L-Glu on the basis of the final product structure.206 Analysis of the genomic 
contexts of uncharacterized nodes in clusters 2 and 5 by antiSMASH suggests that these are 
additional streptolydigin and lipomycin producers, respectively (Table 5.1). 
 
5.5.21 Docking analysis with NcmC and truncated tetramate product 
The nocamycin I structure was truncated in ChemDraw at C7 to eliminate the fused 
tricyclic spiroketal moiety. The structure-data file (sdf) was opened in Molecular Operating 
Environment (MOE) 2016.08 and energy minimized in the gas phase using the MMFF94x 
forcefield (dielectric = 1; exterior = 80).118 The (R/S) forms of the keto tautomer were manually 
built in MOE and similarly energy minimized. The enol and (R/S) keto structures were saved as 
sdf files and opened in the PyMOL Molecular Graphics System (1.7.0.0) containing the 
Autodock/Vina plugin (2.2.0). A ~27,000 Å3 box was centered around the cerulenin binding site 
with a grid spacing of 0.375.77 The NcmC receptor coordinates were prepared by removing 
cerulenin and water from the cocrystal structure. The sdf files were used to generate the enol and 
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(R/S) keto ligands prior to running Vina, and the resultant poses were analyzed in Chimera 1.13.0 
(Fig. 5.26). 
 









Fig. 5.6: Tandem-MS (MS/MS) analysis of nocamycin I from extracts of Saccharothrix syringae 
NRRL B-16468. Fragmentation data were collected using a ThermoFisher Scientific Orbitrap Fusion 
ESI-MS. Collision-induced dissociation (CID) and/or high-energy collisional dissociation (HCD) were 
used to fragment the parent ion at 35%. A ppm error of less than 10 was designated as the threshold for 















a+• 284.1254 284.1278 8.4 HCD 
b+ 220.0968 220.0966 0.9 CID 
b+ 220.0968 220.0964 1.8 HCD 






Fig. 5.7: High-resolution mass spectrum of nocamycin I. (A) Single mass analysis of nocamycin I 
(calculated mass = 504.2234 Da; observed mass = 504.2227; ppm error = 1.4). (B) Full spectrum mass 
analysis of nocamycin I. Both spectra were collected using a Waters Synapt G2-Si ESI-MS equipped with 


































Fig. 5.9: Synthetic route towards 1.6 and N-acetoacetyl-glycyl-S-PCP (1.8). See the Methods for 


































































































Fig. 5.16: High-resolution mass spectrum of 1. (A) Single mass analysis of 1 (calculated mass = 261.0909 
Da; observed mass = 261.0909; ppm error = 0.0). (B) Full spectrum mass analysis of 1. Both spectra were 















Fig. 5.17: LC-MS analysis of the NcmC catalyzed Dieckmann condensation. (A) HPLC trace of the 
reaction with or without enzyme demonstrates an NcmC dependent rate enhancement. (B) Reaction scheme. 
The hydrolytic product 3 was also observed but not shown here (Fig. 2A). (C) High resolution mass 




























Fig. 5.18: Multisequence alignment of NcmC homologs with overlaid secondary structure using 
Aline.207 Positions selected for mutation and constituting part of the Cys-Asp-His catalytic triad are boxed 
in red. Additional residues selected for mutation are boxed in yellow. The deletion of helix a9 in SlgL, 












Fig. 5.19: Superimposition of NcmC and TE domains of EntF (PDB 3TEJ; Z-score of 16.7, RMSD of 3.7 
Å over 207 aligned Ca atoms) and PKS13 (PDB 5V42; Z-score of 15.9 RMSD of 4.0 Å over 219 aligned 
Ca atoms).173,174 Structural conservation is limited primarily to the catalytic a/b-hydrolase subdomain and 





















Fig. 5.20: Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) analysis of 
cerulenin-modified NcmC. (A) Schematic representation of the modification reaction. The region of 
interest (82-101) of NcmC, containing the catalytic Cys89, is represented in sequence form, and flanking 
N/C-terminal residues are represented as thick lines. (B) NcmC (28.5 kDa) was treated with cerulenin (223 
Da) and subjected to MALDI-MS analysis, (C,D) or additionally treated with trypsin and analyzed by 
MALDI-MS. A mass shift of 108 Da was observed in the full-length NcmC+cerulenin reactions (z=2), and 
a mass shift of 223 Da was observed corresponding to the tryptic fragment (82-101) covalently modified 











Fig. 5.21: Spectrophotometric monitoring of NcmC reactions with 1 by a 2,6-
dichlorophenolindophenol (DCPIP) coupled assay.186,187 Generation of a free thiol (i.e. N-
acetylcysteamine) by tetramate formation (or hydrolysis; not shown) reduces DCPIP in the reaction mixture 
to afford the colorless, reduced form of DCPIP and attenuating absorbance at 600 nm (A600). Reaction 
progress was monitored over time for each NcmC variant using an Epoch Microplate Spectrophotometer 
(BioTek Instruments, Inc.) in a 384-well plate format. Differences in absorbance at individual time points 
between NcmC variants is attributed to differences in protein-induced reduction of DCPIP by Cys89, 











Fig. 5.22: MALDI-MS analysis of the Sfp-catalyzed phosphopantetheinylation of apo-PCP using 1.7 















Fig. 5.23: Probing complex formation between NcmC and holo-PCP by analytical size-exclusion 
chromatography. Pre-incubating NcmC and holo-PCP before analyzing by gel-filtration results in their 
co-migration (first black peak) evidenced by relative absorbances and a shorter elution time relative to 


















Fig. 5.24: Model of a trans-acting DC (NcmC) interacting with an NRPS. (A) NcmC (DC), holo-EntF 
(PCP-TE), and holo-EntF(C-A-PCP) were superimposed onto holo-AB3403 (see panel B for PDB 
IDs).173,175 Note the highly separated PCP domains (~38 Å) reflecting different states of the NRPS catalytic 
cycle. The helical bundle regions of EntF and NcmC are highlighted in orange and are mostly proximal to 
the PCP. (B) Domain organization of the NRPSs used in structural alignment. Solid and dashed lines 
represent the domain regions for which there is structural resolution or not, respectively. NcmC is the only 










Fig. 5.25: Electrostatic complementarity between NcmC and apo-PCP (NcmB1020-1094). Electrostatic 
potential maps were generated using the Adaptive Poisson-Boltzmann Solver (APBS) functionality in 
UCSF Chimera 1.13.208,209 Active site residues Cys89 and Ser1056 in NcmC and NcmB, respectively, are 
represented as ball and sticks. The coordinates were generated by superposing a SWISS-MODEL-generated 
homology model of apo-PCP (NcmB1020-1094) onto the PCP-domain of EntF in the previous structural 
alignment (Fig. S17) and translating NcmC and apo-PCP (NcmB1020-1094) apart (~10 Å, without rotation) to 



























Fig. 5.26: Docking analysis of NcmC keto/enol truncated tetramate products. Docking was performed 
using the AutoDock/Vina plugin for PyMOL.77 Lowest energy poses are represented as sticks in purple 
(enol), light blue (R-keto), or chartreuse (S-keto) and top 10 poses are tabulated. NcmC active site residues 
















Fig. 5.27: Template-guided homology models (HMs) of NcmC homologs. HMs for LipX2 (grey), Var15 
(blue), SlgL (orange), and the crystal structure of NcmC (green) with key residues in the putative aminoacyl 
binding site represented as sticks. The region spanning helix a9 in NcmC and equivalent regions in the 
HMs are colored red to highlight the difference in surface area (~800 Å2 less area on average, compared to 
NcmC). The Sg atoms from catalytic Cys residues are represented as yellow spheres. 2D structures of 

























Fig. 5.28: (A) Individual SEC chromatograms for NcmC variants. (B) Standard curve (adjusted R2=0.96) 
generated by running similar SEC with protein standards (Millipore Sigma), indicating NcmC elutes as a 
monomer. (C) SDS-PAGE analysis of NcmC variants. “M” denotes the SDS Broad Range Ladder (Bio-
Rad Laboratories, Inc.) protein standard. Predominant bands correspond to NcmC variants (28.5 kDa). All 
NcmC variants contain His6-SUMO impurity (between 22 and 14 kDa bands) which co-eluted in all stages 

















Fig. 5.29: SDS-PAGE analysis of holo-PCP standard. Lanes “1” and “2” correspond to the first two 
desalting fractions containing holo-PCP. “M” denotes the SDS Broad Range Ladder (Bio-Rad Laboratories, 
Inc.) protein standard, and “precip” denotes the precipitate fraction following acetone addition (see SI 











Table 5.1: Annotation of nodes in the sequence similarity network (SSN). Adjacent PKS/NRPS genes 
were determined by RODEO analysis 210.  Color coding is consistent with the nodes in Figure 4A. Adjacent 
PKS/NRPS genes are listed as upstream (up) or downstream (down) to the gene of interest. Reversal of 
directionality in the adjacent PKS/NRPS open reading frames is denoted as “-rev”.   













1 A0A0F4K5Z7 WP_045933948.1     PKS (up) PKS, NRPS 
1 A0A0M8V9Z7 WP_053663421.1     NRPS (down) PKS 
1 A0A0Q8ZXB5 WP_057581822.1     NRPS (down) PKS 
1 A0A0K9XBY7 WP_049717535.1     NRPS (down) PKS 
1 A0A1Q5D7W2 WP_073865700.1     NRPS (down) PKS 
1 A0A1Q5JDB0 WP_073865700.1     NRPS (down) PKS 
1 A0A0C1X845 WP_041991951.1       PKS, NRPS 
1 A0A0N6ZGX9 WP_061441807.1     NRPS (down) PKS 
1 A0A1Q5MN15 WP_073920103.1     NRPS (down) PKS 
1 A0A1X9WEN9 WP_033435885.1 ncmC nocamycin NRPS (down) PKS 
1 A0A1H2H606 WP_063274578.1       PKS, NRPS 
1 A0A1W2LL55 WP_063274578.1       PKS, NRPS 
1 A0A290Z691 WP_096493684.1     NRPS (down) PKS 
1 A0A0A0NF48 AGP55856.1     NRPS (down) PKS 
1 F1DI35 WP_108908231.1 trdC tirandamycin NRPS (down) PKS 
1 A0A1H5KKH3 SEE65275.1     NRPS (down) PKS 
1 A0A2M8XPG9 SEE65275.1     NRPS (down) PKS 
1 D3Y1I7 ADC79641.1 tamC tirandamycin NRPS (down) PKS 
1 A0A1Y2NJQ2 OSY47118.1     
PKS (up), 
NRPS (down) PKS 
1 A0A1V2Q4P3 ONI83211.1     NRPS (down) PKS  
1 A0A0P4R466 GAO07620.1     
PKS (up), 
NRPS (down) PKS 
1 A0A1C6N4C4 SCK25965.1     
PKS (up), 
NRPS (down) PKS 
1 A0A1V3ZZ37 WP_077974123.1     NRPS (down) PKS 
1 E4NIK2 BAJ32800.1 facHI factumycin NRPS (down) PKS 
1 B0B508 CAN89637.1 kirHI kirromycin 
PKS (up), 
NRPS (down) PKS 
1 S5VFF6 CAN89637.1  kirHI kirromycin  
PKS (up), 
NRPS (down) PKS 
1 A0A1D2I704 ODA70255.1     PKS (up) PKS 
2 A0A1D7VJN8 WP_069568946.1   
streptolydigin 
(put.) NRPS (down) PKS 
2 A0A2G6YFS2 WP_033271195.1 slgL streptolydigin NRPS (down) PKS 
2 D1GLT3 WP_033271195.1 slgL streptolydigin NRPS (down) PKS 
2 A0A081XIT3 WP_037940301.1       NRPS 
2 A0A1Q4ZI93 WP_073719472.1       NRPS 
2 A0A1Q5FGX4 WP_073878011.1       NRPS 
2 A0A1H9JGW2 SEQ85765.1       NRPS 
2 A0A0N9LX19 ALG65322.1 cal14 WS9326   NRPS 
2 A0A1W5XJW7 WP_084770204.1   
streptolydigin 
(put.) NRPS (down) PKS 
2 D9XLE7 EFL41629.1       NRPS 
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2 A0A1C5GDX1 WP_089001688.1     NRPS (down) PKS, NRPS  
2 A0A1C6U8U6 WP_091621404.1     NRPS (down) PKS, NRPS  
2 A0A0F4K9S3 KJY42834.1         
2 A0A2N3ZBK3 WP_101414461.1     NRPS (down) PKS, NRPS  
3 S3BZ19 EPD93919.1     NRPS (down)   
3 A0A0N0HWT3 WP_031032748.1     NRPS (down)   
3 A0A1D8BYT1 AOS63965.1     NRPS (down)   
3 A0A2M9IFQ0 WP_100570700.1     NRPS (down) PKS, NRPS  
3 A0A0P4RCI1 WP_042159217.1     NRPS (down) PKS, NRPS  
4 A0A243S3G0 WP_086602300.1     NRPS (down)   
4 Q9FB38 AAG02344.1 none bleomycin NRPS (down) NRPS 
4 A0A0T6LQ39 WP_018384057.1     NRPS (down) NRPS 
4 M3B3U0 WP_004942709.1     NRPS (down) NRPS 
5 A0A2G7F626 WP_099931426.1       PKS, NRPS  
5 Q30CS4 ABB05100.1 lipX2 lipomycin NRPS (down) PKS 
5 A0A0N1NPE0 WP_054213280.1       NRPS 
5 A0A0N6W4Z6 WP_061441796.1     NRPS (down) PKS 
6 A0A1H9XTL3 WP_093781955.1       PKS 
6 A0A2I6SBD0 AUO14856.1   
vancoresmycin 
(put.)   PKS, NRPS  
6 R1HZ43 WP_003069915.1 var15 vancoresmycin   PKS, NRPS  
7 A0A248YPN6 WP_095565839.1     NRPS (down) PKS 
7 A0A2I0SD64 WP_103554186.1     NRPS (up-rev) PKS 
7 K7QRJ3 AFV71307.1 pyrG2 pyrroindomycin NRPS (up-rev) PKS 
8 R4LG32 WP_015620564.1     
PKS (up), 
NRPS (down)  PKS 
8 A0A101N5D4 WP_067010779.1     NRPS (down) PKS 
8 A0A2N8MH05 WP_101607287.1     NRPS (down) PKS 
9 A0A2A2D3K0 WP_095583395.1     
PKS (up-rev), 
NRPS (down) PKS, NRPS  
9 A0A1Z2KZ73 WP_087925822.1     
PKS (up-rev), 
NRPS (down) PKS, NRPS  
9 A0A2N8NW41 WP_102919109.1     
PKS (up-rev), 
NRPS (down) PKS, NRPS  
10 A0A1B1ZJB9 WP_068796317.1         
10 A0A1C4RPF7 WP_100564308.1       PKS, NRPS 
10 A0A2M9L770 WP_100564308.1       PKS, NRPS 
singleton A0A1Q4XTQ2 WP_073893670.1     NRPS (up) NRPS 
singleton A0A1C6UKU8 WP_091623539.1     
NRPS (down-
rev) PKS, NRPS 
singleton A0A1H9WUG6 WP_090069547.1       PKS, NRPS 
singleton A0A1C5GC05 SCG17082.1       NRPS 
singleton A0A1C6V190 SCL60065.1     NRPS (up) PKS, NRPS 
singleton A0A285QT70 WP_097237205.1       PKS, NRPS 
singleton A0A1H9XTC3 WP_093781959.1       PKS 
singleton A0A209CPB4 WP_087771923.1       NRPS 
singleton A0A2N3UYX7 WP_101384298.1     NRPS (down) NRPS 
Table 5.1 cont. (part 2 of 2) 
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Table 5.2: Adenylation (A) domain specificity prediction for A-domains in tirandamycin-like 
biosynthetic gene clusters. Color coding is consistent with the nodes in Figure 4A. Inferences in the A-

















1 A0A0M8V9Z7 WP_053663421.1     D I L Q L G V I Gly 
1 A0A0Q8ZXB5 WP_057581822.1     D I L Q I G M I Gly 
1 A0A0K9XBY7 WP_049717535.1     D I L Q - G V V N/A 
1 A0A1Q5D7W2 WP_073865700.1     D I L Q V G A I Gly 
1 A0A1Q5JDB0 WP_073865700.1     D I L Q V G A I Gly 
1 A0A0N6ZGX9 WP_061441807.1     D A W E A G L V Gln 
1 A0A1Q5MN15 WP_073920103.1     D T L Q L G V I Gly 
1 A0A1X9WEN9 WP_033435885.1 ncmC nocamycin D I L Q L G V I Gly (Gly) 
1 A0A290Z691 WP_096493684.1     D I L Q L G P I Gly 
1 A0A0A0NF48 AGP55856.1     D I L Q L G V I Gly 
1 F1DI35 WP_108908231.1 trdC tirandamycin D I L Q V G V I Gly (Gly) 
1 A0A1H5KKH3 SEE65275.1     D I L Q L G V I Gly 
1 A0A2M8XPG9 SEE65275.1     D I L Q L G V I Gly 
1 D3Y1I7 ADC79641.1 tamC tirandamycin D I L Q V G V I Gly (Gly) 
1 A0A1Y2NJQ2 OSY47118.1     D I L A L G V I Gly 
1 A0A1V2Q4P3 ONI83211.1     D I L Q L G V I Gly 
1 A0A0P4R466 GAO07620.1     D I L A L G V I Gly 
1 A0A1C6N4C4 SCK25965.1     D I L Q L G V I Gly 
1 A0A1V3ZZ37 WP_077974123.1     D I L X L G V I Gly 
1 E4NIK2 BAJ32800.1 facHI factumycin D T L Q L G V I Gly (β-Ala) 
1 B0B508 CAN89637.1 kirHI kirromycin D T L Q L G V I Gly (β-Ala) 
1 S5VFF6 CAN89637.1 kirHI kirromycin D T L Q L G V I Gly (β-Ala) 
2 A0A1D7VJN8 WP_069568946.1     unknown N/A 








2 A0A1W5XJW7 WP_084770204.1     unknown N/A 
5 Q30CS4 ABB05100.1 lipX2 lipomycin unknown N/A (L-Glu) 
5 A0A0N6W4Z6 WP_061441796.1     unknown N/A 
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CHAPTER 6: STRUCTURAL AND BIOCHEMICAL CHARACTERIZATION OF AN 





Stemming from its impressively high degree of post-translational modification (PTM), the 
proteusin natural product, polytheonamide B (pTB), presents fertile ground in areas of synthetic 
biology and biosynthetic engineering of peptidic drugs. In addition to its extreme cytotoxic 
potency, the 49-residue modified-peptide assumes a unique b-helical structure giving rise to its 
unimolecular ion-channel function. With N- and C-methylations at the exterior providing a 
hydrophobic coating, the 0.4 x 4.5 nm b-helical barrel spans cellular membranes allowing passive 
diffusion of monovalent cations, thereby disrupting electrostatic potentials; the primary driver of 
its toxicity. Structural features of the b-helical toxin include alternating a-epimerizations, D-Asn 
Ng-methylations, b-C-methylations, as well as b-C-hydroxylations. The former two have been 
highlighted as early-stage modifications and most critical for ion-channel activity, however, the 
minimal set of PTMs necessary for ion-channel function remains to be definitively understood. 
Here we take a detailed look into the D-Asn Ng-methylation stage of aeronamide biosynthesis (a 
terrestrial ortholog of pTB) providing insight both into the mechanism of iterative D-Asn Ng-
methylation as well as ion-pore maturation. We show that the N-methyltransferase, AerE, penta-
N-methylates its peptidic substrate with pseudo-(N-to-C)-directionality. Finally, our structural and 
biochemical data support a recent in silico analysis which points to the importance of N-
methylation in maintaining b-helicity.211  
 
6.2 INTRODUCTION 
The prototypical proteusin, polytheonamide B (pTB), has been isolated from a bacterial 
symbiont of the marine sponge Theonella swinhoei and is among the most highly post-
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translationally modified peptides known.212–216 Just seven enzymes have been implicated in 
carrying out 42 post-translational modifications (PTMs) within a 49-residue core peptide (CP) 
resulting in 18 a-epimerizations, 4 b-C-hydroxylations, 12 b-C-methylations, and 8 N-
methylations collectively transforming the peptide into a bioactive 6.3-residue-turn b-helical 
structure.217 The resultant wide-bore (0.4 nm) helix has been shown to facilitate ion passage of 
monovalent cations (H+, Na+, K+, Rb+, and Cs+) by insertion of pTB into planar bilayers, 
suggesting a toxification strategy by disruption of membrane potentials.214 This hypothesis was 
recently tested by administration of fluorescently labeled pTB to mammalian cells, revealing a 
two-pronged mechanism whereby membrane depolarization is accompanied by endocytic 
internalization of pTB.218 Specifically, pTB localizes to lysosomes inside MCF-7 human breast 
cancer cells, triggering the transportation of H+ across the organellar membrane and neutralization 
of the pH gradient necessary for cellular homeostasis.  
A new proteusin, aeronamide, from the free-living, terrestrial bacterium Microvirgula 
aerodenitrificans DSM 15089 is currently under investigation and putatively assigned to be an 
ortholog of pTB in terms of its structure and function. Similar to the pTB biosynthetic machinery, 
M. aerodenitrificans DSM 15089 harbors corresponding genes encoding for the radical S-adenosyl 
methionine (SAM) epimerase (aerD), SAM-dependent N-methyltransferase (NMT) (aerE), 
LanM-like dehydratase (aerF), B12-dependent C-methyltransferase (aerB), and C1A cysteine 
protease (aerH) in the aeronamide biosynthetic gene cluster (BGC) (Fig. 6.1a-c).  
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Fig. 6.1: Core peptide alignment, AerD/AerE-catalyzed modifications, aeronamide biosynthetic gene cluster, 
and b-helical model of aeronamide. a, AerA/PoyA core peptide alignments with epimerized residues boxed in 
yellow. Sites of C-methylation and N-methylation are colored blue and green, respectively. The five D-Asn residues 
methylated in AerA are fully conserved and boxed in black. b, Reaction scheme depicting the unidirectional a-
epimerizations installed by the radical SAM-dependent, [4Fe-4S]-containing epimerase, AerD, and D-Asn Ng-
methylations catalyzed by SAM N-methyltransferase, AerE (R1=Ala or Thr side chains; R2=Val, Ala, Thr side chains, 
or H [Gly]). c, Aeronamide biosynthetic gene cluster. d-e, Model of b-helical aeronamide in two, 90°-related, 
orientations.  
 
pTB biosynthesis, the activity of NMT PoyE has been suggested to parallel the timing of a-
epimerizations catalyzed by the radical SAM-dependent epimerase, PoyD. In vitro experiments 
demonstrate that an epimerized PoyA substrate is sufficient for full octa-N-methylation catalyzed 
by PoyE and N-methylation efficiency corelates with extent of epimerization.217  
What has remained unclear is how and when during proteusin maturation the b-helicity is 
established, and what are the minimal set of PTMs sufficient for ion-channel activity. Molecular 
dynamics simulations point to the importance of N-methylations in maintaining the co-axial H-
bond network after systematically removing PTMs in pTB and evaluating hypothetical precursors 
for their stability in silico.211 Future design and enzymatic syntheses of proteusin analogs with 
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tailored membrane selectivities will rely on a thorough understanding of the substrate tolerances 
and requisite chemical features for bioactivity. Thus, detailed biochemical and biophysical 
characterization of the critical biosynthetic enzymes will be highly important in meeting these 
aims.  
In this study, we look into the mechanism of AerE-catalyzed N-methylation of five D-Asn 
residues in the aeronamide CP. We provide evidence that AerE utilizes SAM to iteratively 
methylate the lowly-nucleophilic g-nitrogen of D-Asn side-chains by a putative structural-ion 
mediated Lewis acid type activation. Guided by cocrystal structures of AerE in complex with its 
epimerized AerA substrate, our data also support notions from Renevey et al. that b-helicity is 
driven by N-methylation.211  
 
6.3 RESULTS 
6.3.1 In vitro penta-N-methylation  
To confirm the expected Asn-N-methyltransferase activity of AerE vitro, we 
heterologously expressed an epimerized His6-tagged AerA substrate (AerADL) in E. coli by co-
expression with the radical SAM epimerase AerD, as previously described.217 Purification of 
AerADL under denaturing conditions afforded a putative substrate of AerE with alternating 
epimerizations along the CP (by homology to pTB). AerE was similarly expressed in E. coli as an 
N-terminal SUMO fusion-protein and purified to homogeneity as a tag-free monomer by size-
exclusion chromatography (SEC). Following incubation of AerE with AerADL in the presence of 
SAM and trypsinization of the peptide products, we observed a +70 Da mass shift in the CP-
containing fragment by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS), suggestive of full penta-N-methylation catalyzed by AerE (Fig. 
6.2a,b). Compared to in vitro methylation assays with PoyA and the PoyE NMT lasting upwards 
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of 10 days to observe full octa- N-methylation, it is noted that penta-N-methylation of AerADL 
required much shorter (1.5 h) incubation times.   
 
6.3.2 Leader peptide and partial core peptide independence  
To delineate a minimal substrate of AerE, we took advantage of previous observations that 
core-epimerizations protect PoyA against proteinase K digestion to yield LP-free PoyA CP-
fragments.217 Correspondingly, incubation of AerADL with proteinase K and subsequent HPLC 
purification provided a panel of AerADL CP-fragments ranging from 31-35 out of 46 CP-residues 
and containing all five D-Asn methyl-acceptors (Fig. 6.2a). Owing to the difficulty in separating 
these fragments by reversed-phase HPLC with C4/C18 resins, we incubated them as an HPLC-
purified mixture with AerE and SAM. Following overnight incubation gave +70.2 Da mass shifts 
for all five species, thereby revealing full leader-peptide and partial core-peptide independence of 
AerE (Figs. 6.2c and 6.6). To confirm this observation with a homogenous and fully epimerized 
substrate, we synthesized the AerADL(34mer) peptide (Fig. 6.2a) containing all appropriate D-
residues by solid-phase peptide synthesis (SPPS) and again observed full penta-N-methylation, 
supporting these minimal substrate requirements (Fig. 6.5a,b).   
 
6.3.3 Progress and directionality of AerE D-Asn-N-methylation 
The progress of D-Asn-N-methylation was probed by heat-precipitating the enzyme at 
various time points between 0-16.5 hours and quantifying relative peak intensities of methylated 
AerADL intermediates by MALDI-TOF MS. Comparing the normalized peak intensities of mono-
, di-, tri-, tetra-, and penta-N-methylated AerADL over time is indicative of a loss in processivity of 
AerE as more extensively methylated AerADL intermediates appear to have longer lifetimes (Fig. 
6.2d,e). Given the time-dependent relative populations of mono- through penta-N-methylated 
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AerADL, after reaction heat-quenching and trypsinization, we HPLC-isolated mono-, di-, and tri-
N-methylated AerADL21 intermediates to study the directionality of AerE by electrospray ionization 
(ESI) tandem MS (MS/MS) (Fig. 6.3). In the case of mono- N-methylated AerADL21, we 
predominantly observed y-ions with no mono-N-methylation beyond D-Asn25 and only two y-
ions (y19+Me/y19-NH3+Me) with methylation of a fragment born of cleavage between D-Asn25 
and D-Asn31, suggesting D-Asn25 is an early methyl acceptor. Fragmentation of di-, and tri-N-
methylated AerADL21 reveals a lack of regioselectivity with respect to D-Asn31, D-Asn37, and D-
Asn41 for the second and third methylation events. Importantly, in all cases, only one y-ion 
(y5+Me) was observed in the tri-N-methylated AerADL21 species corresponding to methylation at 
D-Asn43, suggesting it is the slowest to be methylated (Fig. 6.3b). To reconcile the observed 
pseudo-(N-to-C)-directionality of AerE, we manually built a b-helical model of the AerA CP based 
on the pTB solution NMR structure (Fig. 6.1d,e).214 Inspection of the model reveals D-Asn25, D-
Asn31, D-Asn37, and D-Asn43 to exist on the same face of the b-helix with D-Asn41 separated by 
~120° about the helical axis (Fig. 1d,e), indicating that D-Asn recognition by AerE may be more 
a function of its local residue environment than position within a b-helical structure. If b-helical 
structure influenced accessibility of D-Asn to AerE, then we might expect all D-Asn residues on 
the same face (i.e., D-Asn25, D-Asn31, D-Asn37, and D-Asn43) to be methylated before D-Asn41, 
but this was not the case. A potential explanation for the sluggish methylation of D-Asn43 relative 
to D-Asn41 is explained in light of the structural data below. 
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Fig. 6.2: Probing the minimal substrate and processivity of AerE-catalyzed N-methylation. a, Sequence 
representation of AerADL21 (tryptic fragment) with the aeronamide core peptide residues in bold and sites of 
proteinase K cleavage yielding 31-35mer epimerized AerADL peptides. b, AerADL treated with (green) or without 
(black) AerE confirms the AerE-dependent +70 Da mass shift suggesting penta-N-methylation observed by 
MALDI-TOF MS. c, The shortest proteinase K fragment, AerADL(31mer), isolated by HPLC is similarly penta-
N-methylated in the presence of AerE (green) as observed by MALDI-TOF MS (Note: each proteinase K 
fragment differs by one Ala at the N-terminus corresponding to a +71.1 Da mass shift which is close in mass to 
that calculated for five added methyl groups [+70.2 Da], however, the mass accuracy was sufficient to resolve 
the monoisotopic differences). d, Reactions containing AerE (tag-free), AerADL, and SAM were heat-quenched 
at various time points between 0-16.5 h and treated with trypsin to analyze AerADL21 fragments containing 0 
through 5 methylations (0Me – 5Me) by MALDI-TOF MS. e, AerE processivity towards AerADL appears to 
diminish as the substrate becomes more methylated. For each time point, normalized peak intensities are plotted 
against time. From 300-900 min there is a break in the X-axis demarcated with a grey dotted line.   
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6.3.4 Overall structure of AerE and in complex with its substrates 
To gain a framework for further mechanistic studies, we solved the crystal structure of 
AerE in complex with S-adenosyl homocysteine (SAH) to 1.51 Å resolution in the trigonal space 
group P 32 2 1 (Fig. 6.4a). Overall, AerE resembles two other characterized class I SAM-dependent 
NMTs: GenN (PDB 5U18; Dali Z-score of 24.9, root mean square deviation [RMSD] of 2.8 Å 
over 274 aligned Ca atoms) and PrmC (formerly HemK; PDB 2B3T; Dali Z-score of 17.9, RMSD 
of 3.9 Å over 216 aligned Ca atoms).143 The former catalyzes N-methylation of a secondary amine 
in biosynthesis of the aminoglycoside gentamycin,219 while the latter N5-methylates a Gln within 
a tripeptide motif (GGQ) of prokaryotic translation termination release factors (RF1 and 
RF2).220,221 Superimposing the structures reveals two insertions in AerE (Gln23-Arg60 and 
Ala315-Leu350) which are lacking in GenN and PrmC; accounted for by 86 additional residues in 
AerE, on average (Fig. 6.7). Features of the C-terminal Rossmann-like subdomain bearing the 
SAM binding-site (Ile138-Ser316) are well aligned, whereas the primarily a-helical N-terminal 
subdomain (Met1-Glu131) only partially aligns with GenN and is highly divergent with respect to 
PrmC. In PrmC, this a-helical N-terminal region employs 13 residues (out of 29) to make protein-
protein contact with its methyl-acceptor substrate RF1.221 In the case of GenN, it was proposed 
that the N-terminal domain interfaces with other enzymes in the gentamycin BGC.219  
To better understand the AerA CP recognition of AerE, we co-crystallized a ternary 
complex between AerE, AerADL(34mer), and SAH to 1.71 Å resolution in the same space group 
(P 32 2 1) (Fig. 6.4b-e). Global comparison of the two structures suggests AerE binds to its peptide 






Fig. 6.3 (cont.): Pseudo-(N-to-C)-Directionality of AerE-catalyzed D-Asn Ng-methylation analyzed by ESI-
MS/MS. a, Fragmentation analysis of non-methylated AerADL with observed y-ions mapped onto the structure 
and corresponding collision-induced dissociation (CID) mass spectrum below (representative set of high-
abundance y-ions are labeled). b, Similar fragmentation analysis for the HPLC-purified mono-, di-, and tri-N-
methylated AerADL intermediates (1Me, 2Me, and 3Me). Observed y-ions with no methylation are demarcated 
above the peptide in black dotted lines, whereas methylated intermediates are below the peptide in green. A 
threshold of 5 ppm mass error was designated for peak assignment.  
 
atoms including SAH). The peptide binds as an unstructured loop embedded into the methyl-
acceptor binding site shared with other NMTs and akin to the interaction between the looped GGQ-
motif of RF1 bound to PrmC.219–221 Ten of the 34 residues in AerADL(34mer) are visible by 
electron density corresponding to Thr19-Gly28 of the AerA CP (Fig. 6.4c). D-Asn25 is 
unambiguously located closest to the site of SAM-mediated methylation, in agreement with the 
tandem MS data which suggest its role as an early methyl acceptor. Moreover, the ternary complex 
structure offers a potential explanation for the slow methylation of D-Asn43 by inspection of the 
neighboring residue environments. Specifically, survey of the -2 through +2 residues with respect 
to each D-Asn in the core peptide reveals a preference for Gly, D/L-Ala, D/L-Val, and D/L-Thr 
excepting D-Asn41 and D-Asn43 which have D-Asn in their +2 and -2 positions, respectively. In 
the crystal structure, the -2 residue (D-Ala23) of D-Asn25 is oriented with its side-chain pointing 
into a hydrophobic surface of AerE (towards Pro321 and Ile322), whereas the +2 residue (D- 
Val27) is more solvent exposed and directed away from AerE, perhaps explaining why a D-Asn 
is more tolerated at the +2 position. 
In the active site, the g-nitrogen of D-Asn25 is 3.7 Å away from the sulfur of SAH where 
it would be directly poised for nucleophilic attack of the SAM S-methyl group (Fig. 6.4e). 




Fig. 6.4: Structural analysis of AerE bound to SAH and its methyl-acceptor substrate AerADL(34mer). a, 
Overall ribbon diagram of AerE bound to SAH (salmon). b, Two (90°-related) orientations of the AerE-SAH-
AerADL(34mer) ternary complex. c, Sequence representation of AerA CP where amide bond cleavage between 
Ala12-Ala13 results in the C-terminal fragment AerADL(34mer) synthesized by SPPS with the epimerized 
residues boxed in yellow, N-methyl acceptor D-Asn residues in green, and the 10 residue region observed by 
electron density boxed in blue. d, Simulated annealing difference Fourier map (Fobs-Fcalc) contoured at 
2s centered around the 10  blue-boxed residues in AerADL(34mer). D-configured residues are yellow (or green 
for D-Asn25) with a black outline. e, Close-up of the AerE active site where AerE residues are in grey, SAH in 
salmon, and AerADL(34mer) coloring-scheme consistent with panel d. An unidentified structural-ion is depicted 
as a green sphere. With the exception of D-Asn25 g-nitrogen and SAH sulfur bond distance of 3.7 Å, only ≤  3 
Å bond distances are labeled for clarity.  
 
resonance, we considered the possibility of a Lewis acid type activation where coordination of the 
amide oxygen and a heavier atom (e.g. Na+, K+, Mg2+, or Ca2+) might serve to lower the rotational 
barrier of the amide C-N bond; thus freeing up the lone-pair electrons for increased nucleophilicity. 
Indeed, the difference Fourier map (Fobs - Fcalc) presents sufficient electron density adjacent to the 
D-Asn25 amide to model the above heavy atoms, however, the true atom identity remained 
ambiguous. We attempted to inhibit AerE by incubation with an excess of EDTA accompanied by 
overnight dialysis. While methylation activity was attenuated by comparison to the untreated 
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enzyme at various time points, AerE remained fully capable of penta-N-methylating 
AerADL(34mer) following overnight incubation.  
Interestingly, AerE is near fully inhibited by low stoichiometric amounts (4 eq.) of Zn2+ in 
reactions with SAM/AerADL(34mer), and the inhibition is not rescued by addition of excess Na+, 
K+, Mg2+, Ca2+, or Mn2+ (Figs. 6.5a and 6.8). 
  
6.3.5 Site-directed mutagenesis and N-methylation activity of AerE 
Considering sequence conservation and active-site proximity, we generated point 
mutations of AerE corresponding to H134A, Y137A, Y137F, D141A, S142A, and N231A AerE 
variants, and tested their N-methylation activities with the simple substrate AerADL(34mer) (Fig. 
6.5b). After prolonged incubation of the wild-type and above AerE variants with SAM and 
AerADL(34mer), analysis of the MALDI-TOF MS data reveal Y137A, Y137F, D141A, S142A, 
and N231A variants are nearly devoid of all activity with trace amounts of mono- and di-
methylation. The H134A variant is attenuated considerably, but still capable of achieving tri-
methylation under these reaction conditions. Structurally, H134 appears to play a substrate binding 
role, as it makes contact (2.7 Å) with the methyl-acceptor +1 position by H-bonding with the 
backbone amide oxygen of Val26 in AerADL(34mer) (Fig. 6.4e). Given that the Y137A and Y137F 
variants gave comparable losses in methylation activity, we looked at the Y137 side chain hydroxyl 
interactions and observed H-bonding (2.6 Å) with the side chain carboxylate of D141, as well as 
H-bonding (3.2 Å) with the backbone amide nitrogen of D-Asn25. D141 further adheres the 
substrate-enzyme H-bond network by directly connecting to the substrate D-Asn25 side chain 
amide oxygen (2.0 Å) and the N231 side chain amide (3.1 Å); interactions which are collectively 
essential for activity. Moreover, the AerE-D141A/SAH co-crystal structure reveals a 1.3 Å motion 
of the Y137 side chain towards SAH that would be deleterious for the Y137/substrate-backbone 
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interactions; a potential contributor to activity loss. The dysfunctional S142A variant may be a 
result of impaired SAM binding, as it forms a 2.7 Å H-bond with the carboxylate of SAH. The 
N231 side chain may also serve this role of stabilizing the bound SAM by making similar H-bond 
contacts (3.1 Å), however it likely exerts additional influence by structural-ion coordination (2.6 
Å), aforementioned D141 interaction (3.1 Å), as well as side chain g-nitrogen interaction with D-
Asn25 of the substrate (3.3 Å). AerE-N231A was crystallized under similar conditions to the wild-
type enzyme and appears to have lost structural-ion binding ability by comparison of the difference 




Oligonucleotides were purchased from Integrated DNA Technologies, Inc. (IDT) and 
enzymes for PCR, plasmid digestion, and Gibson Assemblies were purchased from New England 
Biolabs (NEB). Buffers, media, and other reagents were purchased from Thermo Fisher Scientific, 
Sigma-Aldrich (MilliporeSigma), and Cayman Chemical. 
 
6.4.2 General Methods 
Protein affinity and size-exclusion chromatography were carried out using an ÄKTAprime 
plus purifier (GE Healthcare). High-performance liquid chromatography (HPLC) was performed 
with a Shimadzu Prominence Liquid Chromatography system. Matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) data were collected on 
UltrafleXtreme and Autoflex Speed MS instruments (Bruker Daltonics).  
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6.4.3 Cloning and heterologous expression of AerA, AerD, and AerE (wild-type and site-directed 
variants)  
AerA and AerD: The aerA and aerD genes from M. aerodenitrificans DSM 15089 were 
cloned as previously described into expression vectors encoding for His6-AerA in pACYCDuet-1 
and tag-free AerD in a pCDFDuet-1 derivative plasmid (pBADcdf) containing the arabinose-
inducible promoter (pBAD). Following co-transformation of E. coli BL21 (DE3) using the above 
plasmids, we grew transformants in 4 L of terrific broth (TB) medium until an optical density at 
600 nm (OD600) of 1.6-2.0 was achieved. Cells were cooled on ice for 30 min and His6-AerA 
expression was induced by addition of 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
with growth at 18 °C for 1 h followed by addition of 0.2% L-arabinose for induction of AerD and 
continued growth for 20 h at 18 °C.  
AerE: All aerE expression plasmids were constructed using the pET hexahis (His6) small 
ubiquitin-like modifier (SUMO) tobacco etch virus (TEV) protease ligation-independent cloning 
(LIC) vector (2S-T). This vector was a gift from Scott Gradia (Addgene plasmid # 29711). Primers 
designed to include the LICv1 tags were used for PCR amplification of aerE from Microvirgula 
aerodenitrificans DSM 15089 gDNA. Amplicons were used in a Gibson Assembly reaction with 
SspI-linearized 2S-T following the manufacturer (NEB) protocol and products were used to 
transform E. coli DH5a. Site-directed mutations were incorporated by three-component Gibson 
Assemblies containing two aerE gene-fragments containing the PCR-derived mutations. 
Transformant plasmids were isolated using a QIAprep Spin Miniprep Kit (QIAGEN) and 
sequenced by services from ACGT, Inc. (Wheeling, IL). Sequence-verified His6-SUMO-AerE 
plasmids were used to transform E. coli Rosetta (DE3) competent cells for protein overexpression. 
Protein was overexpressed by growth at 37 °C in Luria-Broth (LB) to an OD600 of 0.4-0.6. Protein 
expression was then induced by addition of 0.5 mM IPTG and growth for 18-20 h at 18 °C. 2-4 L 
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of LB media was used for the overexpression of wild-type and site-directed variants of His6-
SUMO-AerE. 
 
6.4.4 Protein purification 
6.4.4.1 AerE (tag-free) 
Cells from a 4 L culture were harvested by centrifugation at 3,000 ´ g for 30 min at 4 °C 
and resuspended in buffer A (0.5 M NaCl, 20 mM tris-HCl pH 8.0, and 10% glycerol (v/v)) before 
lysing via sonication. The lysate was cleared by centrifugation at 15,400 ´ g for 1 h at 4 °C and 
the supernatant was injected onto a 5 mL HisTrap nickel-nitrilotriacetic acid (Ni-NTA) affinity 
column (GE Healthcare) equilibrated with buffer B (1 M NaCl, 30 mM imidazole, 20 mM tris-
HCl pH 8.0). The column was washed with 70 mL of buffer B prior to eluting the bound protein 
with a linear gradient of increasing buffer C (1 M NaCl, 500 mM imidazole, 20 mM tris-HCl pH 
8.0). Fractions containing His6-SUMO-AerE were pooled and treated with 30 µg/mL of tobacco 
etch virus (TEV) protease while dialyzing against 0.2 M NaCl, 2.5 mM β-mercaptoethanol (BME), 
and 20 mM tris-HCl pH 8.1 for 12 h at 4 °C. Dialysis was continued for another 4 h against a 
similar buffer lacking BME before injecting the sample onto a 5 mL Ni-NTA affinity column (GE 
Healthcare) equilibrated with buffer A for subtractive Ni-affinity purification. The column was 
subsequently washed with buffer A (50 mL) and eluted using the following step-wise gradient of 
increasing buffer B: 10%, 20%, 30%, 40%, 50%, and 100% in 5-10 mL increments. Tag-free AerE 
primarily eluted at 30% B. Pooled AerE fractions were concentrated to ≤5 mL and purified by 
size-exclusion chromatography (SEC) by injecting the sample onto a 120 mL Superdex 200 10/300 
GL column (GE Healthcare) with 300 mM KCl, 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid HEPES pH 7.5 used for equilibration and running buffer.  
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6.4.4.2 SUMO-AerE (wild-type and SDMs) 
Cells from a 2 L culture were harvested, lysed, and centrifuged as described for tag-free AerE. The 
clarified lysate was added to 3 mL of Ni-NTA resin (Thermo Fisher Scientific) and allowed to 
bind by gravity elution. The loaded resin was washed with 70 mL of buffer B and eluted with 2 
mL fractions of 10% C (2x), 50% C (2x), and 100% C (5x). Pooled fractions were concentrated 
and used directly in N-methylation assays (Fig. 6.5b).  
 
6.4.5 In vitro N-methylation assays 
Initial N-methylation assays with substrate AerADL were carried out at 22 °C with 20 µL 
reaction volumes containing 25 µM AerE (tag-free; following SEC), 100 µM AerADL, and 1 mM 
SAM in reaction buffer 1 (50 mM KCl, 50 mM K2HPO4 pH 8, 200 µM MgCl2, 10% glycerol). 
Reactions were terminated by heat-precipitating the enzyme at 95 °C for 5 min. The precipitate 
was removed by centrifugation, and the peptide products in the supernatant were trypsinized (0.4 
µg/µL) for 30 min at 22 °C before desalting with a C4 ZipTip (Millipore Sigma) following the 
manufacturer instructions. Full extent of methylation (+70 Da) was observed by MALDI-TOF MS 
after 16 h incubation (Fig. 6.2b).  
 
6.4.6 Processivity analysis of AerE 
Reactions were carried out and terminated as described (see 6.4.5 In vitro N-methylation 
assays), except 20 µM enzyme was used and a larger volume of 300 µL. At each time point, 20 
µL were extracted for heat-quenching, trypsinization, desalting, and MALDI-TOF MS analysis. 
The peak intensities were calculated using Bruker Analysis software and normalized before 
plotting in OriginPro 2016 (OriginLab) software.  
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6.4.7 Tandem MS analysis (ESI MS/MS) of methylated AerADL intermediates 
Four 100 µL reactions were setup as described (see 6.4.5 In vitro N-methylation assays) 
and quenched at four different time points (i.e. 5, 30, 75, and 200 min) to isolate mono-, di-, tri-, 
and tetra-N-methylated AerADL intermediates. After heat-denaturing and trypsinization, the 
reaction products were isolated by HPLC using a GRACE Denali C18 (120 A; 5 um; Part No. 
238DE54; length 250 mm; ID 4.6 mm), flow-rate of 1 mL/min, and a detection wavelength of 280 
nm. Elution consisted of a mobile phase of H2O/ACN (A/B) + 0.1% formic acid and a linear 
gradient of 2-70% B over 35 min followed by a linear step to 90% B held for 10 min. Mono-, di-, 
and tri-methylated AerADL21 peptides eluted between 35-42 min (determined by MALDI-TOF 
MS). HPLC-isolated peptides were directly infused into a ThermoFisher Scientific Orbitrap Fusion 
electrospray-ionization mass-spectrometer (ESI-MS) using an Advion TriVersa Nanomate 100. 
The following parameters were used: resolution = 120,000; isolation width (MS/MS) = 2 m/z; 
normalized collision energy (MS/MS) = 35; activation q value (MS/MS) = 0.4; and activation time 
(MS/MS) = 30 ms. Collision-induced dissociation (CID) and high-energy collisional dissociation 
(HCD) were used to fragment the parent ion at 35%. Data analysis was performed in the 
Qualbrowser application of Xcalibur software (Thermo Fisher Scientific). Only peaks with less 
than 5 ppm error were tabulated and included in the analysis.  
 
6.4.8 Solid-phase peptide synthesis (SPPS) of AerADL(34mer) 
 Automated SPPS was carried out using a Rainin PS3 synthesizer on a 0.1 mM scale with 
Fmoc-Ala Wang resin. Coupling reactions contained 4 eq of the appropriate Fmoc-amino acid and 
4 eq of HCTU dissolved in DMF + 0.4 M N-methylmorpholine. Each coupling step was performed 
twice prior to deprotection with 20% (v/v) piperidine in DMF. Following all rounds of double-
coupling/deprotection, the protected resin-bound product corresponded to: Fmoc-a-A-a-A-v-V-
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ttBu-YtBu-l-G-a-A-nTrt-V-v-G-a-A-nTrt-G-ttBu-V-ttBu-A-nTrt-A-v-A-n-TtBu-nTrt-A-v-A -- Wang resin 
(D-configured amino acids in lowercase and side-chain protecting groups in superscript). The 
product was washed with DCM and dried with a N2 stream. Resin-bound, crude peptide was 
globally deprotected by incubation with 4 mL of 95% trifluoroacetic acid (TFA), 2.5% 
triisopropylsilane (TIPS), and 2.5% H2O for 1 h at 20 °C. The resin was removed by filtration 
through glass wool and the peptide was precipitated by collecting the filtrate in cold ether (-20 °C). 
The precipitate was spun down (3,000 ́  g for 10 min at 4 °C), supernatant discarded, and the pellet 
resuspended in ice-cold ether. This process was iterated two more times before the crude-peptide 
pellet was dried under a stream of N2.  
 
6.4.9 HPLC purification of AerADL(34mer) from SPPS, AerADL21 (trypsin fragment), and AerADL 
(proteinase K fragments; 31-35mer) 
6.4.9.1 AerADL(34mer) from SPPS 
The deprotected, crude peptide was purified by reversed phase HPLC using a Macherey Nagel VP 
250/10 NUCLEODUR C8 Gravity (5 um) column with a mobile phase consisting of H2O/ACN 
(A/B) + 0.1% FA, flow-rate of 3 mL/min, and a detection wavelength of 280 nm. A linear gradient 
of 2-50% B over 35 min eluted the peptide at 26 min as detected by MALDI-TOF MS.  
6.4.9.2 AerADL21 (trypsin fragment) 
Following trypsinization of AerADL to afford AerADL21, (reaction quenching protocol) the peptide 
products were purified by HPLC using a GRACE Denali C18 (120 A; 5 um; Part No. 238DE54; 
length 250 mm; ID 4.6 mm), flow-rate of 1 mL/min, and a detection wavelength of 220 nm. Elution 
consisted of a mobile phase of H2O/ACN (A/B) + 0.1% FA with the following linear gradient: 2-
70% B over 40 min. AerADL21 eluted at 22.5 min as detected by MALDI-MS TOF.  
 
 152 
6.4.9.3 AerADL (proteinase K fragments; 31-35mer) 
Following overnight proteinase K treatment, (reaction quenching protocol) a mixture of proteinase 
K fragments (Fig. 6.2) were purified by HPLC as described for AerADL21 and co-eluted at 30 min 
as detected by MALDI-TOF MS. The mixture was used directly in in vitro N-methylation assays.   
 
6.5 SUPPORTING FIGURES 
Fig. 6.5: Zinc inhibition and site-directed mutagenesis of AerE. a, Dose-dependent inhibition of AerE-catalyzed 
AerADL(34mer) N-methylation by ZnCl2. Full inhibition is observed between 60-250 µM, as observed by MALDI-
TOF MS. b, Methylation activity of site-directed AerE variants towards substrate AerADL(34mer). Enzymes were 
assayed directly following Ni-NTA purification, except for WT (SEC) which denotes the wild-type AerE enzyme  
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Fig 6.5 (cont.) which underwent multiple purification steps terminating in SEC (see Methods). The substrate, 
AerADL(34mer), was analyzed alone for comparison in the bottom spectrum of panels a-b.   
 
 
Fig. 6.6: MALDI-MS analysis of the AerE-catalyzed penta-N-methylation of proteinase K-derived fragments 
(32-35mer) of AerADL. The 31-35mer fragments co-eluted by HPLC and were incubated as a mixture with 
AerE/SAM. All species gave rise to a 70.2 Da mass shift, indicative of penta-N-methylation. Note: each species varies 
by an Ala, which is very close in mass to (71.1 Da) the calculated mass of 5 methylations (70.2 Da). Despite this, the 




















Fig. 6.7: Structural alignment of AerE (green and orange) with N-methyltransferases GenN (purple; left) and 
PrmC (blue; right). The orange regions (i.e. Gln23-Arg60; Ala315-Leu350) represent the structural insertions 



























Fig. 6.8: MgCl2, CaCl2, and MnCl2 do not rescue Zn-inhibited AerE N-methylation. MALDI-TOF MS analysis 
of reactions containing AerE, AerADL(34mer), ZnCl2, and SAM supplemented with either 25 mM MgCl2, CaCl2, or 
MnCl2. The substrate, AerADL(34mer), was analyzed alone for comparison in the bottom spectrum.  
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CHAPTER 7: MECHANSTIC INSIGHT INTO TRNA-DEPENDENT LANTHIPEPTIDE 
AND 
THIOPEPTIDE SIDE-CHAIN DEHYDRATION 
 
7.1 ABSTRACT 
The class I lantibiotic nisin, from Lactococcus lactis, has been employed extensively for 
agricultural and food preservative applications since the early/mid 20th century with minimal 
development of resistance. Despite decades of study, however, the first insights into the 
biosynthetic mechanisms of class I lantibiotics had remained elusive until recently. Herein, we 
describe our efforts to further examine the structure and mechanism of class I lantibiotic and 
thiopeptide dehydratases through the use of non-reactive substrate mimics. In particular, we report 
the development of a glutamylated-NisA analogue as a structural probe for the elimination domain 
of NisB, as well as a puromycin-like analogue, 5¢-phosphoryl-N6-desmethylglutamycin, to mimic 
glutamyl-tRNAGlu and probe the structure of the glutamylation domain, TbtB, involved in 
thiomuracin biosynthesis (from Thermobispora bispora). Our results support current hypotheses 
regarding the mode of substrate recognition and provide insight into the mechanism of this 
enzymatic transformation.  
 
7.2 INTRODUCTION 
Ribosomally synthesized and posttranslationally modified peptides (RiPPs) are an 
important class of genetically encoded peptide natural products with numerous biological 
functions, most notable are their antimicrobial properties.  Broadly speaking, RiPP biosynthesis 
involves the enzymatic tailoring of a genetically encoded precursor peptide, or LanA. This peptide 
is composed of a C-terminal core peptide (CP) region, where posttranslational modifications 
(PTMs) occur, and an N-terminal leader peptide (LP) region, which is often essential for 
recognition by the modification machinery and ultimately removed in the mature RiPP. Chemical 
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modification of the core region usually involves PTM by one or more tailoring enzyme included 
in the gene cluster in an iterative or sequential fashion. Of the many tailoring enzymes known, 
major interest lies with the class I lantibiotic dehydratases, which are involved in the biosynthesis 
of several classes of RiPPs, including lanthipeptides and thiopeptides. 
 Class I lantibiotic dehydratases (generally referred to as LanBs) are responsible for 
converting target serine and threonine residues in the core region of the precursor peptide to 
dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively. This class of enzyme can be 
further categorized based on homology and domain architecture into subclasses referred to as: full-
length LanBs, split-LanBs, and small-LanBs (Figure 1a). Although the general function of small-
LanBs is still under investigation, it has been well established that full-length and split-LanBs 
utilize aminoacyl-tRNA to install Dha and Dhb into the maturing LanA. Specifically, these 
enzymes transfer glutamate from glutamyl-tRNAGlu to the side-chain hydroxyl-groups of target 
serines and threonines in the CP. These glutamylated intermediates are subsequently eliminated 
by specialized domains or stand-alone enzymes, yielding Dha and Dhb products. This reliance on 
aminoacyl-tRNA stands in stark contrast to class II, III, and IV lantibiotic synthetases, which 
utilize NTPs to phosphorylate Ser/Thr side-chains for activation and subsequent elimination to 
afford the dehydrated residues.39 
 Structural insight into how these transformations are achieved was originally derived from 
crystallographic studies of NisB and MibB, which are full-length LanBs involved in the 
biosynthesis of the nisin and microbisporicin (NAI-107) lanthipeptides, respectively.53,101 Despite 
relatively low amino acid sequence identity (~20%), these proteins are quite similar in terms of 
their overall domain structure, with a smaller (~30 kDa) C-terminal domain responsible for 
elimination of the glutamyl-LanA intermediates and a larger (~90 kDa) N-terminal glutamylation 
domain that installs them (Fig. 7.1). Furthermore, the N-terminal region contains an embedded 
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subdomain, the RiPP recognition element (RRE), which is often essential for binding to the leader 
region of the LanA and promoting modification of the CP.83 While the structure for NisB was 
originally obtained with sufficient electron density to model a portion of the NisA LP bound, the 
MibB structure was determined in its apo-form. In both cases, neither tRNAGlu nor the CP regions 
of their respective LanAs were bound to the enzyme at either the glutamylation or elimination 
active sites. Thus, our current understanding of active site substrate recognition and catalysis is 
restricted to inference based on mutational analysis of conserved amino acids of the enzyme and 
nucleotides of the tRNAGlu cosubstrate 101,222 
In addition to addressing the gaps in knowledge outlined above, we also set out to expand 
our structural knowledge through the examination of the related split-LanB system from 
Thermobispora bispora involved in thiomuracin biosynthesis (TbtBC). The dehydratases from the 
split-LanB subclass are often found in thiopeptide biosynthetic gene clusters and their activity is a 
prerequisite for the ultimate formation of the six-membered nitrogenous heterocycles that are a 
structural hallmark of this class of RiPPs.39 As the name suggests, split-LanBs are composed of 
two separate proteins: the C-terminal elimination domain (TbtC) and N-terminal 
RRE/glutamylation domain (TbtB) that are thought to act in complex along with additional 
biosynthetic machinery. In the case of thiomuracin biosynthesis, it was previously demonstrated 
that the installation of thiazole/oxazole modifications in the maturing CP precedes dehydration by 
TbtB and TbtC.89 This implies that TbtB is capable of recognizing structural features of the 
partially modified CP that are not found in lanthipeptides modified by full-length LanBs. 
Furthermore, given that TbtB exhibits glutamyl-transferase activity in vitro independent of both 
the LP and TbtC, this enzyme provides a valuable and simplified platform for examining how the 
glutamylation domain engages its tRNA and peptidic substrates.86  
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 The interactions between tRNA, CP, and LanBs are thought to be very transient and 
facilitated in large part through binding of the LP with the RRE.83,223 This is likely a mechanistic 
imperative for LanBs given both their iterative nature and diverse product structures. However, 
this also presents a challenge for the development of structural probes with sufficient affinity to 
target the active site of interest. Central to our goal of better defining the active sites of both the 
elimination and glutamylation domains was the synthesis of non-reactive substrate mimics for 
these enzymes. These molecules were designed to be chemically inert but near-isosteric with either 
the glutamyl-tRNAGlu cosubstrate that binds to the glutamylation domain, or the glutamylated-
LanA intermediate that subsequently interacts with the elimination domain. The general structural 
concept for the design of these mimics is shown in Figure 7.1. Substitution of an amide linkage in 
place of an ester for both molecules was expected to prevent transesterification by the 
glutamylation domain and β-elimination by the elimination domain while keeping the steric 
features nearly identical to the natural substrates.  
 Herein, we report the structure of the glutamylation domain of TbtB bound to a small-
molecule aminoacyl-tRNA mimic inspired by puromycin, which we refer to as PDG (5¢- 
phosphoryl-N6-desmethylglutamycin; Fig. 7.1B). Moreover, we also report the structure of NisB 
bound to a non-reactive glutamyl-NisA mimic (NisA-Dap3Glu; Fig. 7.1C) in the elimination 
domain. Together, these data reveal key molecular features involved in LanB substrate recognition 
and active site structure. Accordingly, we carried out structure-guided mutagenesis and activity 
experiments to understand the relevance of individual residues to binding and/or catalysis. These 
findings expand upon our prior understanding of enzyme-catalyzed Dha/Dhb formation by 
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enabling a more detailed mechanistic understanding and may serve to inform future works aimed 
at heterologous expression or bioengineering of RiPP systems.  
Fig. 7.1: LanB domain architecture and substrate mimic design philosophy. (A) General domain layout for full-
length and split-LanB enzymes. (B) glutamyl-tRNAGlu served as inspiration for the design of the glutamylation domain 
substrate mimic, PDG. (C) glutamylated-NisA provided inspiration for the design of a non-eliminable substrate mimic 
to probe the LanB elimination domain (Figure credit: Ian Bothwell).  
 
7.3 RESULTS 
7.3.1 Overall structure of TbtB 
 Structural investigations were initiated on the glutamylation domain, TbtB, from the split 
dehydratase involved in thiomuracin biosynthesis. Apo TbtB was crystallized and its structure 
solved to 2.1 Å resolution using diffraction data from crystals soaked in thiomersal. The overall 
structure of TbtB resembles the NisB and MibB glutamylation domains (NisB5-729, RMSD = 5.0 
Å, over 2889 atoms; MibB4-809, RMSD = 3.5 Å, over 2586 atoms) with a distinguishing coiled-
coil subdomain at the N-terminus (residues 36-153; helices a2-a5) which is absent in the type I 
lanthipeptide dehydratases NisB and MibB (Fig. 7.2; for structure-based multisequence alignment 
see Fig. 7.3).53,101 Genome neighborhood analysis using RODEO suggests this extended N-
terminal subdomain is a feature common to thiopeptide and other split LanB containing 
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biosynthetic clusters (Fig. 7.4).202 The PqqD-like RRE domain in TbtB, implicated in LP 
recognition,83 recapitulates the structural organization observed in NisB and MibB (TbtB strands 
b6-b7-b8, helices a10-a11, and strand b9; Fig. 7.3), however, previous bioinformatic and binding 
experiments suggest a LP independent substrate recognition instead driven by features of the azole-
containing core region of TbtA.86  
 
7.3.2 Co-crystal structure of TbtB and PDG 
Upon soaking apo TbtB crystals with PDG and obtaining diffraction data, the 
corresponding electron density maps revealed occupancy of PDG in the same AMP binding site, 
providing the first glimpse of a RiPP dehydratase bound to a glutamyl donor substrate-mimic. In 
the cocrystal structure, the adenine ring of PDG wedges between the phenyl side-chain of Phe783 
and the guanidinium of Arg743 forming a p-p-cation interaction (Fig. 7.5). The exocyclic amine 
of the adenine ring also H-bonds with the Glu829 carboxylate and backbone amide oxygen of 
Glu830. The 2¢-hydroxyl and Thr202 side-chain engage by H-bonding, and an electrostatic 
interaction is observed between the a-ammonium of PDG and the carboxylate of Glu851 in TbtB. 
Additional electrostatic interactions are present between the 5¢-phosphate of ligand and side-chains 
of Arg197 and Lys201. Somewhat unexpectedly, the γ-carboxylate of the 3¢-Glu of PDG is 
disordered in the crystal structure, despite being situated near to Arg22. 
 
7.3.3 Structural analysis of NisB and non-eliminable glutamyl-NisA mimic  
Previous studies identified several residues important for glutamate elimination in 
NisB.101,222 To better understand their context in the mechanism of elimination, we determined the 
structure of the covalent complex between NisB variant V169C bound to NisA-Dap3Glu. The 
overall structure of NisB is highly similar to that of the previously elucidated structure with an 
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RMSD of 0.4 Å over 9196 atoms. The same region of the LP (i.e. residues -21 to -10) is visible 
and interfaces as an antiparallel b-sheet with b7 of the NisB RRE (Fig. 7.2). Electron density 
supports the existence of the engineered disulfide linkage at residues Cys169 and Cys(-12) of the 
protein and substrate mimic, respectively. In addition, residues 2-4 of the CP are visible in the 
elimination domain active site with the side-chain of the glutamate adduct inserted into a cavity 
containing residues previously shown to be important for catalysis (Fig. 7.6). Notably, the 
imidazole t-nitrogen of His961 is situated 3.0 Å away from the a-carbon of the Dap3Glu (D3G) 
residue where it is directly poised for proton abstraction, suggesting it plays the role of catalytic 
base in the glutamate elimination reaction. Moreover, Arg786 forms an electrostatic interaction 
with the carboxylate of the D3G side-chain, reaffirming its importance for binding and providing 
a structural basis for glutamate selectivity.  
 
7.4 METHODS 
7.4.1 Cloning and heterologous TbtB protein expression 
Plasmids containing tbtB WT or site-directed mutations for heterologous protein 
expression in E. coli were constructed using the pET hexahis (His6) small ubiquitin-like modifier 
(SUMO) tobacco etch virus (TEV) protease ligation-independent cloning (LIC) vector (2S-T). 
This vector was a gift from Scott Gradia (Addgene plasmid #29711). Mutations were generated 
via PCR using primers containing the LICv1 cloning tags and ligated into SspI-treated 2S-T via 
the Gibson Assembly.197 The resulting His6-SUMO-TbtB encoding plasmids were propagated in 
E. coli DH5a for plasmid isolation, and sequence-verified plasmids were used to transform E. coli 
Rosetta (DE3) competent cells for protein expression. Transformants were used to inoculate 50 
mL or 4 L (for downstream activity or structural applications, respectively) of Luria-Broth (LB) 
medium and cells were grown at 37 °C with shaking (220 rpm) until an optical density at 600 
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(OD600) of 0.4-0.6 was achieved. The cells were then cooled in an ice bath for 15 min and protein 
expression was induced by the addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
and further incubated at 18 °C with shaking (220 rpm) for 20 h.  
 
7.4.2 Preparation of SeMet-NisB-V169C 
SeMet-derivatized NisB-V169C was generated using similar growth conditions to TbtB 
variants with substitution of LB medium for M9 minimal medium containing (0.4% (w/v) glucose, 
11.2 g/L Na2HPO4×7H2O, 3 g/L KH2PO4, 1 g/L NH4Cl, 0.12 g/L MgSO4, and 0.5 g/L NaCl) 
supplemented with 4.2 mg/L FeSO4, 0.5 mg/L thiamine hydrochloride, 0.1 g/L L-Lys, 0.1 g/L L-
Phe, 0.1 g/L-Thr, 50 mg/L L-Leu, 50 mg/L L-Ile, 50 mg/L L-Val, and 50 mg/L L-SeMet.  
 
7.4.3 Protein purification 
7.4.3.1 SUMO-TbtB wild type and site-directed variants: Cells were harvested by 
centrifugation at 3,000 ´ g and cell pellets were suspended in 25 mL of buffer A (0.5 M NaCl, 
10% glycerol (v/v), and 20 mM Tris-HCl pH 8.0). Suspended cells were lysed via sonication and 
the lysate was cleared by centrifugation at 15,400 ´ g for 1 h at 4 °C. Supernatant was applied to 
2 mL of HisPur nickel-nitrilotriacetic (Ni-NTA) resin (Thermo Scientific) by gravity elution. The 
resin was washed with 40 mL of buffer B (1 M NaCl, 30 mM imidazole, and 20 mM Tris-HCl pH 
8.0) prior to eluting the protein with buffer C (1 M NaCl, 0.1 M imidazole, and 20 mM Tris-HCl 
pH 8.0) in 1 mL increments for 2 total fractions followed by buffer D (1 M NaCl, 0.5 M imidazole, 
and 20 mM Tris-HCl pH 8.0) in 1 mL increments for 8 total fractions. Proteins at this point 




7.4.3.2 His6-TbtB: Cells were harvested and lysed as described for the His6-SUMO-TbtB 
variants. Supernatant was injected onto a 5 mL Ni-NTA HisTrap HP column (GE Healthcare) 
equilibrated with buffer A using an ÄKTApurifier (GE Healthcare). The column was washed with 
50 mL of buffer B followed by a linear gradient elution of 0-100% buffer D over 40 mL (2 
mL/min). Thrombin protease was added (1 U/mg substrate; Millipore Sigma) to elution fractions 
to remove the His6-tag while dialyzing into 0.3 M NaCl, 3 mM b-mercaptoethanol (BME), 20 mM 
Tris-HCl pH 8.0 for 12 h. Dialysis was repeated in a similar buffer lacking BME for another 4 h 
before injecting protein onto a Ni-NTA HisTrap HP column (GE Healthcare) equilibrated with 
buffer A for subtractive Ni-affinity purification. The column was washed with 40 mL of buffer A 
before eluting with a stepwise gradient of increasing buffer B (i.e. 5, 10, 15, 20, 25, 30, 50, and 
100 %B). Increments of 5 mL were used between each step unless a peak was observed by 
absorbance at 280 nm, in which case, the %B composition was maintained for the entire peak 
elution. The majority of tag-free TbtB protein eluted between 15-25 %B as monitored by SDS-
PAGE. Pooled fractions of tag-free TbtB were concentrated to ≤5 mL and injected onto a 120 mL 
Superdex 200 10/300 GL column (GE Healthcare) to purify by size-exclusion chromatography 
(SEC) using 300 mM KCl, 20 mM 4-(2-hydroxylethyl)-1-piperazineethanesulfonic acid (HEPES) 
pH 7.5 as running buffer. TbtB eluted as a monomer and appeared ³90% pure by SDS-PAGE (Fig. 
7.7). 
7.4.3.3 His6-SeMet-NisB-V169C (SM-NisB-V169C): Cells were harvested, lysed, and 
protein from the supernatant was purified by Ni-affinity chromatography as described for His6-
TbtB. Pooled fractions of SM-NisB-V169C were used to methylate surface exposed Lys residues 
following reported procedures.224 The reductive amination reaction was quenched by addition of 
0.1 M tris pH 7.5, and the protein was further purified by SEC as described for TbtB. Methylated 
SM-NisB-V169C eluted as a dimer and appeared ³90% pure by SDS-PAGE (Fig. 7.7). 
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7.4.4 Protein crystallization and substrate analogue soaking 
7.4.4.1 TbtB: TbtB purified by SEC was concentrated to 2 mg/mL prior to crystallizing in 
2 µL hanging drops by mixing (1:1; v/v) protein and reservoir solution (0.2 M ammonium citrate 
pH 7.0 and 15.0% polyethylene glycol (PEG) 3350) and incubating at 20 °C. Ellipsoid-shaped 
crystals grew to maximum size within a week. 
7.4.4.2 TbtB+PDG (soak): Drops containing apo TbtB crystals were supplemented with 
10 mM PDG (dissolved in H2O) and incubated for 8 h at 20 °C.  
7.4.4.3 SM-NisB-V169C+NisA-Dap3Glu: Methylated SM-NisB-V169C purified by SEC 
was concentrated to 9 mg/mL and incubated with 2x NisA-Dap3Glu (150 µM) for 30 min on ice. 
The covalent complex was crystallized in 2 µL hanging drops by mixing (1:1; v/v) protein and 
reservoir solution (18.3% PEG 6000, 0.1 M bicine pH 8.0, and 1 mM dithiothreitol (DTT)) and 
incubating at 9 °C. Hexagonal-shaped crystals grew to maximum size with 72 h. Under these 
conditions the RRE-peptide disulfide linkage does not appear to be reduced in the crystals, on the 
basis of electron density.  
 
7.4.5 X-ray diffraction data collection and structure solution 
Crystals were cryoprotected prior to data collection by immersing them briefly in similar 
reservoir solutions supplemented with 20% ethylene glycol and plunging into liquid nitrogen. Data 
were collected at sector 21 of the Advanced Photon Source (Argonne National Laboratory) using 
the Life Science Collaborative Access Team (LS-CAT) 21-ID-D, 21-ID-F, and 21-ID-G 
beamlines. An MD2 diffractometer (Arinax Scientific Instrumentation) was used for crystal 
mounting and 100 K temperature maintenance under an aerosolized nitrogen stream. TbtB crystals 
were soaked with 10 mM thiomersal for 8 h at room temperature prior to cryoprotection and data 
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collection at 12.35 keV to obtain anomalous signal for phasing. Data were processed using XDS 
and autoPROC to obtain structure factors, and phases were determined by the single-wavelength 
anomalous diffraction technique implemented in Phenix AutoSol.33,71,199 The initial TbtB model 
was rebuilt in Phenix AutoBuild and refined using Phenix Refine and REFMAC5 with additional 
manual refining in Coot.34–36,38 Diffraction data for SM-NisB-V169C crystals were collected at 
12.67 keV and structure factors were obtained similarly to TbtB. Phases were determined by 
molecular replacement using the NisB coordinates previously reported (PDB 4WD9) in Phaser 
MR.72 The protein coordinates were refined in a similar fashion to TbtB. Ligand parameters for 
PDG and residue NisA-Dap3Glu were generated by creating a structure-data file (sdf) in ChemDraw 
Professional 17.1. The sdf file was input into Phenix eLBOW, and the output cif and pdb files 















7.5 SUPPORTING FIGURES 
 
 
Fig. 7.2: Apo TbtB superimposed onto NisB-V169C bound to NisA-Dap3Glu (b-sheets colored brown for TbtB 
and khaki for NisB-V169C). One NisB-V169C monomer is made 80% transparent for clarity. Helices of the 
glutamylation and elimination domains of NisB-V169C are colored purple and green, respectively. Two molecules of 
NisA-Dap3Glu are shown in blue and orange where electron density is supported (i.e. -21 through -10 of the LP and 2-
4 of the CP). Note that each molecule is modeled as a bidentate interaction across NisB monomers (i.e. LP bound at 
the NisB-RRE of one monomer and the core region bound at the elimination domain of the other monomer). Distance 
and entropic considerations favor this intermonomer interaction, where the corresponding intramonomer interaction 
would separate the Lys(-10) C-terminus an additional 18 Å from the N-terminus of Thr2 in the core. Moreover, the 
intramonomer interaction would require a back-and-forth threading of the maturing NisA peptide through a narrow 











Fig. 7.3: A structural-based multiple sequence alignment between NisB1-706 and TbtB generated by 
PROMALS3D.225 Residues targeted for mutagenesis which gave partial or no impairment to activity are highlighted 












Fig. 7.4 (part 1 of 2) 
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Fig 7.4 cont. (part 2 of 2) 
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Fig. 7.4 (cont.) Multisequence alignment of split LanBs and NisB/MibB glutamylation domains generated in 
Aline.207 TbtB and NisB residues (numbered according to TbtB) targeted for mutagenesis which gave partial or no 
impairment to activity are highlighted in yellow, and residues critical for activity are highlighted in red (associated 
homologous sequences are also boxed). The coiled-coil subdomain boundaries are boxed in blue for the split LanB 
sequences. A majority (11/14) of the split LanB sequences are derived from thiopeptide biosynthetic gene clusters 
(BGCs) with the remaining three sequences from the pinensin BGC (PinB1), goadsporin BGC (GodF), and the as-yet 










Fig. 7.5: Structural analysis of the glutamylation active site of TbtB. (A) TbtB bound to PDG (2.15 Å; PDB 6EC8) 
with active-site residues targeted for mutagenesis represented as sticks. A simulated annealing difference Fourier map 
(Fobs - Fcalc) contoured at 2 s is shown for the PDG ligand (green sticks).  Interatomic distances ≤ 3 Å are labeled in 
purple. (B) Analysis of TbtB mutant activity in vitro. His6 SUMO-TbtB mutants were incubated with TbtC, TbtA-














Fig. 7.6: (A) NisB-V169C bound to NisA-Dap3Glu (2.79 Å; PDB 6M7Y) showing elimination domain active-site 
residues tested previously (Y776, R784, R786, E823, R826, Y827, and H961;101,222 and in this study (W737, Y739, 
F772, and F840) as sticks. A simulated annealing difference Fourier map (Fobs - Fcalc) contoured at 2 s is shown for 
three residues of the CP (2-4 in blue sticks) containing the non-eliminable Dap3Glu adduct. Interatomic distances < 3 
Å are labeled in purple. (B) Proposed mechanism of elimination catalyzed by NisB (Figure credit [panel B]: Ian 
Bothwell).   
 
 
Fig. 7.7: SDS-PAGE analysis of N-terminal His6-SUMO tagged TbtB (SUMO-TbtB) variants used in activity assays 
(Fig. 7.5B) in addition to tag-free TbtB and methylated His6-SeMet-NisB-V169C (NisB*) used for crystallization. 
“M” denotes protein standard.  
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